

BANCORP RHODE ISLAND INC  
Form S-3/A  
March 31, 2005  
Table of Contents

As filed with the Securities and Exchange Commission on March 31, 2005

Registration Statement No. 333-122968

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**PRE-EFFECTIVE AMENDMENT NO. 2**

*TO THE*

**FORM S-3**

**REGISTRATION STATEMENT**

*UNDER*

*THE SECURITIES ACT OF 1933*

---

**BANCORP RHODE ISLAND, INC.**

(Exact name of registrant as specified in its charter)

**Rhode Island**  
(State or other jurisdiction of  
incorporation or organization)

**05-0509802**  
(I.R.S. Employer  
Identification No.)

**One Turks Head Place**

**Providence, Rhode Island 02903**

**(401) 456-5000**

Edgar Filing: BANCORP RHODE ISLAND INC - Form S-3/A

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Merrill W. Sherman**

**President and Chief Executive Officer**

**Bancorp Rhode Island, Inc.**

**One Turks Head Place**

**Providence, Rhode Island 02903**

**(401) 456-5000**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**Margaret D. Farrell, Esq.**  
**Hinckley, Allen & Snyder LLP**  
**50 Kennedy Plaza, Suite 1500**  
**Providence, RI 02903-3293**  
**Telephone : (401) 274-2000**  
**Telecopy: (401) 277-9600**

**William P. Mayer, Esq.**  
**Kathryn I. Murtagh, Esq.**  
**Goodwin Procter LLP**  
**Exchange Place**  
**Boston, MA 02109**  
**Telephone: (617) 570-1534**  
**Telecopy: (617) 523-1231**

**Approximate date of commencement of proposed sale to public:** As soon as practicable after this Registration Statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: "

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: "

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: "

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box: "

---

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), shall determine.**

---

---

**Table of Contents**

**The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.**

**Subject to completion, dated March 31, 2005**

**PROSPECTUS**

**550,000 SHARES**

**COMMON STOCK**

---

Bancorp Rhode Island, Inc. is the holding company for Bank Rhode Island, a commercial bank chartered as a financial institution in the State of Rhode Island and headquartered in Providence. We are offering for sale 550,000 shares of our common stock in an underwritten public offering. Our shares of common stock trade on the Nasdaq National Market under the symbol **BARI**. The last reported sale price of our common stock on March 30, 2005 was \$37.20 per share.

**Investing in our common stock involves risks, including the possible loss of principal. Therefore, before buying any shares of our common stock, you should carefully consider the section of this prospectus entitled Risk Factors beginning on page 8.**

**None of the Securities and Exchange Commission (SEC) or any state securities commission or other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

**The securities offered by this prospectus are not savings accounts, deposits or obligations of any bank and are not insured by the Federal Deposit Insurance Corporation (FDIC) or any other governmental agency.**

|                       | <u>Per Share</u> | <u>Total</u> |
|-----------------------|------------------|--------------|
| Public offering price | \$               | \$           |

Edgar Filing: BANCORP RHODE ISLAND INC - Form S-3/A

|  |    |    |
|--|----|----|
| Underwriting commission to be paid by us | \$ | \$ |
| Net proceeds, before expenses, to us     | \$ | \$ |

The underwriters are offering shares of our common stock as described in the section of this prospectus entitled "Underwriting". The underwriters may also purchase from us up to an additional 82,500 shares of our common stock, at the public offering price less the underwriting discount and commissions, to cover over-allotments, if any, within 30 days from the date of this prospectus. If the underwriters exercise this option in full, the total underwriting discounts and commissions will be \$ \_\_\_\_\_ and the total proceeds, before expenses, to us will be \$ \_\_\_\_\_. Delivery of the shares will be made on or about \_\_\_\_\_, 2005.

---

The date of this prospectus is \_\_\_\_\_, 2005.

**Table of Contents**

**Table of Contents**

As a prospective investor, you should rely only on the information incorporated by reference or contained in this prospectus. Neither we nor the underwriters have authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. If anyone provides you with additional, different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell nor is it seeking an offer to buy shares of our common stock in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, and information incorporated by reference is accurate only as of the date of the incorporation by reference, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed since those dates, respectively.

**TABLE OF CONTENTS**

|   |    |
|---|----|
| <u>PROSPECTUS SUMMARY</u>   | 1  |
| <u>    WHO WE ARE</u>   | 1  |
| <u>    THE OFFERING</u>   | 5  |
| <u>    SELECTED CONSOLIDATED FINANCIAL AND OTHER DATA</u>             | 6  |
| <u>RISK FACTORS</u>   | 8  |
| <u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>              | 13 |
| <u>USE OF PROCEEDS</u>  | 13 |
| <u>CAPITALIZATION</u>   | 14 |
| <u>MARKET FOR COMMON STOCK AND DIVIDENDS</u>                          | 15 |
| <u>MANAGEMENT</u>   | 16 |
| <u>SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS</u> | 18 |
| <u>UNDERWRITING</u>   | 20 |
| <u>LEGAL MATTERS</u>  | 21 |
| <u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>                  | 21 |
| <u>WHERE YOU CAN FIND MORE INFORMATION</u>                            | 21 |
| <u>DOCUMENTS INCORPORATED BY REFERENCE</u>                            | 22 |

**Table of Contents**

**PROSPECTUS SUMMARY**

*This summary highlights important features of this offering and the information included or incorporated by reference in this prospectus. Because this is a summary, it may not contain all of the information that you should consider before investing in our common stock. Therefore, you should read the entire prospectus carefully, especially the risks of investing in our common stock discussed under Risk Factors, as well as the consolidated financial statements and the other information that is incorporated by reference to this prospectus before making a decision to invest in our common stock. Unless the context otherwise requires, references in this prospectus to the Company, we, us, and our refer to Bancorp Rhode Island, Inc. and its consolidated subsidiaries. References to the Bank refer to our principal operating subsidiary, Bank Rhode Island.*

*Unless we indicate otherwise, the information in this prospectus assumes that the underwriters will not exercise their over-allotment option to purchase additional shares of common stock.*

**WHO WE ARE**

Bancorp Rhode Island, Inc. is the holding company for Bank Rhode Island, a commercial bank chartered as a financial institution in the State of Rhode Island and headquartered in Providence. The Bank was formed in March 1996 as a result of the acquisition of 12 branches divested by Fleet Financial Group as part of the Fleet/Shawmut merger. The Bank became our wholly-owned subsidiary upon completion of our reorganization into a holding company on September 1, 2000. As of December 31, 2004, we had total assets of \$1.2 billion, total deposits of \$880.7 million and total shareholders' equity of \$78.9 million.

We provide a community banking alternative in the greater Providence area, where we currently operate 14 branches in Rhode Island's three most populous counties. We augment our branch network through online banking services and automatic teller machines (ATMs), both owned and leased, located throughout the state.

The Bank is the fifth largest bank in Rhode Island, based on total deposits as of June 30, 2004 (excluding one bank that draws its deposits primarily from the internet), and the only mid-sized commercially focused bank headquartered in Providence, the state's capital. We offer a wide variety of commercial real estate, business, residential and consumer loans, deposit products, nondeposit investment products, cash management and online banking services and other products and services designed to meet the financial needs of individuals and small- to mid-sized businesses.

We have a cohesive, experienced and locally-focused management team, many of whom have been with the Bank since inception, who foster an energetic and entrepreneurial culture. While we regularly promote from within, we have not hesitated to recruit senior executive talent to augment our management capabilities as we grow and our business becomes more complex. We have a diverse board of directors with strong personal and business ties to our community, which strengthens our ability to cultivate relationships with local businesses and individuals.

**Our Growth and Profitability**



## Edgar Filing: BANCORP RHODE ISLAND INC - Form S-3/A

Our business has experienced significant growth. Since inception we have concentrated our asset generation efforts on commercial and consumer loans, allowing our residential mortgage loan portfolio to decline as a percentage of loans. Our deposit generation efforts have focused on relationship-based core deposit accounts, checking and savings. Since December 31, 2000, our total assets have grown from \$739.4 million to over \$1.2 billion, our total loans have increased from \$518.8 million to \$886.3 million, and our total deposits have increased from \$631.6 million to \$880.7 million. During the same five-year period, our net income has grown from \$4.4 million to \$8.6 million and our diluted earnings per share have grown from \$1.14 to \$2.04. We had positive growth in net income and earnings per share in all years during this period except 2003, a year in which we invested heavily in our infrastructure. Through this five-year span, our return on average assets and return on average equity ranged from 0.69% to 0.83% and 10.45% to 12.37%, respectively.

## **Table of Contents**

For the year ended December 31, 2004, our growth and profitability were as follows:

Total assets increased 13.3%, from \$1.09 billion to \$1.24 billion;

Commercial loans increased 21.2%, from \$332.3 million to \$402.8 million; and

Consumer loans increased 44.6%, from \$115.8 million to \$167.4 million.

Deposits increased 8.6%, from \$811.3 million to \$880.7 million.

Net income increased 19.4%, from \$7.2 million in 2003 to \$8.6 million in 2004.

Diluted earnings per share increased 15.3%, from \$1.77 in 2003 to \$2.04 in 2004.

Return on average assets increased from 0.69% in 2003 to 0.74% in 2004.

Return on average equity increased from 10.45% in 2003 to 11.53% in 2004.

## **Our Market Area**

Greater Providence is a densely populated urban area. Based upon information provided by Claritas, Providence is the second most populous city in New England, after Boston. It ranks second in the rate of population growth, both since 2000 and projected over the next five years, relative to the ten largest cities in New England. Additionally, Rhode Island's employment growth rate was the highest of the New England states between August 2003 and August 2004 according to the U.S. Bureau of Labor Statistics.

Like Boston, Providence boasts a number of institutions of higher learning. The City is home to Brown University, Rhode Island School of Design, Johnson & Wales University and Providence College. Additionally, a number of hospitals and other health care providers are headquartered in the Providence area, as are state and other governmental offices. These sectors, as well as the local national airport, T.F. Green, which was significantly expanded in 1995, are key drivers of the state's economy.

The profile of the state's businesses is decidedly small business-oriented. According to data furnished by the Rhode Island Department of Labor and Training (RIDLT), more than 95% of Rhode Island's businesses have fewer than 50 employees. Since 1992, Rhode Island has experienced significant growth in the service, finance, insurance and real estate sectors, offsetting a substantial loss of manufacturing jobs and reflecting a dramatic realignment of what was once primarily a manufacturing based economy. While this growth is indicative of national trends, Rhode Island's shift to these sectors has been significantly greater than the nation's. Additionally, the RIDLT projects that Rhode Island's growth rate in the service and finance sectors will surpass the nation's growth rate in such sectors over the next five to seven years.

## Edgar Filing: BANCORP RHODE ISLAND INC - Form S-3/A

The City of Providence itself is enjoying an urban renaissance. It has preserved its architecturally distinctive flavor and enjoys numerous restaurants, theaters and other cultural venues, has a strong arts community and offers easy access to numerous recreational amenities. In recent years, both the Governor of Rhode Island and Mayor of Providence were elected on reform platforms and have taken steps to restore a sense of confidence and integrity to state and local government.

Thirteen of our fourteen branches are located in Providence and Kent Counties, the two most populous counties in Rhode Island. These counties contain 75% of the state's population, 72% of its businesses and 79% of its jobs. The six largest cities in the state are located in these two counties, and we have branches in five of these six cities. We recently expanded into Washington County, the third most populous county in the state, with the successful opening of our North Kingstown branch. In the nine months since opening, the branch has surpassed our expectations by garnering over \$25 million in deposits.

The Rhode Island banking market is dominated by three large banks, one national and two regional. Their combined market share in Providence and Kent Counties represents approximately 84% of the deposits (excluding the internet-based bank), reflecting an exceptionally high degree of market concentration. The smallest of these institutions has total assets in excess of \$56 billion. We have just under 6% of the deposits in Providence and Kent Counties and the remainder is scattered among a dozen other institutions. None of these other institutions has a branch footprint similar to ours in Providence and Kent Counties. As a result, we regard the three large banks in our area as our primary competition.

## **Table of Contents**

The Rhode Island market has experienced slow to moderate economic growth over the past decade. Accordingly, our future growth depends largely on our ability to continue to attract business away from these large banks by continuing to increase our penetration in existing markets and successfully expanding in new markets. We believe we will enjoy continued success in winning business by offering a combination of competitive pricing for our services, quick decision making processes and a high level of personalized customer service to commercial, small business and other customers in the area who are seeking an alternative to the larger financial institutions.

### **Our Business Strategy**

Our core strategy is to sufficiently differentiate ourselves from the large banks so as to attract business away from them. We seek to accomplish this through superior, relationship-based personal service, responsiveness, and our ability to set policies and procedures, as well as make decisions, locally. We believe we have a sophisticated commercial lending group and a solid footprint of branches which enable us to compete against the larger banks.

We believe we are well positioned to capitalize on the opportunities our marketplace, expertise and customer base afford us. Three primary opportunities are:

The consolidation of the banking industry in Rhode Island and our relatively small market share provides the opportunity for us to grow by continuing to increase our market penetration and expanding our market presence.

The prevalence of small businesses, our target customers, supports our focus on commercial lending as our primary business driver. We believe that service-oriented, relationship banking is meaningful to many businesses, and that our branch footprint has sufficient touch-points to make us accessible to these businesses.

Our customer relationships and core competencies provide opportunities for cross selling products to our existing customers and for developing new business lines that utilize our knowledge base.

Specifically, we plan to focus on the following specific operating and growth strategies:

*Providing Superior, Relationship-Based Customer Service.* We have distinguished ourselves from the larger institutions in our region by providing high touch, individualized, responsive, quality service. To provide this personalized service, we strive to recruit and train highly motivated employees who are able to make decisions and respond quickly to customers' needs. We emphasize to our employees the importance of delivering a consistent and superior level of service and building further relationships with our customers. We believe our consistent, customer-focused approach across our entire organization provides us with a competitive advantage over the larger banks in our market.

*Expanding Our Commercial Banking Relationships.* Building on our past success in commercial lending, we seek to position ourselves as the bank for business in our market. Our strategy revolves around providing ready access to a knowledgeable, experienced commercial lending officer with a relationship orientation, able to respond to a broad range of business needs on a customized basis. Our lenders provide continuity and consistency in approach as well as value-added advice. We believe our ability to know our commercial customers, to provide a significant level of personal contact and to respond to their lending and banking needs on a more individualized basis will enable us to continue to attract relationship-oriented customers dissatisfied with the service and responsiveness of our larger competitors.

*Growing Our Core Deposits.* We stress growing the Bank's core deposit base, namely checking and savings deposits. These deposits provide both a low cost source of funds for our lending operations and a potential source of fee income. These accounts, which generally represent a customer's primary banking relationship, also present opportunities for cross-selling other products. We rely mainly on quality customer service and diversified products, as well as competitive pricing policies and advertising, to attract and retain these deposits.

## **Table of Contents**

*Diversifying Our Products and Services and Increasing Noninterest Income.* Over the years we have introduced new products and services in order to more fully service our customers as well as to broaden our sources of noninterest income. Such services and products include cash management and a nondeposit investment program which offers customers a variety of mutual funds and annuities. We have also expanded our consumer loan generation (largely home equity lines of credit and home equity term loans) through marketing programs with other local organizations and increased our residential mortgage origination capacity. We plan to continue to leverage off our knowledge base and customer relationships to diversify our business lines and sources of noninterest income.

*Expanding Our Branch Network.* We plan to broaden and deepen our branch footprint in order to provide more touch points for our customers, increase market awareness of our presence and enhance our franchise generally. While we expect that most of our growth will continue to be organic, we will consider acquisitions of individual branches or other institutions should attractive opportunities arise. We recently announced an expansion plan which calls for the construction and development of six branches over the next three to four years, using three branch models: a traditional branch, a smaller Xpress design tailored to commuters and drive-up traffic and a flagship Xcel model, which features innovative design, the latest technology and expanded hours and services. In April 2004, we opened an Xcel branch in North Kingstown, Rhode Island, which garnered in excess of \$25 million in deposits in its first nine months of operation. We plan to open an Xpress branch adjacent to our operations center in Lincoln, Rhode Island in the Spring of 2005, a traditional branch in East Greenwich, Rhode Island in the Summer of 2005 and a traditional branch in Pawtucket, Rhode Island in early 2006.

*Maintaining Our Strong Asset Quality.* While increasing our commercial business, commercial real estate and consumer loans, we have maintained strong asset quality. We believe that this experience is the result of conservative underwriting standards, experienced loan officers, diligent monitoring of our loan portfolio, ability to know our customers and a stable economy. At December 31, 2004, our nonperforming loans as a percentage of total loans was 0.08%.

## **Recent Developments**

On January 10, 2005, we entered into a non-binding letter of intent to purchase substantially all of the operating assets of a lease financing business (the Leasing Company ) located in the greater New York metropolitan area for a maximum aggregate purchase price of \$1.9 million. Completion of this acquisition is subject to the successful negotiation of a purchase and sale agreement. If the transaction is consummated, the purchase price will be paid in shares of our common stock with \$250,000 paid at the closing of the acquisition, up to \$750,000 payable upon the achievement of certain performance goals over a three-year period and up to an additional \$900,000 subject to an earn-out over five years.

In 2004, the Leasing Company originated approximately \$20.4 million in leases. In November 2004, we acquired approximately \$3.0 million of leases from the Leasing Company. Following consummation of the acquisition, we currently anticipate that we will retain a significant portion of the leases generated by the Leasing Company.

## **Corporate Information**

Our executive offices are located at One Turks Head Place, Providence, Rhode Island 02903, our telephone number is (401) 456-5000 and our Internet address is <http://www.bankri.com>. The information on our Internet website is not incorporated by reference in this prospectus.

**Table of Contents**

**THE OFFERING**

|  |   |
|--|---|
| Common stock we are offering   | 550,000 shares <sup>1</sup>   |
| Common stock outstanding after the offering                                | 4,560,554 shares <sup>2</sup>   |
| Net proceeds   | The net proceeds of the offering will be approximately \$18.8 million without the underwriters over-allotment option, assuming an offering price of \$37.20 per share (based upon the closing price of our common stock on March 30, 2005).   |
| Use of proceeds  | We intend to retain the net proceeds from the offering of shares of common stock by us at the Company level for general business purposes and working capital and intend to downstream such proceeds to the Bank as necessary to provide regulatory capital to support our asset growth and continued expansion of the Bank's business. The proceeds from the offering should enable us to maintain our status as a well-capitalized institution as we execute our growth strategy. |
| Dividends on common stock  | We have historically paid quarterly cash dividends on our common stock, and currently intend to do so in the future. See Market for Common Stock and Dividends.   |
| Nasdaq National Market symbol  | BARI  |
| Common stock purchased by Directors and Executive Officers in the offering | Certain of our officers and directors have indicated an intent to participate in the offering through the purchase of approximately 42,500 shares, in the aggregate. In anticipation of this participation, we have directed 42,500 shares to be reserved specifically for purchase by such officers and directors.   |
| Risk Factors   | Before investing, you should carefully review the information contained under Risk Factors beginning at page 8.   |

<sup>1</sup> The number of shares of common stock offered assumes that the underwriters' over-allotment option is not exercised. If the over-allotment option is exercised in full, we will issue and sell 632,500 shares.

<sup>2</sup> The number of shares of common stock outstanding after the offering is based on the number of shares outstanding as of December 31, 2004 and assumes that the underwriters' over-allotment option is not exercised. It excludes an aggregate of 598,017 shares reserved for issuance under our stock incentive plans, under which options to purchase 487,805 shares at a weighted average exercise price of \$19.30 had been granted and were outstanding as of December 31, 2004.

**Table of Contents**

**SELECTED CONSOLIDATED FINANCIAL AND OTHER DATA**

The following tables set forth selected consolidated historical financial and other data of the Company for the years ended December 31, 2004, 2003, 2002, 2001 and 2000. The selected consolidated financial data is derived in part from our Consolidated Financial Statements, which have been audited by KPMG LLP. The selected consolidated financial data set forth below does not purport to be complete and should be read together with, and are qualified in their entirety by, the more detailed information, including the Consolidated Financial Statements and related Notes, and Management's Discussion and Analysis of Financial Condition and Results of Operations, incorporated by reference into this prospectus from our Annual Report on Form 10-K for the fiscal year ended December 31, 2004.

As of and for the year ended December 31,

| 2004  | 2003      | 2002      | 2001 | 2000 |
|---|-----------|-----------|------|------|
| (Dollars in thousands, except Per Share Data) |           |           |      |      |
|   | 57,719    | \$ 51,773 |      | \$   |
|   | 19,625    | 19,453    |      |      |
|   | 38,094    | 32,320    |      |      |
|   | 900       | 1,600     |      |      |
|   | 8,581     | 8,830     |      |      |
|   | 32,865    | 28,790    |      |      |
|   | 12,910    | 10,760    |      |      |
|   | 4,296     | 3,546     |      |      |
|   | 8,614     | \$ 7,214  |      | \$   |
|   | 2.17      | \$ 1.89   |      | \$   |
|   | 2.04      | \$ 1.77   |      | \$   |
|   | 0.58      | \$ 0.56   |      | \$   |
|   | 28.4%     | 31.6%     |      |      |
|   | 19.68     | \$ 18.53  |      | \$   |
|   | 16.99     | \$ 15.76  |      | \$   |
|   | 3,975,413 | 3,819,232 |      | 3,7  |
|   | 4,222,856 | 4,085,878 |      | 3,9  |



|  |           |              |        |
|--|-----------|--------------|--------|
|  | 1,239,069 | \$ 1,093,971 | \$ 1,0 |
|  | 104,600   | 98,595       | 1      |
|  | 159,946   | 106,618      | 1      |
|  | 402,770   | 332,266      | 2      |
|  | 316,135   | 366,230      | 2      |
|  | 167,396   | 115,786      |        |
|  | 886,301   | 814,282      | 6      |
|  | 11,906    | 11,078       |        |
|  | 10,766    | 10,766       |        |

our business grows, it is foreseeable that we will eventually exceed the SBIR size limitations, in which case we may be required to seek alternative sources of revenues or capital.

in government research contract awards or government funding for existing or future government research contracts, including SBIR contracts, could adversely affect our revenues, cash flows and ability to fund our growth. Technology Development segment revenues, which consist primarily of government-funded research, accounted for 49% and of our total revenues for the years ended December 31, 2018 and 2017, respectively. As a result, we are vulnerable to changes in our revenues and cash flows if a significant number of our research contracts and subcontracts were to be adversely delayed or canceled for budgetary, performance or other reasons. For example, the U.S. government may cancel contracts at any time without cause or may change its requirements, programs or contract budget, any of which could reduce our revenues and cash flows from U.S. government research contracts. Our revenues and cash flows from U.S. government research contracts and subcontracts could also be reduced by declines or other changes in U.S. defense, homeland and other federal agency budgets. In addition, we compete as a small business for some of these contracts, and in order to maintain our eligibility to compete as a small business, we, together with any affiliates, must continue to meet size and revenue limitations established by the U.S. government.

Our contract research customer base includes government agencies, corporations and academic institutions. Our customers are not required to extend their agreements with us and may elect not to do so. Also, our customers' priorities regarding funding for certain projects may change and funding resources may no longer be available at previous levels.

Due to contract cancellations and changes in agency budgets, our future financial results may be adversely affected by curtailment of or restrictions on the U.S. government's use of contract research providers, including curtailment due to budget reductions and related fiscal matters or any legislation or resolution limiting the number or amount of awards we receive. These or other factors could cause U.S. defense and other federal agencies to conduct research internally rather than through commercial research organizations or direct awards to other organizations, to reduce their overall contract research commitments or to exercise their rights to terminate contracts. Alternatively, the U.S. government may discontinue the SBIR program or its funding altogether. Also, SBIR regulations permit increased competition for SBIR awards from companies that have previously been eligible, such as those backed by venture capital operating companies, hedge funds and private equity. Any of these developments could limit our ability to obtain new contract awards and adversely affect our revenues, cash flows and ability to fund our growth.

Our ability to attract, train and retain skilled employees or members of our senior management and to obtain necessary security clearances for such persons or maintain a facility security clearance would adversely affect our business and operating results. The availability of highly trained and skilled technical and professional personnel is critical to our future growth and profitability. Competition for scientists, engineers, technicians and professional personnel is intense and our competitors aggressively recruit key employees. In the past, we have experienced difficulties in recruiting and hiring these personnel as a



Table of Contents

of the tight labor market in certain fields. Any difficulty in hiring or retaining qualified employees, combined with our growth strategy and future needs for additional experienced personnel, particularly in highly specialized areas such as aerial manufacturing and fiber optic sensing technologies, may make it more difficult to meet all of our needs for these in a timely manner. Although we intend to continue to devote significant resources to recruit, train and retain qualified employees, we may not be able to attract and retain these employees, especially in technical fields in which the supply of qualified candidates is limited, or at the senior management level. Any failure to do so would have an adverse effect on our business. Any loss of key personnel could have a material adverse effect on our ability to meet key operational objectives, including timely and effective project milestones and product introductions, which in turn could adversely affect our business, results of operations and financial condition.

Our operations include certain services to the U.S. government that require us to maintain a facility security clearance and for certain of our officers and our board chairman to hold security clearances. In general, the failure for necessary persons to obtain or retain security clearances, any loss by us of a facility security clearance or any public reprimand related to security matters could result in a U.S. government customer terminating an existing contract or choosing not to renew a contract or prevent us from bidding on or winning certain new government contracts.

In addition, our future success depends in a large part upon the continued service of key members of our senior management team. We do not maintain any key-person life insurance policies on our officers. The loss of any members of our management team or other key personnel could seriously harm our business.

Our business is subject to the cyclical nature of the markets in which we compete and any future downturn may reduce demand for our products and revenue.

Factors beyond our control affect our business, including consumer confidence in the economy, interest rates, fuel prices and the general availability of credit. The overall economic climate and changes in Gross National Product growth have a direct impact on some of our customers and the demand for our products. We cannot be sure that our business will not be adversely affected as a result of an industry or general economic downturn.

Customers may reduce capital expenditures and have difficulty satisfying liquidity needs because of continued turbulence in the U.S. and global economies, resulting in reduced sales of our products and harm to our financial condition and results of operations.

Historically, our historical results of operations have been subject to substantial fluctuations, and we may experience substantial quarter-to-quarter fluctuations in future results of operations. Any future downturn in the markets in which we compete could significantly reduce the demand for our products and therefore may result in a significant reduction in revenue or increase the price of our common stock. Our revenue and results of operations may be adversely affected in the future due to changes in demand from customers or cyclical changes in the markets utilizing our products.

In addition, the telecommunications industry has, from time to time, experienced, and may again experience, a pronounced downturn. To respond to a downturn, many service providers may slow their capital expenditures, cancel or delay new product developments, reduce their workforces and inventories and take a cautious approach to acquiring new equipment and technologies from original equipment manufacturers, which would have a negative impact on our business. Weakness in the economy or a future downturn in the telecommunications industry may cause our results of operations to fluctuate from quarter-to-quarter and year-to-year, harm our business, and may increase the volatility of the price of our common stock.

Customer acceptance of our products is dependent on our ability to meet changing requirements, and any decrease in acceptance could adversely affect our revenue.

Customer acceptance of our products is significantly dependent on our ability to offer products that meet the changing requirements of our customers, including telecommunication, military, medical and industrial corporations, as well as government agencies. Any decrease in the level of customer acceptance of our products could harm our business. Our products must meet exacting specifications, and defects and failures may occur, which may cause customers to return or stop buying our products.

Customers generally establish demanding specifications for quality, performance and reliability that our products must meet. Our products are highly complex and may contain defects and failures when they are first introduced or as new versions are introduced. Our products are also subject to rough environments as they are integrated into our customer products for use by the customers. If defects and failures occur in our products, we could experience lost revenue, increased costs, including expense and costs associated with customer support, delays in or cancellations or rescheduling of orders or shipments,

product returns or discounts, diversion of management resources or damage to our

Table of Contents

ation and brand equity, and in some cases consequential damages, any of which would harm our operating results. In delays in our ability to fill product orders as a result of quality control issues may negatively impact our relationship omers. We cannot assure you that we will have sufficient resources, including any available insurance, to satisfy any asserted claims.

changing standards and regulations could make our products obsolete, which would cause our revenue and results of operations to suffer.

design products to conform to our customers' requirements and our customers' systems may be subject to regulations d by governments or industry standards bodies worldwide. Because some of our products are designed to conform to ific industry standards, if competing or new standards emerge that are preferred by our customers, we would have to icant expenditures to develop new products. If our customers adopt new or competing industry standards with which are not compatible, or the industry groups adopt standards or governments issue regulations with which our products atible, our existing products would become less desirable to our customers and our revenue and results of operations would suffer.

for many of our products are characterized by changing technology which could cause obsolescence of our products, and we may incur substantial costs in delivering new products.

markets for many of our products are characterized by changing technology, new product introductions and product ts, and evolving industry standards. The introduction or enhancement of products embodying new technology or the ence of new industry standards could render existing products obsolete, and result in a write down to the value of our y, or result in shortened product life cycles. Accordingly, our ability to compete is in part dependent on our ability to continually offer enhanced and improved products.

The success of our new product offerings will depend upon several factors, including our ability to:

- accurately anticipate customer needs;
- innovate and develop new technologies and applications;
- successfully commercialize new technologies in a timely manner;
- price products competitively and manufacture and deliver products in sufficient volumes and on time; and
- differentiate our product offerings from those of our competitors.

Our inability to find new customers or retain existing customers could harm our business. Business is reliant on our ability to find new customers and retain existing customers. In particular, customers normally certain of our products and incorporate them into products that they, in turn, sell in their own markets on an ongoing result, the historical sales of these products have been dependent upon the success of our customers' products and our ormance is dependent upon our success in finding new customers and receiving new orders from existing customers. al markets, the quality and reliability of our products are a major concern for our customers, not only upon the initial ure of the product, but for the life of the product. Many of our products are used in remote locations for higher value making servicing of our products unfeasible. Any failure of the quality or reliability of our products could harm our business.

mer demand for our products is difficult to accurately forecast and, as a result, we may be unable to optimally match production with customer demand, which could adversely affect our business and financial results. anning and spending decisions, including determining the levels of business that we will seek and accept, production inventory levels, component procurement commitments, personnel needs and other resource requirements, based on es of customer requirements. The short-term nature of commitments by many of our customers and the possibility of cted changes in demand for their products reduce our ability to accurately estimate future customer requirements. On customers may require rapid increases in production, which can strain our resources, cause our manufacturing to be vely impacted by materials shortages, necessitate higher or more restrictive procurement commitments, increase our ng yield loss and scrapping of excess materials, and reduce our gross margin. We may not have sufficient capacity at e to meet the volume demands of our customers, or one or more of our suppliers may not have sufficient capacity at e to meet our volume demands. Conversely, a downturn in the markets in which our customers compete can cause, and in the past have caused, our customers to significantly reduce or delay



Table of Contents

nt of products ordered or to cancel existing orders, leading to lower utilization of our facilities. Because many of our operating expenses are relatively fixed, reduction in customer demand due to market downturns or other reasons would have a negative effect on our gross margin, operating income and cash flow.

of our operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers' businesses and levels of business activity.

economic and political conditions affect our customers' businesses and the markets they serve. A severe or prolonged downturn or a negative or uncertain political climate could adversely affect our customers' financial conditions and the levels of business activity of our customers and the industries we serve. This may reduce the demand for our products pricing for our products and have a material adverse effect on our results of operations. Changes in global economic conditions could also shift demand to products or services for which we do not have competitive advantages, and this could affect the amount of business we are able to obtain. In addition, if we are unable to successfully anticipate changing and political conditions, we may be unable to effectively plan for and respond to those changes, and our business could be negatively affected as a result.

history of losses, and because our strategy for expansion may be costly to implement, we may experience losses and may not maintain profitability or positive cash flow.

history of net losses from operations and only recently generated positive net income from continuing operations of million for the year ended December 31, 2018. We expect to continue to incur significant expenses as we pursue our initiatives, including increased expenses for research and development, sales and marketing and manufacturing. We may pursue our business in part through acquisitions of additional companies and complementary technologies which could cause us to incur greater than anticipated transaction expenses, amortization or write-offs of intangible assets and other related expenses. As a result, we may incur net losses in the future, and these losses could be substantial. At a certain level net losses could impair our ability to comply with Nasdaq continued listing standards, as described further below. Our ability to generate additional revenues and to become profitable will depend on our ability to execute our key growth initiatives regarding the development, marketing and sale of sensing products, develop and commercialize innovative products, expand our contract research capabilities and sell the products that result from those development initiatives. We may not be able to sustain or increase our profitability on a quarterly or annual basis.

We may require additional capital to support and expand our business.

to continue to make investments to support our business growth, including developing new products, enhancing our products, obtaining important regulatory approvals, enhancing our operating infrastructure, completing our development projects and building our commercial scale manufacturing facilities. To the extent that we are unable to become or remain profitable and to finance our activities from continuing operations, we may require additional funds to support these initiatives and to grow our business.

If we are successful in raising additional funds through issuances of equity or convertible debt securities, our existing securities could suffer significant dilution, including as the result of the issuance of warrants in connection with the financing. New equity securities we issue could have rights, preferences and privileges superior to those of our existing common stock. Moreover, such financings may jeopardize our ability to apply for SBIR grants or qualify for SBIR contracts or grants. Dependence on SBIR grants may restrict our ability to raise additional outside capital. If we raise additional funds through financings, these financings may involve significant cash payment obligations and covenants that restrict our ability to operate our business and make distributions to our stockholders.

Unable to obtain adequate financing or financing terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be significantly limited.

and will face substantial competition in several different markets that may adversely affect our results of operations. We face and will face substantial competition from a variety of companies in several different markets. As we focus on developing and marketing and selling fiber optic sensing products, we may also face substantial and entrenched competition in that market.

Some of our competitors have longer operating histories, greater name recognition, larger customer bases and significantly more financial, sales and marketing, manufacturing, distribution, technical and other resources than we do. These competitors may be able to adapt more quickly to new or emerging technologies and changes in customer requirements.





Table of Contents

dition, current and potential competitors have established or may establish financial or strategic relationships among themselves or with existing or potential customers or other third parties. Accordingly, new competitors or alliances among competitors could emerge and rapidly acquire significant market share. We cannot assure you that we will be able to compete successfully against current or new competitors, in which case our revenues may fail to increase or may decline. Competition in our markets could result in aggressive business tactics by our competitors, including aggressively pricing products or selling older inventory at a discount. If our current or future competitors utilize aggressive business tactics, as described above, demand for our products could decline, we could experience delays or cancellations of customer orders, or we could be required to reduce our sales prices.

Shifts in product mix may result in declines in gross profit. Profit margins vary among our product platforms, and are generally highest on our test & measurement instruments. Gross profit may fluctuate from period to period as a result of a variety of factors including shifts in product mix, the introduction of new products, and decreases in average selling prices for older products. If our customers decide to buy more of products with low gross profit margins or fewer of our products with high gross profit margins, our total gross profits could be harmed.

## Risks Relating to our Operations and Business Strategy

Unable to successfully integrate acquired businesses, it could have an adverse effect on our future results and the market price of our common stock.

In 2018 we acquired the assets of Micron Optics, Inc., a leading provider of provider of innovative optical components and fiber-based equipment that advance the quality of optical measurements. In March 2019 we acquired General Photonics, a leading provider of innovative components, modules and test equipment focused on the generation, measurement and control of polarized light critical in fiber optic-based applications. In the future, we may continue to seek acquisition targets consistent with our growth strategy. The success of an acquisition will depend, in large part, on sales of the acquired company's products and the realization of operating synergies. To realize these anticipated benefits, we must successfully integrate the acquired company's business into our existing business. Such integrations may be complex and time-consuming. The failure to successfully integrate and manage the challenges presented by the integration process may result in our failure to achieve some or all of the anticipated benefits of the acquisition. Potential difficulties that may be encountered in the integration process include the following:

- loss of sales and customers as a result of customers deciding not to do business with us;
- complexities associated with managing the larger combined company with distant business locations;
- integrating personnel while maintaining focus on providing consistent, high quality products;
- loss of key employees;
- potential unknown liabilities associated with the acquisition;

Shortfalls as a result of the diversion of management's attention caused by completing the acquisition and integrating the acquired business. If these events were to occur, our ability to maintain relationships with the customers, suppliers and employees or our ability to achieve the anticipated benefits of the acquisition could be adversely affected, or could reduce our future earnings or otherwise adversely affect our business and financial results and, as a result, adversely affect the market price of our common stock.

Unable to successfully transition our revenue mix from contract research revenues to product sales and license revenues, we may not be able to fully execute our business model or grow our business. Our business model and future growth depend on our ability to transition to a revenue mix that contains significantly more product sales and revenues from the provision of services or from licensing. Product sales and these revenues potentially offer greater scalability than contract research revenues. Our current plan is to increase our sales of commercial products, our sales of services and our provision of non-research services to customers so as to represent a larger percentage of our total revenues. If we are unable to develop and grow our product sales and revenues from the provision of services or from licensing to replace our contract research revenues, however, our ability to execute our business model or grow our business could suffer.

There can be no assurance that we will be able to achieve increased revenues in this manner.



Table of Contents

...e to develop, introduce and sell new products or failure to develop and implement new technologies, could adversely impact our financial results. ...ss will depend on our ability to develop and introduce new products that customers choose to buy. The new products market requires tend to be increasingly complex, incorporating more functions and operating at faster speeds than old ts. If we fail to introduce new product designs or technologies in a timely manner or if customers do not successfully y systems or products incorporating our products, our business, financial condition and results of operations could be materially harmed.

If we are unable to manage growth effectively, our revenues and net loss could be adversely affected. ...eed to expand our personnel resources to grow our business effectively. We believe that sustained growth at a higher ce a strain on our management as well as on our other human resources. To manage this growth, we must continue to tain qualified management, professional, scientific and technical and operating personnel. If we are unable to recruit umber of qualified personnel, we may be unable to staff and manage projects adequately, which in turn may slow the rate of growth of our contract research revenues or our product development efforts.

We may not be successful in identifying market needs for new technologies or in developing new products. ...business model depends on our ability to correctly identify market needs for new technologies. We intend to identify market needs, but we may not always have success in doing so in part because our contract research largely centers on n and development of unproven technologies, often for new or emerging markets. Furthermore, we must identify the ising technologies from a sizable pool of projects. If our commercialization strategy process fails to identify projects ercial potential or if management does not ensure that such projects advance to the commercialization stage, we may not successfully commercialize new products and grow our revenues.

...rowth strategy requires that we also develop successful commercial products to address market needs. We face several ges in developing successful new products. Many of our existing products and those currently under development are logically innovative and require significant and lengthy product development efforts. These efforts include planning, d developing and testing at the technological, product and manufacturing-process levels. These activities require us to gnificant investments. Although there are many potential applications for our technologies, our resource constraints focus on specific products and to forgo other opportunities. We expect that one or more of the potential products we elop will not be technologically feasible or will not achieve commercial acceptance, and we cannot predict which, if our products we will successfully develop or commercialize. The technologies we research and develop are new and ging and advancing. The products that are derived from these technologies may not be applicable or compatible with of technology or demands in existing markets. Our existing products and technologies may become uncompetitive or solete if our competitors adapt more quickly than we do to new technologies and changes in customers' requirements. e, we may not be able to identify if and when new markets will open for our products given that future applications of oduct may not be readily determinable, and we cannot reasonably estimate the size of any markets that may develop.

If we are not able to successfully develop new products, we may be unable to increase our product revenues.

We face risks associated with our international business.

...ntly conduct business internationally and we might considerably expand our international activities in the future. Our al business operations are subject to a variety of risks associated with conducting business internationally, including:

- comply with U.S. export control regulations and policies that restrict our ability to communicate with non-U.S. d supply foreign affiliates and customers;
- changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products, perform es or repatriate profits to the United States;
- the imposition of tariffs;
- hyperinflation or economic or political instability in foreign countries;
- limitations on, or increase of withholding and other taxes on remittances and other payments by foreign r joint ventures;
- conducting business in places where business practices and customs are unfamiliar and unknown;
- the imposition of restrictive trade policies;

the imposition of inconsistent laws or regulations;

Table of Contents

the imposition or increase of investment and other restrictions or requirements by foreign governments;  
uncertainties relating to foreign laws and legal proceedings;  
having to comply with a variety of U.S. laws, including the Foreign Corrupt Practices Act ("FCPA"); and  
having to comply with licensing requirements.

not know the impact that these regulatory, geopolitical and other factors may have on our international business in the future.

Developments relating to the United Kingdom's referendum vote in favor of withdrawal from the European Union could adversely affect us.

held a referendum on June 23, 2016, in which a majority voted for the UK's withdrawal from the EU, commonly known as 'Brexit'. As a result of this vote, on March 29, 2017, the UK officially started the separation process and commenced negotiations to determine the terms of the UK's withdrawal from the EU. The UK is currently scheduled to leave the EU at 11 p.m. GMT on March 29, 2019. If the UK and the EU are unable to negotiate acceptable withdrawal terms, barrier-free trade between the UK and other European Member States or among the EEA overall could be diminished or eliminated. The terms of the exit are expected to be far-reaching and will depend on any agreements (or lack thereof) between the UK and the EU. In particular, any arrangements for the UK to retain access to EU markets either during a transitional period or more long-term. Given the level of uncertainty, Brexit, and the perceptions as to its impact, may adversely affect business activity and economic conditions in the UK, Europe and globally and could continue to contribute to instability in global financial and capital markets, asset valuations and credit ratings. Brexit could also have the effect of disrupting and potentially hindering the free movement of goods, services and people between the UK and the EU, which may negatively affect our operations together with those of our customers and suppliers.

For example, it is unclear at this time what Brexit's impact will have on our intellectual property rights and the process for obtaining, maintaining, defending and enforcing such rights. For example, while current guidance provided by the UK's Intellectual Property Office suggests that trademarks granted by the EU, known as EU registered trademarks or EUTMs, will be continued to be enforceable in the UK after Brexit, it is unclear whether we will be required to refile our trademarks and other intellectual property rights domestically in the UK and whether any other steps will be required for us to protect our trade marks in the UK in the future. As a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership in the EU. Given these possibilities and others we may not anticipate, as well as the lack of comparable precedent, we are not certain of the full extent to which Brexit could adversely affect our business, results of operations and financial condition.

We may also be required to dispose of or discontinue existing product lines and technology developments, which may adversely impact our future results.

On a going concern basis, we evaluate our various product offerings and technology developments in order to determine whether any should be discontinued or, to the extent possible, divested. In addition, if we are unable to generate the amount of cash needed to support the operations of our business, we may be forced to sell one or more of our product lines or technology developments. We do not guarantee that we have correctly forecasted, or that we will correctly forecast in the future, the right product lines and technology developments to dispose or discontinue or that our decision to dispose of or discontinue various investments, products and technology developments is prudent if market conditions change. In addition, there are no assurances that the discontinuance of various product lines will reduce operating expenses or will not cause us to incur material charges associated with the decision. Furthermore, the discontinuance of existing product lines entails various risks, including the risk that we will be unable to find a purchaser for a product line or the purchase price obtained will not be equal to at least the book value of the assets for the product line. Other risks include managing the expectations of, and maintaining good relations with, our customers who previously purchased products from a disposed or discontinued product line, which could prevent us from selling other products to them in the future. We may also incur other significant liabilities and costs associated with disposal or discontinuance of product lines, including employee severance costs and excess facilities costs.

We may also be negatively affected by a security breach, either through cyber-attack, cyber-intrusion or other significant disruption of our IT networks and related systems.

the risk, as does any company, of a security breach, whether through cyber-attack or cyber-intrusion over the internet, computer viruses, attachments to e-mails, persons inside our organization or persons with access to systems inside our organization, or other significant disruption of our IT networks and related systems. The risk of a security breach or

Table of Contents

particularly through cyber-attack or cyber-intrusion, including by computer hackers, foreign governments and cyber, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.

technology company, and particularly as a government contractor, we may face a heightened risk of a security breach or from threats to gain unauthorized access to our proprietary, confidential or classified information on our IT networks systems. These types of information and IT networks and related systems are critical to the operation of our business critical to our ability to perform day-to-day operations, and, in some cases, are critical to the operations of certain of our In addition, as certain of our technological capabilities become widely known, it is possible that we may be subjected to attack or cyber-intrusion as third parties seek to gain improper access to information regarding these capabilities and a cyber-intrusion could compromise our confidential information or our IT networks and systems generally, as it is not as a business matter to isolate all of our confidential information and trade secrets from email and internet access. To date we have not experienced a significant cyber-intrusion or cyber-attack. There can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. A security breach or other significant disruption involving these types of information and IT networks and related systems could disrupt the proper functioning of these networks and systems and therefore our operations, compromise our confidential information and trade secrets, or damage our reputation among our customers and the public generally. We have not identified any material security breaches or experienced other significant disruptions of these types to date. Any of these developments in the future could have a negative impact on our results of operations, financial condition and cash flows.

## Risks Relating to our Regulatory Environment

Our operations are subject to domestic and foreign laws, regulations and restrictions, and noncompliance with these laws, rules and restrictions could expose us to fines, penalties, suspension or debarment, which could have a material adverse effect on our profitability and overall financial position.

Our operations, particularly our international sales, subject us to numerous U.S. and foreign laws and regulations, including export control regulations relating to imports, exports (including the Export Administration Regulations and the International Traffic in Arms Regulations), technology transfer restrictions, anti-boycott provisions, economic sanctions and the FCPA. The development of many of our various emerging technologies, the development of many of which has been funded by the Department of Defense, is subject to many regulatory challenges. Failure by us or our sales representatives or consultants to comply with these laws and regulations could result in administrative, civil, or criminal liabilities and could result in suspension of our export privileges, which could have a material adverse effect on our business. Changes in regulation or political environment may affect our ability to conduct business in foreign markets including investment, procurement and repatriation of earnings.

Environmental regulations could increase operating costs and additional capital expenditures and delay or interrupt operations. The electronics industry, as well as the semiconductor industry, are subject to governmental regulations for the protection of the environment, including those relating to air and water quality, solid and hazardous waste handling, and the promotion of occupational safety. Various federal, state and local laws and regulations require that we maintain certain environmental permits. We believe that we have obtained all necessary environmental permits required to conduct our manufacturing processes, if we were found to be in violation of these laws, we could be subject to governmental fines and liability for damages resulting from such violations.

The aforementioned laws and regulations or the enactment of new laws, regulations or policies could require increases in operating costs and additional capital expenditures and could possibly entail delays or interruptions of our operations. If our manufacturing facilities do not meet Federal, state or foreign country manufacturing standards, we may be required to temporarily cease all or part of our manufacturing operations, which would result in product delivery delays and negatively impact revenues.

Our manufacturing facilities are subject to periodic inspection by regulatory authorities and our operations will continue to be regulated by the FDA for compliance with Good Manufacturing Practice requirements contained in the quality systems standards. We are also required to comply with International Organization for Standardization ("ISO"), quality system standards in order to produce certain of our products for sale in Europe. If we fail to continue to comply with Good

Table of Contents

ing Practice requirements or ISO standards, we may be required to cease all or part of our operations until we comply with such regulations. Obtaining and maintaining such compliance is difficult and costly. We cannot be certain that our facilities will be required to comply with Good Manufacturing Practice requirements or ISO standards in future inspections and audits by regulatory authorities. In addition, if we cannot maintain or establish manufacturing facilities or operations that comply with such requirements or do not meet the expectations of our customers, we may not be able to realize certain economic opportunities in our current or future supply arrangements.

Subject to additional significant foreign and domestic government regulations, including environmental and health and safety regulations, and failure to comply with these regulations could harm our business. Our operations and current and proposed activities involve the use of a broad range of materials that are considered hazardous under applicable laws and regulations. Accordingly, we are subject to a number of foreign, federal, state and local laws and regulations relating to health and safety, protection of the environment and the storage, use, disposal of, and exposure to, hazardous materials and wastes. We could incur costs, fines and civil and criminal penalties, personal injury and third party property damage claims, or could be required to incur substantial investigation or remediation costs, if we were to violate or become liable under environmental, health and safety laws. Moreover, a failure to comply with environmental laws could result in the revocation of environmental permits, which could prevent us from conducting our business. Liability under environmental laws can be joint and several and without regard to fault. There can be no assurance that violations of environmental and health and safety laws will not occur in the future as a result of the inability to obtain permits, human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could harm our business. Accordingly, violations of future environmental laws could restrict our ability to expand facilities, pursue certain technologies, and could require us to acquire costly equipment or incur potentially significant costs to comply with environmental regulations. Non-compliance with foreign, federal, state and local environmental laws and regulations represents a small part of our present operations. Failure to comply with any such laws or regulations, however, a government entity may levy a fine on us or require us to take costly measures to ensure compliance. Any such fine or expenditure may adversely affect our development. We cannot predict the extent to which future legislation and regulation could cause us to incur additional operating expenses, capital expenditures or restrictions and delays in the development of our products and properties.

#### Risks Relating to our Intellectual Property

Our proprietary rights may not adequately protect our technologies. Our commercial success will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection of our technologies in the United States and other jurisdictions as well as successfully enforcing this intellectual property and defending it against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable intellectual property protections, such as patents or trade secrets, cover our technologies. In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes. The degree of future protection of our proprietary rights is uncertain because legal means of intellectual property protection provide limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. The degree of future protection of our proprietary rights is also uncertain for products that are currently in the early stages of development because we cannot predict which of these products will ultimately reach the commercial market or whether the commercial versions of these products will incorporate proprietary technologies. Our intellectual property protection position is highly uncertain and involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example:

• our licensors might not have been the first to make the inventions covered by each of our pending patent applications and

;

• we or our licensors might not have been the first to file patent applications for these inventions;

• others may independently develop similar or alternative technologies or duplicate any of our technologies;

• that none of our pending patent applications or the pending patent applications of our licensors will result in issued

• patents may issue to third parties that cover how we might practice our technology;



ents and issued patents of our licensors may not provide a basis for commercially viable technologies, may not  
th any competitive advantages, or may be challenged and invalidated by third parties; and  
•we may not develop additional proprietary technologies that are patentable.

Table of Contents

ny not be issued for any pending or future pending patent applications owned by or licensed to us, and claims allowed ny issued patent or future issued patent owned or licensed by us may not be valid or sufficiently broad to protect our s. Moreover, protection of certain of our intellectual property may be unavailable or limited in the United States or in untries, and we have not sought to obtain foreign patent protection for certain of our products or technologies due to rns about enforceability or other reasons. Any issued patents owned by or licensed to us now or in the future may be , invalidated, or circumvented, and the rights under such patents may not provide us with competitive advantages. In petitors may design around our technology or develop competing technologies. Intellectual property rights may also ilable or limited in some foreign countries, and in the case of certain products no foreign patents were filed or can be ould make it easier for competitors to capture or increase their market share with respect to related technologies. We ur substantial costs to bring suits in which we may assert our patent rights against others or defend ourselves in suits inist us. An unfavorable outcome of any litigation could have a material adverse effect on our business and results of operations.

so rely on trade secrets to protect our technology, especially where we believe patent protection is not appropriate or inable. However, trade secrets are difficult to protect. We regularly attempt to obtain confidentiality agreements and provisions with our collaborators, employees and consultants to protect our trade secrets and proprietary know-how. agreements may be breached or may not have adequate remedies for such breach. While we use reasonable efforts to ct our trade secrets, our employees, consultants, contractors or scientific and other advisors, or those of our strategic y unintentionally or willfully disclose our information to competitors. If we were to enforce a claim that a third party y obtained and was using our trade secrets, our enforcement efforts would be expensive and time consuming, and the ould be unpredictable. In addition, courts outside the United States are sometimes unwilling to protect trade secrets. f our competitors independently develop equivalent knowledge, methods and know-how, it will be more difficult for us to enforce our rights and our business could be harmed.

ot able to defend the patent or trade secret protection position of our technologies, then we will not be able to exclude from developing or marketing competing technologies and we may not generate enough revenues from product sales to justify the cost of developing our technologies and to achieve or maintain profitability.

also rely on trademarks to establish a market identity for our company and our products. To maintain the value of our , we might have to file lawsuits against third parties to prevent them from using trademarks confusingly similar to or utive of our registered or unregistered trademarks. Also, we might not obtain registrations for our pending trademark s, and we might have to defend our registered trademark and pending trademark applications from challenge by third ies. Enforcing or defending our registered and unregistered trademarks might result in significant litigation costs and damages, including the inability to continue using certain trademarks.

may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.

arious U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in our areas. Such third parties may claim that we infringe their patents. Because patent applications can take several years patent issuance, there may be currently pending applications, unknown to us, which may later result in issued patents nnologies may infringe. For example, we are aware of competitors with patents in technology areas applicable to our equipment products. Such competitors may allege that we infringe these patents. There could also be existing patents a we are not aware that our technologies may inadvertently infringe. We have from time to time been, and may in the ure be, contacted by third parties, including patent assertion entities or intellectual property advisors, about licensing s that also contain claims that we are infringing on third party patent rights. If third parties assert these claims against incur extremely substantial costs and diversion of management resources in defending these claims, and the defense claims could have a material adverse effect on our business, financial condition and results of operations. Even if we have not infringed on a third party's patent rights, we may have to settle a claim on unfavorable terms because we afford to litigate the claim. In addition, if third parties assert claims against us and we are unsuccessful in defending claims, these third parties may be awarded substantial damages as well as injunctive or other equitable relief against ould effectively block our ability to make, use, sell, distribute or market our products and services in the United States or abroad.

cial application of nanotechnologies in particular, or technologies involving nanomaterials, is new and the scope and patent protection is uncertain. Consequently, the patent positions of companies involved in nanotechnologies have not been tested, and there are complex legal and factual questions for which important legal principles will be developed or may be resolved. In addition, it is not clear whether such patents will be subject to interpretations or legal doctrines that differ from traditional patent law principles. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our nanotechnology-related intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our nanotechnology-related patents or in third party

Table of Contents

the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our efforts to obtain the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

A portion of our technology is subject to retained rights of our licensors, and we may not be able to prevent the loss of those rights or the grant of similar rights to third parties.

A substantial portion of our technology is licensed from academic institutions, corporations and government agencies. Under licensing arrangements, a licensor may obtain rights over the technology, including the right to require us to grant a license to one or more third parties selected by the licensor or that we provide licensed technology or material to third parties for commercial research. The grant of a license for any of our core technologies to a third party could have a material and adverse effect on our business. In addition, some of our licensors retain certain rights under the licenses, including the right to sublicense to a substantial portion of our core technology to third parties for non-commercial academic and research purposes. It is difficult to monitor and enforce such non-commercial academic and research uses, and we cannot predict whether the third party licensees would comply with the use restrictions of such licenses. We have incurred and could incur substantial costs to enforce our rights against them. We also may not fully control the ability to assert or defend those patents or other intellectual property which we have licensed from other entities, or which we have licensed to other entities.

Under some of our licenses with academic institutions we have the right to use certain technology previously developed by these institutions. In certain cases we also have the right to practice improvements on the licensed technology to the extent not encompassed by the licensed patents and are within our field of use. Our licensors may currently own and may in the future obtain additional patents and patent applications that are necessary for the development, manufacture and commercial sale of anticipated products. We may be unable to agree with one or more academic institutions from which we have obtained licenses whether certain intellectual property developed by researchers at these academic institutions is covered by our existing licenses. In the event that the new intellectual property is not covered by our existing licenses, we would be required to negotiate a license agreement. We may not be able to reach agreement with current or future licensors on commercially reasonable terms, if at all, or the terms may not permit us to sell our products at a profit after payment of royalties, which could harm our business.

Some of our patents may cover inventions that were conceived or first reduced to practice under, or in connection with, U.S. government contracts or other federal funding agreements. With respect to inventions conceived or first reduced to practice under a federal funding agreement, the U.S. government may retain a non-exclusive, non-transferable, irrevocable, paid-up license to use or have practiced for or on behalf of the United States the invention throughout the world. We may not succeed in our efforts to retain title in patents, maintain ownership of intellectual property or in limiting the U.S. government's rights in our technologies and intellectual property when an issue exists as to whether such intellectual property was developed in connection with the performance of a federal funding agreement or developed at private expense.

In order to obtain the right to use the intellectual property rights of others which are necessary to operate our business, and to protect their intellectual property, our business and results of operations will be adversely affected. We have licensed certain technologies for use in our products. In the future, we may choose, or be required, to license our intellectual property from third parties in connection with the development of our products. We cannot assure you that third-party licenses will be available on commercially reasonable terms, if at all. Our competitors may be able to obtain licenses to cross-license their technology, on better terms than we can, which could put us at a competitive disadvantage. Also, we may enter into confidentiality agreements with such third parties in which we agree to protect and maintain their proprietary confidential information, including at times requiring our employees to enter into agreements protecting such information. There can be no assurance that the confidentiality agreements will not be breached by any of our employees or that such third parties will not make claims that their proprietary information has been disclosed.

**RISKS RELATING TO OUR COMMON STOCK**

The United States Tax Cuts and Jobs Act of 2017 could adversely affect our business and financial condition. The Tax Cuts and Jobs Act (the "TCJA") significantly reforms the US Internal Revenue Code. The TCJA, among other things, contains significant changes to U.S. federal corporate income taxation, including reduction of the U.S. federal corporate

income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest

Table of Contents

30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to current year taxable income and elimination of net operating loss carrybacks, immediate deductions for certain new instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and general net operating losses arising in taxable year ending after December 31, 2017, will be carried forward indefinitely under the TCJA. We continue to examine the impact this tax reform legislation may have on our business. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA is uncertain and our business and financial results could be adversely affected. The impact of this tax reform on holders of our common stock is also uncertain and could vary. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock.

Substantial sales of our common stock, or the perception that such sales may occur, our stock price could decline. If our stockholders were to sell substantial amounts of our common stock, the market price of our common stock may decline, which might make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we find appropriate. Substantial sales of our common stock, or the perception that such sales may occur, may have a material adverse effect on the prevailing market price of our common stock.

Carilion holds approximately 4.1 million shares of our common stock (including approximately 1.3 million shares issuable upon conversion of shares of Series A Convertible Preferred Stock that Carilion holds). All of these shares have been registered for sale on a Form S-3 registration statement and, accordingly, may generally be freely sold by Carilion at any time. Future sales of these shares, or the perception that future sales of shares may occur by Carilion or any of our other significant stockholders, may have a material adverse effect on the market price of our stock. Any such continuing material adverse effect on the market price of our stock could impair our ability to comply with Nasdaq's continuing listing standards in respect of our minimum stock price, as further described below.

We have been involved in securities class action litigation that could divert management's attention and harm our business and our insurance coverage may not be sufficient to cover all costs and damages.

The market has from time to time experienced significant price and volume fluctuations that have affected the market prices of the common stock of technology companies. These broad market fluctuations may cause the market price of our common stock to fluctuate. In the past, following periods of volatility in the market price of a particular company's securities, securities class action litigation has often been brought against that company. Securities class litigation also often follows certain significant transactions, such as the sale of a business division or a change in control transaction. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management's attention and resources, which could adversely affect our business.

The market price of our common stock has been volatile and we expect that the price of our common stock will fluctuate substantially in the future, which could cause you to lose all or a substantial part of your investment.

The trading price for our common stock is volatile and may fluctuate significantly. Since January 1, 2009, our common stock has traded between a high of \$5.00 per share and a low of \$0.26 per share. Among the factors, many of which we cannot control, that could cause material fluctuations in the market price for our common stock are:

- sales of our common stock by our significant stockholders, or the perception that such sales may occur;
- earnings estimates, investors' perceptions, recommendations by securities analysts or our failure to achieve analysts' estimates;
- changes in our status as an entity eligible to receive SBIR contracts and grants;
- quarterly variations in our or our competitors' results of operations;
- challenges integrating our recent or future acquisitions, including the inability to realize any expected synergies;
- market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;
- announcements by us, or by our competitors, of acquisitions, new products, significant contracts, commercial relationships or other developments;
- pending or threatened litigation;
- a major change in our board of directors or management or any competing proxy solicitations for director nominees;

- changes in governmental regulations or in the status of our regulatory approvals;
  - announcements related to patents issued to us or our competitors;
  - a lack of, limited or negative industry or securities analyst coverage;

Table of Contents

ons of our company or our stock price by the financial and scientific press and online investor communities; and  
general developments in our industry.

the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to  
operating performance of those companies. These factors may materially and adversely affect the market price of our  
common stock.

internal control over financial reporting is found not to be effective or if we make disclosure of existing or potential  
ial weaknesses in those controls, investors could lose confidence in our financial reports, and our stock price may be  
adversely affected.

of the Sarbanes-Oxley Act of 2002 requires us to include an internal control report with our Annual Report on Form  
eport must include management's assessment of the effectiveness of our internal control over financial reporting as of  
the end of the fiscal year.

our existing internal control over financial reporting based on the framework issued by the Committee of Sponsoring  
izations of the Treadway Commission. During the course of our ongoing evaluation of the internal controls, we may  
y areas requiring improvement, and may have to design enhanced processes and controls to address issues identified  
review. Remedying any deficiencies, significant deficiencies or material weaknesses that we identify may require us  
ificant costs and expend significant time and management resources. We cannot assure you that any of the measures  
plement to remedy any such deficiencies will effectively mitigate or remedy such deficiencies. Investors could lose  
a our financial reports, and our stock price may be adversely affected, if our internal controls over financial reporting  
ot to be effective by management or if we make disclosure of existing or potential significant deficiencies or material  
weaknesses in those controls.

estimates relating to our critical accounting policies are based on assumptions or judgments that change or prove to be  
operating results could fall below expectations of financial analysts and investors, resulting in a decline in our stock  
price.

ion of financial statements in conformity with U.S. GAAP requires our management to make estimates, assumptions  
ments that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our  
historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the  
ich form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses  
readily apparent from other sources. Our operating results may be adversely affected if our assumptions change or if  
instances differ from those in our assumptions, which could cause our operating results to fall below the expectations  
nancial analysts and investors, resulting in a decline in our stock price. Significant assumptions and estimates used in  
ng our consolidated financial statements include those related to revenue recognition, stock-based compensation and  
e taxes. Moreover, the new revenue recognition guidance, ASC Topic 606, Revenue from Contracts with Customers,  
requires more judgment than did the prior guidance.

Our financial results may be adversely affected by changes in accounting principles applicable to us.  
are subject to interpretation by the FASB, the SEC, and other bodies formed to promulgate and interpret appropriate  
g principles. For example, in May 2014, the FASB issued ASC Topic 606, Revenue from Contracts with Customers,  
sedes nearly all existing revenue recognition guidance under U.S. GAAP. We adopted this guidance as of January 1,  
ost significant impact relates to changing the revenue recognition for custom optoelectronics to an over time method.  
e adoption of this standard, we deferred the recognition of revenue until products were shipped to the customer. Any  
es in implementing these pronouncements or adequately accounting after adoption could cause us to fail to meet our  
financial reporting obligations, which could result in regulatory discipline and harm investors' confidence in us.

r provisions in our amended and restated certificate of incorporation and bylaws and Delaware law could discourage  
change in control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price  
adversely and prevent attempts by our stockholders to replace or remove our current management.

amended and restated certificate of incorporation and bylaws and Delaware law contain provisions that might delay or  
nt a change in control, discourage bids at a premium over the market price of our common stock and adversely affect





Table of Contents

market price of our common stock and the voting and other rights of the holders of our common stock. These provisions include:

- a classified board of directors serving staggered terms;
- advance notice requirements to stockholders for matters to be brought at stockholder meetings;
- a majority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws; and
- the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential acquirer.

These provisions are also subject to provisions of the Delaware General Corporation law that, in general, prohibit any business combination with any beneficial owner of 15% or more of our common stock for three years unless the holder's acquisition of our stock was approved in advance by our board of directors or certain other conditions are satisfied. The presence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2. PROPERTIES

We have approximately 4,400 square feet of office space in Roanoke, Virginia, which serves as our corporate headquarters and is used for general and administrative functions. This lease expires March 31, 2020. We also lease approximately 42,000 square feet of space in Blacksburg, Virginia, near Virginia Tech, which is used by both our Technology Development segment and our Products and Licensing segment. This lease expires December 31, 2024. We lease approximately 11,000 square feet of space in Ann Arbor, Michigan, for research, development and manufacturing of our THz product platform. This lease expires December 31, 2021. We lease approximately 19,600 square feet of space in Charlottesville, Virginia, near the University of Virginia, for use by certain groups in our Technology Development segment. This lease expires December 31, 2020. We lease approximately 21,000 square feet of space in Atlanta, Georgia, for use by our Products and Licensing segment. This lease expires October 31, 2020. We lease a 24,000 square foot facility in Danville, Virginia for use by certain groups in our Technology Development segment. We lease approximately 28,000 square feet of space in Chino, California, for manufacture and support of our GP products. We believe that our existing facilities are adequate for our current needs and suitable additional or substitute space will be available as needed to accommodate expansion of our operations.

ITEM 3. LEGAL PROCEEDINGS

In December 2018, we received a notice of claim (the "Claim") from Macom Technology Solutions, Inc. ("Macom"), who acquired our HSOR business in August 2017 pursuant to an asset purchase agreement. Under the asset purchase agreement, we indemnify Macom for certain matters, including, among other things, the collection of accounts receivable from certain customers, and placed \$4.0 million of the purchase price into an escrow account for the potential settlement of any valid claims. The Claim received from Macom totaled \$2.1 million under various indemnity provisions. We have disputed our obligation of right to payment for the matters described in the Claim. It is uncertain what amount, if any, will be owed in connection with the Claim. As of December 31, 2018, \$1.5 million of the escrow balance had been received with the remaining \$2.5 million in the escrow account pending resolution of the dispute. Periodically, from time to time, we may become involved in litigation or claims arising out of our operations in the normal course of business. Management currently believes the amount of ultimate liability, if any, with respect to these actions will not materially affect our financial position, results of operations, or liquidity.



Table of Contents

|                                 |  |
|---------------------------------|--|
| ITEM 4. MINE SAFETY DISCLOSURES |  |
| Not applicable.                 |  |

25

---

PART II

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER  
PURCHASES OF EQUITY SECURITIES

STOCKHOLDERS

Our common stock is listed on the Nasdaq Capital Market under the symbol "LUNA." As of March 12, 2019, we had 28,125,598 shares of common stock outstanding held by 100 holders of record. The actual number of stockholders is greater than this number of holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

STOCK PERFORMANCE GRAPH

The graph set forth below compares the cumulative total stockholder return on our common stock for the previous five years, which our common stock was traded on the Nasdaq Capital Market, as compared to the cumulative total return of the Nasdaq Composite Index and the Russell 2000 Index over the same period. This graph assumes the investment of \$100,000 in our common stock at the closing price on January 1, 2014, and an equivalent amount in the Nasdaq Composite Index and the Russell 2000 Index on that date, and assumes the reinvestment of dividends, if any. We have never paid dividends on our common stock and have no present plans to do so.

There is no published industry or line-of-business index for our business reflective of our performance, nor do we believe we can reasonably identify a peer group, we measure our performance against issuers with similar market capitalizations. We selected the Russell 2000 Index because it measures the performance of a broad range of companies with lower market capitalizations than those companies included in the S&P 500 Index.

The performance shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.

Table of Contents

preceding Stock Performance Graph is not deemed filed with the Securities and Exchange Commission and shall not be deemed by reference in any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

**DIVIDEND POLICY**

Inception, we have never declared or paid any cash dividends on our common stock. We currently expect to retain any cash flows for use in the operation and expansion of our business, and therefore do not anticipate paying any cash dividends in the foreseeable future. In addition, our debt facility with Silicon Valley Bank restricts us from paying cash dividends on our common capital stock without the bank's prior written consent.

**Unregistered Sales of Equity Securities**

**Common Stock Dividend Payable to Carilion**

On January 12, 2010, we issued 1,321,514 shares of Series A Preferred Stock, par value \$0.001 per share, to Carilion Clinic in January 2010, which were issued in reliance on the exemptions from registration under the Securities Act provided by Sections 3(a)(9) and 4(b)(1) of the Securities Act of 1933. The Series A Preferred Stock accrues dividends at the rate of \$0.2815 per share per annum, payable quarterly in cash. Dividends are payable in shares of our common stock, with the number of shares being equal to the quotient of the unaccrued aggregate balance of accrued but unpaid dividends on each share of Series A Preferred Stock divided by (ii) the current market price of the Series A Preferred Stock, which is currently \$4.69159 per share. For the period from January 12, 2010, to the original issue date of the Series A Preferred Stock, through December 31, 2018, the Series A Preferred Stock issued to Carilion Clinic has accrued \$1,417,633 in dividends. The accrued dividend as of December 31, 2018 will be paid by the issuance of 710,985 shares of our common stock, which we will issue at Carilion's written request. As the Series A

Table of Contents

and Stock was issued in reliance on the exemption provided by Section 3(a)(9), the shares of common stock payable as dividends will also be exempt from registration in reliance on Section 3(a)(9) of the Securities Act.

Purchases of Equity Securities by the Issuer and Affiliated Parties-

Not applicable.

ITEM 6. SELECTED FINANCIAL DATA

Consolidated statement of operations data for each of the years ended December 31, 2018 and 2017 and the consolidated balance sheet data as of December 31, 2018 and 2017 have been derived from our audited consolidated financial statements elsewhere in this report. The consolidated statement of operations data for the years ended December 31, 2016, 2015 and the consolidated balance sheet data as of December 31, 2016, 2015 and 2014 have been derived from our audited consolidated financial statements that do not appear in this report. The following selected consolidated financial data should be read in conjunction with our consolidated financial statements and the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included at Part II, Item 7 in this Annual Report on Form 10-K. The data in this section is not intended to replace the consolidated financial statements, and the historical results are not necessarily indicative of the results to be expected in any future period.

28

---

Table of Contents

|   | Years ended December 31, |            |            |            |            |
|---|--------------------------|------------|------------|------------|------------|
|   | 2018                     | 2017       | 2016       | 2015       | 2014       |
| Items, except share and per share data                          |                          |            |            |            |            |
| Consolidated Statement of Operations Data:                      |                          |            |            |            |            |
| Operating revenues:   |                          |            |            |            |            |
| Technology development  | \$20,968                 | \$ 18,576  | \$ 16,281  | \$ 13,599  | \$ 12,206  |
| Product and licensing   | 21,950                   | 14,505     | 13,323     | 12,975     | 9,054      |
| Other revenues  | 42,917                   | 33,082     | 29,604     | 26,574     | 21,260     |
| Operating expenses:   |                          |            |            |            |            |
| Technology development  | 15,400                   | 13,988     | 12,473     | 10,379     | 9,376      |
| Product and licensing   | 8,079                    | 5,724      | 5,417      | 5,652      | 4,047      |
| Other operating expenses  | 23,479                   | 19,713     | 17,890     | 16,031     | 13,423     |
| Operating profit  | 19,438                   | 13,369     | 11,714     | 10,543     | 7,837      |
| Operating expense   | 18,560                   | 15,577     | 15,840     | 17,359     | 12,342     |
| Operating income/(loss)   | 878                      | (2,208)    | (4,126)    | (6,816)    | (4,505)    |
| Non-operating expense/income, net                               | (17)                     | 26         | 28         | (53)       | 111        |
| Operating income  | 550                      | —          | —          | —          | —          |
| Operating expense, net  | (124)                    | (217)      | (317)      | (218)      | (96)       |
| Income/(loss) from continuing operations before income taxes    | 1,286                    | (2,399)    | (4,414)    | (7,087)    | (4,490)    |
| Income tax expense/(benefit)                                    | 48                       | (1,149)    | (136)      | (602)      | (1,137)    |
| Income/(loss) from continuing operations                        | 1,238                    | (1,250)    | (4,279)    | (6,484)    | (3,353)    |
| Income/(loss) from discontinued operations, net of income taxes | 9,766                    | 15,866     | 1,909      | 8,801      | 9,347      |
| Income/(loss)   | 11,004                   | 14,616     | (2,369)    | 2,317      | 5,994      |
| Stock dividend  | 257                      | 147        | 105        | 86         | 112        |
| Income/(loss) attributable to common stockholders               | \$10,747                 | \$ 14,469  | \$ (2,475) | \$ 2,231   | \$ 5,882   |
| Income/(loss) per share from continuing operations:             |                          |            |            |            |            |
| Continuing operations   | \$0.04                   | \$(0.05)   | \$(0.16)   | \$(0.28)   | \$(0.23)   |
| Discontinued operations   | \$0.04                   | \$(0.05)   | \$(0.16)   | \$(0.28)   | \$(0.23)   |
| Income/(loss) per share from discontinued operations:           |                          |            |            |            |            |
| Continuing operations   | \$0.35                   | \$ 0.58    | \$ 0.07    | \$ 0.38    | \$ 0.63    |
| Discontinued operations   | \$0.30                   | \$ 0.58    | \$ 0.07    | \$ 0.38    | \$ 0.63    |
| Income/(loss) per share attributable to common stockholders:    |                          |            |            |            |            |
| Continuing operations   | \$0.39                   | \$ 0.52    | \$(0.09)   | \$ 0.10    | \$ 0.40    |
| Discontinued operations   | \$0.33                   | \$ 0.52    | \$(0.09)   | \$ 0.10    | \$ 0.40    |
| Weighted-average shares:  |                          |            |            |            |            |
| Continuing operations   | 27,596,402               | 27,579,988 | 27,547,217 | 23,026,494 | 14,880,697 |
| Discontinued operations   | 32,452,228               | 27,579,988 | 27,547,217 | 23,026,494 | 14,880,697 |

|                                  | As of December 31, |          |          |          |         |
|----------------------------------|--------------------|----------|----------|----------|---------|
| In thousands                     | 2018               | 2017     | 2016     | 2015     | 2014    |
| Consolidated Balance Sheet Data: |                    |          |          |          |         |
| Cash and cash equivalents        | \$42,460           | \$36,982 | \$17,464 | \$14,117 | \$7,779 |
| Working capital                  | 56,089             | 43,975   | 23,417   | 15,413   | 10,106  |
| Total assets                     | 75,599             | 66,223   | 58,132   | 27,584   | 19,704  |
| Total current liabilities        | 12,139             | 14,826   | 15,334   | 8,473    | 7,206   |
| Total debt                       | 619                | 2,436    | 6,125    | 625      | 2,125   |

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS



ing discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and the related notes to those statements included elsewhere in this report. In addition to financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those

Table of Contents

ed in these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” and elsewhere in this report.  
Business Overview

der in advanced optical technology, providing high performance fiber optic test products for the telecommunications and distributed fiber optic sensing products for industries utilizing composite and other advanced materials, such as the automotive, aerospace, energy and infrastructure industries. Our distributed fiber optic sensing products help designers and engineers more efficiently develop new and innovative products by providing valuable information such as highly detailed strain, and temperature measurements of a new design or manufacturing process. In addition, our distributed fiber optic products are used to monitor the structural integrity or operational health of critical assets, including large civil structures and bridges. Our communications test products accelerate the development of advanced fiber optic components and networks enabling fast and highly accurate characterization of components and networks. We also provide applied research services, primarily under research programs funded by the U.S. government, in areas of advanced materials, sensing, and healthcare. Our business model is designed to accelerate the process of bringing new and innovative products to market. We use in-house technical expertise across a range of technologies to perform applied research services for companies and for government-funded projects. We continue to invest in product development and commercialization, which we anticipate will lead to increased product sales growth.

organized into two main operating segments, our Products and Licensing segment and our Technology Development segment. Our Products and Licensing segment develops, manufactures and markets distributed fiber optic sensing products, as well as telecommunications test products. We are continuing to develop and commercialize our fiber optic technology for sensing applications for aerospace, automotive, energy, and infrastructure as well as for test and measurement applications in the telecommunications and data communications industries. Our Products and Licensing segment revenues represented approximately 51% and 44% of our total revenues for the years ended December 31, 2018 and 2017, respectively. Our Technology Development segment performs applied research principally in the areas of sensing & instrumentation, advanced materials, and health sciences. Our Technology Development segment comprised approximately 49% and 56% of our total revenues for the years ended December 31, 2018 and 2017, respectively. Most of the government funding for our Technology Development segment is derived from the Small Business Innovation Research ("SBIR"), program coordinated by the U.S. Small Business Administration. Our Technology Development segment revenues have historically accounted for a large portion of our total revenues, and we expect that they will continue to represent a significant portion of our total revenues for the foreseeable future. Within the Technology Development segment, we have historically had a backlog of contracts for which work has been performed, but for which a specified portion of work has not yet been completed. We define backlog as the dollar amount of obligations payable to us under negotiated contracts upon completion of a specified portion of work that has not yet been completed, exclusive of revenues previously recognized for work already performed under these contracts, if any. Total backlog consists of funded backlog, which is the amount for which money has been directly authorized by the U.S. government and for which a purchase order has been received by a commercial customer, and unfunded backlog, representing firm orders for which no purchase order has yet been appropriated. Indefinite delivery and quantity contracts and unexercised options are not reported in total backlog. The approximate value of our Technology Development segment backlog was \$26.0 million and \$23.5 million at December 31, 2018 and 2017, respectively. The approximate value of our Products and Licensing segment backlog was \$5.8 million and \$6.9 million at December 31, 2018 and 2017, respectively.

Our product sales are mostly derived from the sales of our sensing and test & measurement products that make use of distributed fiber optic sensing, or fiber optics. We continue to invest in product development and commercialization, which we anticipate will lead to increased product sales growth. Although we have been successful in licensing certain technology in the past, we do not expect license revenues to represent a significant portion of future revenues. Over time, however, we do intend to increase such revenues. In the near term, we expect revenues from product sales to continue to be primarily in areas related to our fiber optic test & measurement and sensing platforms. In the long term, we expect that revenues from product sales will represent a larger portion of our total revenues and that as we develop and commercialize new products, these revenues will reflect a broader and more diversified mix of products.

Our net income attributable to common stockholders of approximately \$10.7 million for the year ended December 31, 2018, compared to net income attributable to common stockholders of approximately \$14.5 million for the year ended December 31, 2017.

the effects of our HSOR business and our optoelectronics business, which we sold in 2017 and 2018, respectively, we had a net income from continuing operations of \$1.2 million for the year ended December 31, 2018 and a net loss from continuing operations of \$1.3 million for the year ended December 31, 2017. We expect to incur increasing expenses as we seek to expand our business, including expenses for research and development, sales and marketing and manufacturing capabilities. We may continue to grow our business in part through acquisitions of additional companies and complementary technologies, which could cause us to incur transaction expenses, amortization or

Table of Contents

f intangible assets and goodwill and other acquisition-related expenses. As a result, we may incur net losses in future periods, and these losses could be substantial.

## Acquisition of General Photonics Corporation.

On March 1, 2019, we acquired all of the outstanding stock of General Photonics Corporation ("GP"), a leading provider of photonic components, modules and test equipment focused on the generation, measurement and control of polarized light for fiber optic-based applications for aggregate consideration of \$19.0 million. Of the purchase price, \$17.1 million was paid at closing and \$1.9 million was placed into escrow for possible working capital adjustments to the purchase price and satisfaction of certain post-closing indemnification obligations. Additionally, we can become obligated to pay additional consideration of up to \$1.0 million if certain revenue targets for the GP historical business are met for the twelve months following the closing.

## Acquisition of Micron Optics, Inc.

On October 15, 2018, we acquired the assets of the United States operations of Micron Optics, Inc. ("MOI"), a leading provider of innovative optical components and laser-based equipment that advance the quality of optical measurements, allowing the medical imaging, and telecommunications industries to make critical measurements for total cash consideration of \$5 million, including \$4.0 million paid at closing and \$1.0 million placed in escrow until the later of October 1, 2019, or the date that matters are resolved as agreed by us and MOI. The purchase price was subject to adjustment after closing based upon an analysis of final working capital compared to a target amount specified in the purchase agreement. In 2019, we expect to pay an additional \$0.5 million to MOI in connection with the working capital adjustment. With the acquisition of MOI, we expanded our product portfolio to include optical sensors and sensing interrogators capable of a broader range of measurement capabilities, including higher speed measurements such as vibration, and the ability to instrument larger structures over longer distances. In addition, the MOI acquisition adds a product suite of tunable optical filters, optical sensors, and swept lasers.

## Sale of Luna Optoelectronics Business

On December 18, 2018, we sold substantially all of the assets associated with our custom optoelectronic components and sub-assemblies business for total cash consideration of \$17.5 million, paid at closing, in addition to contingent consideration of up to \$1.0 million. The contingent consideration is subject to the optoelectronic business achieving specified revenue targets for the 18 months following the closing date. In addition, the purchase price was subject to adjustment based upon an analysis of final working capital as of the acquisition date compared to a target amount specified in the purchase agreement. Following closing, we received \$15.0 million and additional \$0.7 million in connection with the working capital adjustment. We have been engaged since 2015 in the optoelectronic business as part of our acquisition of Advanced Photonix, Inc.

## Sale of High Speed Optical Receiver Business

On December 15, 2017, we completed the sale of our high speed optical receivers ("HSOR") business, which was part of our Products and Licensing segment, to an unaffiliated third party for an initial purchase price of \$33.5 million, of which \$29.5 million in cash was received, and \$4.0 million was placed into escrow until December 15, 2018 for possible working capital adjustments to the purchase price and potential satisfaction of certain post-closing indemnification obligations. As of December 31, 2018, \$1.5 million of the escrow balance had been received. The remaining \$2.5 million remains in the escrow account pending resolution of a dispute over certain indemnity claims by the buyer.

## Description of Our Revenues, Costs and Expenses

## Revenues

Our revenues from technology development, product sales and commercial product development and licensing activities. Our Private Technology Development segment revenues from providing research and development services to third parties, including government entities, academic institutions and corporations, and from achieving milestones established by some of our contracts. In general, we complete contracted research over periods ranging from six months to three years, and recognize revenues over the life of the contract as costs are incurred. Our Technology Development segment revenues represented approximately 49% and 56% of our total revenues for the years ended December 31, 2018 and 2017, respectively. Our Products and Licensing segment revenues reflect amounts that we receive from sales of our products or development of products for third parties and, to a lesser extent, fees paid to us in connection with licenses or sub-licenses of certain patents







Table of Contents

contract assets on the balance sheet. Amounts billed and due from our customers are classified as receivables on the balance sheet. For non-U.S. government contracts, we typically receive interim payments as work progresses, although for some contracts we may be entitled to receive an advance payment. We recognize a liability for these advance payments and PBPs paid to our customers which are in excess of the revenue recognized and present these amounts as contract liabilities on the balance sheet.

To determine the proper revenue recognition method for research and development contracts, we evaluate whether two or more contracts should be combined and accounted for as one single modified contract and whether the combined or single contract should be accounted for as more than one performance obligation. For instances where a contract has options that were bid with the original contract and awarded at a later date, we combine the options with the original contract when options are awarded. For our research contracts, the customer contracts for research with multiple milestones that are interdependent. Consequently, the contract is accounted for as one performance obligation. The effect of the combined or modified contract on the transaction is measured as a measure of progress for the performance obligation to which it relates, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.

Revenue recognition is measured over time as we perform because of continuous transfer of control to the customer. For government contracts which are typically subject to the Federal Acquisition Regulation, this continuous transfer of control to the customer is supported by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, at a price of cost incurred plus a reasonable profit and take control of any work in process. From time to time, as part of normal business processes, facts may change, causing revisions to estimated total costs or revenues expected. The cumulative impact of revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

For contracts where control is transferring over time, revenue is recognized over time based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the services to be provided. We generally use the input method, more specifically the cost-to-cost measure of progress for our contracts because it best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The underlying bases for our contract research revenues are measurable expenses, such as labor, subcontractor costs and materials, and data that are collected on a regular basis for purposes of preparing our cost estimates. Our research contracts generally have a period of performance of six months to three years, and our estimates of contract costs have historically been consistent with actual results. Changes in these estimates between accounting periods to reflect changing facts and circumstances have not had a material impact on our operating results, and we do not expect future changes in these estimates to be material. The cumulative impact of revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

For cost reimbursable contracts, we are reimbursed for costs that are determined to be reasonable, allowable and allocable to the contract and paid a fixed fee representing the profit negotiated between us and the contracting agency. Revenue from cost reimbursable contracts is recognized as costs are incurred plus an estimate of applicable fees earned. We consider fixed fees on cost reimbursable contracts to be earned in proportion to the allowable costs incurred in performance of the contract.

For time and materials contracts revenue is recognized based on direct labor hours expended at contract billing rates plus other billable direct costs.

Fixed price contracts may include either a product delivery or specific service performance throughout a period. For fixed price contracts that are based on the proportional performance method and involve a specified number of deliverables, we recognize revenue based on the proportion of the cost of the deliverables compared to the cost of all deliverables included in the contract as the method more accurately measures performance under these arrangements. For fixed price contracts that provide for the development and delivery of a specific prototype or product, revenue is recognized based upon the percentage of completion



method.

certain costs under government contracts are allowable is subject to audit by the government. Certain indirect costs are contracts using provisional or estimated indirect rates, which are subject to later revision based on government audits of these costs. Management is of the opinion that costs subsequently disallowed, if any, would not likely have a significant effect on revenues recognized for those contracts. We have agreed on final billing rates with the government through December 31, 2017.

33

---

## Products and Licensing Revenues

To determine the proper revenue recognition method for Products and Licensing contracts, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. We recognize revenue when the performance obligation has been satisfied by transferring the control of the product or service to the customer. For tangible products that contain software that is integral to the tangible product's functionality, we consider the product and software to be a single performance obligation and recognize revenue accordingly. For contracts with multiple performance obligations, we allocate the contract's transaction price to each performance obligation based on their relative stand-alone selling prices. In such circumstances, we use the observable price for the product or services which are sold separately in similar circumstances to similar customers. If these prices are not observable, we estimate the stand-alone selling price using information that is reasonably available. For the majority of our standard products and services, price list and discount structures related to customer type are available. For products and services that do not have a price list and discount structures, we may use one or more of the following: (i) adjusted market assessment approach, (ii) expected cost plus a margin approach, and (iii) residual approach. The adjusted market approach requires us to evaluate the market in which we sell goods or services and estimate the price that a customer in that market would be willing to pay for those goods or services. The expected cost plus margin approach requires us to forecast our expected costs of satisfying the performance obligation and then add a reasonable margin for that good or service. The residual approach decreases the total transaction price by the sum of the observable standalone selling prices if either the company sells the same good or services to other customers for a broad range of amounts or the company has not established a price for the good or service and that good or service has not been sold on a standalone basis. Shipping and handling activities primarily occur after a customer obtains control and are considered fulfillment cost rather than separate performance obligations. Similarly, sales and similar taxes imposed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer are excluded from the measurement of the transaction price.

For standard products, we recognize revenue at a point in time when control passes to the customer. Absent substantial product customization clauses, this is based on the shipping terms. For custom products that require engineering and development based on customer requirements, we will recognize revenue over time using the output method for any items shipped and any finished work in process that is produced for balances of open sales orders. For any finished goods or work in process that has been produced for the balance of open sales orders we recognize revenue by applying the average selling price for such open orders or the lesser of the on hand balance in finished goods or open sales order quantity which we present as a contract asset on the balance sheet. Cost of sales is recognized based on the standard cost of the finished goods and work in process associated with the sales and inventory balances are reduced accordingly. For extended warranties and product rentals, revenue is recognized over time using the output method based on the time elapsed for the warranty or service period. In the case of warranties, we recognize revenue on a contract liability for amounts billed but that are not recognized until subsequent period. A separate contract liability is recognized for the cost associated with warranty repairs based on our estimate of future expense. For testing services where we are performing testing on an asset the customer controls, revenue is recognized over time by the output method using the performance to date. For training where the customer is receiving the benefit of training as it is occurring and for repairs to a customer controlled asset, revenue is recognized over time by the output method using the performance to date. For royalty contracts we apply the practical expedient "royalty exception" recognizing revenue based on the royalty agreement which specifies either a percentage of sales or an amount based on sales or minimum amount, whichever is greater.

For product rental contracts, a customer may be offered a discount on the purchase of an item that would provide for a material right. When a material right has been provided to a customer, a separate performance obligation is established and a contract liability for the rental revenue will be deferred until the future product is purchased or the option expires. This deferred revenue is recorded as a contract liability on the balance sheet. In certain circumstances we may offer a "right of return" to a distributor of our products, in which case a contract liability is calculated based on the terms of the agreement and recorded as a reduction to the contract asset. In addition, a contract asset for the rights to recover products from customers and a reduction of cost of sales is also calculated and recorded.

Income Taxes

our tax liability through calculating our current tax liability, together with assessing temporary differences resulting in the different treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which we record on our balance sheet. Management then assesses the likelihood that deferred tax assets will be realized in future periods. In assessing the need for a valuation allowance against the net deferred tax asset, management

Table of Contents

Factors such as future reversals of existing taxable temporary differences, taxable income in prior carry back years, whether carry back is permitted under the tax law, tax planning strategies and estimated future taxable income exclusive of temporary differences and carry forwards. To the extent that we cannot conclude that it is more likely than not that the benefit of such assets will be realized, we establish a valuation allowance to reduce their net carrying value. Assess our projections of future taxable income or other factors that may impact our ability to generate taxable income in future periods, our estimate of the required valuation allowance may change, which could have a material impact on future earnings or losses.

We recognize tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities. While it is often difficult to predict the final outcome of timing of the resolution of any tax matter, we establish a liability at the time we determine it is probable we will be required to pay additional taxes on certain matters. These liabilities are recorded in accrued liabilities in our consolidated balance sheets. We adjust this liability, including any impact on the related interest and penalties, in light of changing facts and circumstances, such as the results of a tax audit. A number of years may elapse before a particular matter for which we have established a liability is finally resolved. The number of years with open tax audits varies depending on the tax jurisdiction. Settlement of any particular issue would usually require the use of cash. We recognize favorable resolutions of tax matters for which we have previously established liabilities as a reduction to our income tax expense when the amounts involved become known. Differences between federal and state tax law, and accounting principles generally accepted in the United States of America ("GAAP") certain items are included in the tax return at different times than when those items are reflected in the consolidated financial statements. Therefore, the annual tax rate reflected in our consolidated financial statements is different than the rate in our tax return. Some of these differences are permanent, such as expenses that are not deductible in our tax return. Others, such as depreciation expense, reverse over time and create deferred tax assets and liabilities. The tax rates used to calculate deferred tax assets or liabilities are the enacted tax rates in effect for the year in which the differences are expected to be realized. Based on the evaluation of all available information, we recognize future tax benefits, such as net operating loss carry forwards, to the extent that realizing these benefits is considered more likely than not. On September 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from the current rate of 35% to 21%. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities at the enacted rate. This revaluation resulted in a \$1.9 million reduction in the deferred tax asset and a corresponding reduction in the valuation allowance in 2017. In 2018, we realized a benefit of \$0.6 million in recovery of the alternative minimum tax credit from prior periods. The other provisions of the Tax Cuts and Jobs Act did not have a material impact on our consolidated financial statements.

**Stock-Based Compensation**

We recognize stock-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. The calculation of the fair value of our awards requires certain inputs that are subjective and changes to the estimates used to determine the fair values of our stock awards and related stock-based compensation expense to vary. We have elected to use the Black-Scholes-Merton ("Black-Scholes") option pricing model to determine the fair value of stock options. The fair value of a stock option award is affected by our stock price on the date of the grant as well as other assumptions used as inputs in the Black-Scholes model including the estimated volatility of our stock price over the term of the awards, the estimate period of time that employees are expected to hold their stock options and the risk-free interest rate assumption. In addition, we are required to reduce stock-based compensation expense for the effects of estimated forfeitures of awards over the expense recognition period.

Although we estimate the rate of future forfeitures based on historical experience, actual forfeitures may differ.

**Long-lived and Intangible Assets**

Property, plant and equipment, and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the undiscounted net cash flows, the asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less cost to sell.



Table of Contents

viewed for impairment at least annually, or more frequently if events or circumstances indicate that goodwill might be impaired. We have established October 1 as our specified annual date for impairment testing.

Business Combinations  
account for business combinations under the acquisition method of accounting. Under this method, the total estimated consideration is allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Any excess of the fair value of acquisition consideration over the fair value of identifiable intangible assets acquired and liabilities assumed is recorded as goodwill.

Results of Operations  
The following table shows information derived from our consolidated statements of operations expressed as a percentage of total revenues for the periods presented.

|   | Years ended  |        |
|---|--------------|--------|
|   | December 31, |        |
|   | 2018         | 2017   |
| Revenues:   |              |        |
| Technology development  | 48.9 %       | 56.2 % |
| Products and licensing  | 51.1         | 43.8   |
| Total revenues  | 100.0        | 100.0  |
| Cost of revenues:   |              |        |
| Technology development  | 35.9         | 42.3   |
| Products and licensing  | 18.8         | 17.3   |
| Total cost of revenues  | 54.7         | 59.6   |
| Gross profit  | 45.3         | 40.4   |
| Operating expense   | 43.2         | 47.1   |
| Operating income/(loss)                                       | 2.1          | (6.7 ) |
| Total other income/(expense)                                  | 1.0          | (0.6 ) |
| Income/(loss) from continuing operations before income taxes  | 3.1          | (7.3 ) |
| Income/(loss) from continuing operations, net of income taxes | 2.9          | (3.8 ) |
| Income from discontinued operations, net of income taxes      | 22.8         | 48.0   |
| Net income  | 25.7 %       | 44.2 % |

Year Ended December 31, 2018 Compared to Year Ended December 31, 2017

|                                 | Years ended December |              | Revenues      |              |
|---------------------------------|----------------------|--------------|---------------|--------------|
|                                 | 31,                  |              |               |              |
|                                 | 2018                 | 2017         | \$ Difference | % Difference |
| Technology development revenues | \$20,967,556         | \$18,576,383 | \$2,391,173   | 12.9 %       |
| Products and licensing revenues | 21,949,689           | 14,505,482   | 7,444,207     | 51.3 %       |
| Total revenues                  | \$42,917,245         | \$33,081,865 | \$9,835,380   | 29.7 %       |

Technology Development segment revenues increased \$2.4 million to \$21.0 million for the year ended December 31, 2018 compared to \$18.6 million for the year ended December 31, 2017. This increase was attributable primarily to growth in our intelligent systems and biomedical technologies groups. Revenues within these groups increased due to additional contract awards, including higher value Phase II SBIR contracts.

Products and Licensing segment revenues increased \$7.4 million to \$21.9 million for the year ended December 31, 2018 compared to \$14.5 million for the year ended December 31, 2017. This increase was primarily driven by an increase in our sales of backscatter reflectometer instruments and ODISI instruments. In addition, revenues associated with the operations of the business we acquired on October 15, 2018, were \$2.6 million for the period from the completion of the acquisition through December 31, 2018.



Table of Contents

|                              | Years ended December 31, |               |               |              |   |
|------------------------------|--------------------------|---------------|---------------|--------------|---|
|                              | 2018                     | 2017          | \$ Difference | % Difference |   |
| Technology development costs | \$ 15,400,475            | \$ 13,988,378 | \$ 1,412,097  | 10.1         | % |
| Products and licensing costs | 8,078,870                | 5,724,457     | 2,354,413     | 41.1         | % |
| Total costs of revenues      | \$ 23,479,345            | \$ 19,712,835 | \$ 3,766,510  | 19.1         | % |

Technology Development segment costs increased \$1.4 million, to \$15.4 million for the year ended December 31, 2018 compared to \$14.0 million for the year ended December 31, 2017. The overall increase in Technology Development segment costs was driven by increases in direct labor and subcontractor costs consistent with the rate of growth in Technology Development segment revenues.

Products and Licensing segment costs increased \$2.4 million to \$8.1 million for the year ended December 31, 2018 compared to \$5.7 million for the year ended December 31, 2017. The increase in product and licensing cost is attributable to the costs associated with increased volume of optical backscatter reflectometer and ODiSI instrument sales. In addition, revenues associated with the operations of MOI were \$0.7 million for the period from the completion of the acquisition through December 31, 2018. Products and Licensing segment costs increased in accordance with the increase in Products and Licensing segment revenues over the same period taking into account the gross margin effect of the product mix.

## Operating Expense

|   | Years ended December 31, |               |               |              |   |
|---|--------------------------|---------------|---------------|--------------|---|
|   | 2018                     | 2017          | \$ Difference | % Difference |   |
| Selling, general and administrative expense   | \$ 14,794,205            | \$ 12,923,841 | \$ 1,870,364  | 14.5         | % |
| Research, development and engineering expense | 3,766,160                | 2,653,337     | 1,112,823     | 41.9         | % |
| Total operating expense                       | \$ 18,560,365            | \$ 15,577,178 | \$ 2,983,187  | 19.2         | % |

Selling, general and administrative expenses increased \$1.9 million to \$14.8 million for the year ended December 31, 2018 compared to \$12.9 million for the year ended December 31, 2017. The increase in selling, general and administrative expenses included \$0.8 million in transaction-related expenses associated with the acquisition of MOI and \$0.5 million in expenses associated with the operations of MOI for the period from the completion of the acquisition through December 31, 2018. Research, development and engineering expenses increased \$1.1 million to \$3.8 million for the year ended December 31, 2018 compared to \$2.7 million for the year ended December 31, 2017. During 2018, we increased our headcount and other expenses in connection with our Lightwave division in order to accelerate our product development roadmap to continue our growth in the areas of fiber optic-based sensing and communications testing. In addition, the operations of research, development and engineering expense associated with the operations of MOI for the period from the completion of the acquisition through December 31, 2018 were \$0.3 million.

## Interest Expense, Net

Interest expense was \$0.1 million for the year ended December 31, 2018 compared to \$0.2 million for the year ended December 31, 2017. The average monthly loan balance for the year ended December 31, 2018 was \$1.5 million as compared to \$3.3 million for the year ended December 31, 2017, resulting in this decrease in interest expense.

## Investment Income

Investment income was \$0.5 million for the year ended December 31, 2018. During the year ended December 31, 2018, we held a portion of our cash in funds holding U.S. treasury securities. We did not have any investment income for the year ended December 31, 2017.

## Income Tax Expense/(Benefit) from Continuing Operations

For the year ended December 31, 2018, we recorded income tax expense of \$47,818, or 3.7% of our income from continuing operations compared to an income tax benefit of \$1.1 million, or 47.9% of our loss from continuing operations for the year ended December 31, 2017. The change resulted from the recognition of income from continuing operations in 2018 compared to a loss from continuing operations in 2017. The income tax benefit recognized in 2017 was also driven by the





in associated with the discontinued operations of our former HSOR and optoelectronic components business and the related intraperiod tax allocation requirements.

#### Net Income/(Loss) From Continuing Operations

For the year ended December 31, 2018, we recognized income from continuing operations before income taxes of \$1.3 million compared to a loss from continuing operations before income taxes of \$2.4 million for the year ended December 31, 2017. After income taxes, net income from continuing operations was \$1.2 million for the year ended December 31, 2018, compared to a net loss from continuing operations of \$1.3 million for the year ended December 31, 2017.

**Income from Discontinued Operations, Net of Income Taxes**  
For the year ended December 31, 2018, we recognized income from discontinued operations, net of income taxes, of \$9.8 million. For the year ended December 31, 2017, we recognized income from discontinued operations, net of income taxes, of \$15.9 million. Net income from discontinued operations for the year ended December 31, 2018, included an after tax gain recognized on the sale of our optoelectronics business during 2018 of \$8.6 million in addition to \$1.2 million of after-tax income associated with the operations of the optoelectronics business prior to its sale. For the year ended December 31, 2017, our net income from discontinued operations included a \$15.7 million after tax gain recognized on the sale of the HSOR business in addition to a net loss of \$0.2 million related to the operations of both the HSOR and optoelectronics businesses that were disposed of during 2017 and 2018, respectively.

#### Preferred Stock Dividend

In January 2010, we issued 1,321,514 shares of our newly designated Series A Convertible Preferred Stock to Carilion. The Series A Convertible Preferred Stock carries an annual cumulative dividend of 6%, or approximately 79,292 shares of common stock per year. During each of 2018 and 2017, we accrued \$0.3 million and \$0.1 million, respectively, for the dividends payable to Carilion. The dividends are not payable in cash, but rather in shares of our common stock, until liquidation event occurs. As of December 31, 2018 and 2017, 79,292 shares of common stock became issuable to Carilion as dividends and have been recorded in the statement of changes in stockholders' equity.

#### Liquidity and Capital Resources

As of December 31, 2018, our total cash and cash equivalents were \$42.5 million. As described elsewhere in this report, subsequent to year end, we used \$19.0 million of cash to purchase GP.

We have a term loan with SVB which, at December 31, 2018, had a balance of \$0.6 million and matures on May 1, 2019. We may prepay amounts due under the term loan at any time, subject to prepayment penalties of up to 2% of the amount of prepayment. Amounts due under the term loan are secured by substantially all of our assets, including intellectual property, personal property and bank accounts.

The term loan contains customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, a material adverse change, an event of default under any subordinated debt documents, incorrectness of representations or omissions in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may declare due immediately all borrowings under the credit facility and foreclose on the collateral. Furthermore, an event of default under the credit facility would result in an increase in the interest rate on any amounts outstanding. The credit facility requires us to comply with certain operational and financial covenants, including maintaining a minimum cash balance of at least \$4.0 million. As of December 31, 2018, we were in compliance with all covenants under the credit facility.

We maintain a letter-of-credit in the amount of \$1.0 million as a condition of our lease on our Blacksburg office. We believe that our cash and cash equivalents as of December 31, 2018 will provide adequate liquidity for us to meet our capital needs over the next twelve months. Additionally, we believe that should we have the need for increased capital support our planned growth, we will be able to fund such growth through either third-party financing on competitive market terms or through our available cash and cash equivalents.

Table of Contents

Discussion of Cash Flows  
Years ended December 31,  
2018                      2017

|   |               |              |
|---|---------------|--------------|
| Net cash (used in)/provided by operating activities | \$(3,308,825) | \$915,042    |
| Net cash provided by investing activities           | 10,037,123    | 26,181,400   |
| Net cash used in financing activities               | (1,249,564 )  | (2,917,367 ) |
| Net increase in cash and cash equivalents           | \$5,478,734   | \$24,179,075 |

2018, operations used \$3.3 million of net cash, as compared to 2017, when operations provided \$0.9 million of net cash. Our net income of \$11.0 million included a gain on the sale of our optoelectronics business, net of income tax, of \$8.6 million and non-cash expenses which did not impact cash flow for the period. These non-cash expenses were depreciation and amortization of \$1.2 million, and stock-based compensation of \$0.6 million. Additionally, changes in working capital resulted in a net cash outflow of \$7.6 million, principally driven by an increase in accounts receivable of \$6.2 million, an increase in inventory of \$1.0 million, an increase in contract assets of \$0.8 million and decreases in accounts payable and accrued expenses of \$0.5 million and contract liabilities of \$1.0 million, partially offset by a decrease in prepaid expenses of \$1.8 million. For 2017, our net income of \$14.6 million included after-tax income from discontinued operations of \$15.7 million as well as non-cash expenses for depreciation and amortization of \$2.5 million and stock-based compensation of \$0.7 million, each of which were items that do not impact cash flow for the period. Additionally, changes in working capital resulted in a net cash outflow of \$1.4 million, principally driven by an increase in inventory of \$1.9 million and an increase in accounts payable and accrued liabilities of \$0.9 million partially offset by a decrease in accounts receivable of \$1.2 million. Net cash provided by investing activities in 2018 consisted primarily of the proceeds from the sale of our optoelectronics business of \$11.0 million, partially offset by payment of \$5.0 million related to our acquisition of MOI along with \$0.4 million of fixed asset additions and \$0.4 million of capitalized intellectual property costs. Net cash provided by investing activities in 2017 consisted primarily of the proceeds from the sale of our HSOR business of \$28.0 million, partially offset by a cash outflow of \$2.0 million related to the purchase of property and equipment to expand our manufacturing capability as well as capitalized costs associated with securing intellectual property rights.

Net cash used in financing activities for the year ended December 31, 2018 was \$1.2 million, compared to cash used in financing activities of \$2.9 million in 2017. During 2018, we repaid \$1.8 million on our term loans with SVB. We also used \$0.5 million to repurchase our common stock under our stock repurchase program and received \$1.1 million from exercises of stock options and warrants. During 2017, we repaid \$1.8 million on our outstanding term loan with SVB and also used \$1.1 million to repurchase our common stock under our stock repurchase program.

Summary of Contractual Obligations

The following table sets forth information concerning our known contractual obligations as of December 31, 2018 that are fixed and determinable.

|                                    | Total       | Less than 1<br>year | 1 - 3 years | 3 - 5 years | More than<br>5<br>years |
|------------------------------------|-------------|---------------------|-------------|-------------|-------------------------|
| Long-term debt obligations (1)     | \$625,000   | \$625,000           | \$—         | \$—         | \$—                     |
| Operating facility leases (2)      | 4,608,720   | 1,216,124           | 1,758,484   | 1,089,408   | 544,704                 |
| Other leases (3)                   | 147,076     | 53,052              | 72,664      | 21,360      | —                       |
| Purchase order obligation (4)      | 752,448     | 752,448             | —           | —           | —                       |
| MOI working capital adjustment (5) | 542,983     | 542,983             | —           | —           | —                       |
| Other liabilities (6)              | 440,000     | 440,000             | —           | —           | —                       |
| Total                              | \$7,116,227 | \$3,629,607         | \$1,831,148 | \$1,110,768 | \$544,704               |

The amount due under our debt obligations to SVB are payable in monthly installments, plus accrued interest, through May 2019.



we lease our facilities in Blacksburg, Charlottesville and Roanoke, Virginia, Ann Arbor, Michigan, and Atlanta, Georgia under operating leases that as of December 31, 2018, are scheduled to expire between December 2018 and December 2024. Upon expiration of our office leases, we may exercise certain renewal options as specified in the leases. Rental payments associated with these option periods are not included in the table above.

In 2013 and January 2016, we executed leases in the amounts of \$51,000, and \$207,000, respectively, for office equipment. These equipment leases expire in 2018 and 2021, respectively.

Our order obligations included outstanding orders for inventory purchases. In 2017 and 2018, our Luna Technologies executed non-cancelable purchase orders for a total amount of \$2.3 million for multiple shipments of tunable lasers ordered over an 18-month period beginning in November 2017.

The working capital associated with the acquisition of MOI is estimated to be higher than the target value specified in the purchase agreement and therefore such excess amount is payable to the stockholders of MOI.

Our liabilities include remaining amounts payable for minimum royalty payments for certain licensed technologies payable over the remaining patent terms of the underlying technology.

#### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii).

#### Inflation

We do not believe that inflation has had a material effect on our business, financial condition or results of operations.

#### ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices.

We do not hold or issue financial instruments for trading purposes or have any derivative financial instruments. Our exposure to market risk is limited to interest rate fluctuations due to changes in the general level of U.S. interest rates.

#### Interest Rate Risk

We do not use derivative financial instruments as a hedge against interest rate fluctuations, and, as a result, interest income earned on cash equivalents and short-term investments is subject to changes in interest rates. However, we believe that the volatility of these fluctuations does not have a material effect on our financial position due to the immediate available liquidity or short-term nature of these financial instruments.

We are exposed to interest rate fluctuations as a result of our SVB debt facility having a variable interest rate. We do not use derivative instruments to alter the interest rate characteristics of our debt. The principal amount of \$0.6 million under the term loan as of December 31, 2018, is scheduled to amortize in monthly installments through May 2019. A 1% increase in the applicable interest rate during 2018 would have had an insignificant impact in our annual interest expense.

#### Foreign Currency Exchange Rate Risk

As of December 31, 2018, all payments made under our research contracts have been denominated in U.S. dollars. Our product sales to customers are also generally denominated in U.S. dollars, and we do not receive payments in foreign currency. As a result, we are not directly exposed to significant currency gains or losses resulting from fluctuations in foreign exchange rates.

Table of Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Index to Consolidated Financial Statements

|  |           |
|--|-----------|
| <u>Report of Independent Registered Public Accounting Firm</u>   | <u>42</u> |
| <u>Consolidated Balance Sheets at December 31, 2018 and 2017</u>   | <u>43</u> |
| <u>Consolidated Statements of Operations for the years ended December 31, 2018 and 2017</u>                      | <u>44</u> |
| <u>Consolidated Statements of Changes in Stockholders' Equity for the years ended December 31, 2018 and 2017</u> | <u>46</u> |
| <u>Consolidated Statements of Cash Flows for the years ended December 31, 2018 and 2017</u>                      | <u>47</u> |
| <u>Notes to Consolidated Financial Statements</u>  | <u>48</u> |

41

---

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders

Luna Innovations Incorporated

Opinion on the financial statements

audited the accompanying consolidated balance sheets of Luna Innovations Incorporated (a Delaware corporation) and subsidiaries (the "Company") as of December 31, 2018 and 2017, the related consolidated statements of operations, changes in equity, and cash flows for each of the two years in the period ended December 31, 2018, and the related notes and statement schedule included under Item 15(a) (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

Financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.

Accordingly, we express no such opinion.

Our audits also included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, supporting the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting estimates used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ GRANT THORNTON LLP

We have served as the Company's auditor since 2005.

Arlington, Virginia

March 14, 2019

Table of Contents

## CONSOLIDATED BALANCE SHEETS

|  | December<br>31, 2018 | December<br>31, 2017 |
|--|----------------------|----------------------|
| Equivalents  | \$42,460,267         | \$36,981,533         |
| Receivable, net  | 13,037,068           | 5,929,042            |
| Proceeds from sale of HSOR business  | 2,500,000            | 4,000,976            |
| Prepaid expenses   | 2,422,495            | 1,778,142            |
| Other current assets   | 6,873,742            | 4,634,781            |
| Assets held for sale   | 935,185              | 1,140,999            |
| Intangible assets  | —                    | 4,336,105            |
| Equipment, net   | 68,228,757           | 58,801,578           |
| Leases, net  | 3,627,886            | 2,854,641            |
| Contract assets  | 3,302,270            | 1,727,390            |
| Assets held for sale   | 101,008              | —                    |
|  | 336,820              | 209,699              |
|  | 1,995                | 1,995                |
|  | —                    | 2,627,333            |
|  | \$75,598,736         | \$66,222,636         |
| Liabilities and stockholders' equity   |                      |                      |
| Liabilities:   |                      |                      |
| Portion of long term debt obligations  | \$619,315            | \$1,833,333          |
| Portion of capital lease obligations   | 40,586               | 43,665               |
| Accounts payable   | 2,395,984            | 2,111,077            |
| Other liabilities  | 6,597,458            | 6,547,230            |
| Other liabilities  | 2,486,111            | 3,318,379            |
| Liabilities held for sale  | —                    | 972,451              |
| Other liabilities  | 12,139,454           | 14,826,135           |
| Accrual of deferred rent   | 1,035,974            | 1,184,438            |
| Other obligations  | —                    | 603,007              |
| Capital lease obligations  | 68,978               | 71,275               |
| Other liabilities  | 13,244,406           | 16,684,855           |
| Contingencies  |                      |                      |
| Equity:  |                      |                      |
| Common stock, par value \$0.001, 1,321,514 shares authorized, issued and outstanding at December 31, 2018 and 2017   | 1,322                | 1,322                |
| Common stock, par value \$0.001, 100,000,000 shares authorized, 29,209,506 and 28,354,822 shares issued and 27,401 and 27,283,918 shares outstanding at December 31, 2018 and 2017, respectively | 30,120               | 29,186               |
| Retained earnings at cost, 1,253,105 and 1,070,904 shares at December 31, 2018 and 2017, respectively  | (2,116,640 )         | (1,649,746 )         |
| Additional paid-in capital   | 85,744,750           | 83,563,208           |
| Accumulated deficit  | (21,305,222 )        | (32,406,189 )        |
| Other stockholders' equity   | 62,354,330           | 49,537,781           |
| Liabilities and stockholders' equity   | \$75,598,736         | \$66,222,636         |

The accompanying notes are an integral part of these consolidated financial statements.





Table of Contents

## CONSOLIDATED STATEMENTS OF OPERATIONS

|   | Years ended December 31, |              |
|---|--------------------------|--------------|
|   | 2018                     | 2017         |
| Development   | \$20,967,556             | \$18,576,383 |
| Licensing   | 21,949,689               | 14,505,482   |
| Other   | 42,917,245               | 33,081,865   |
| Revenues:   |                          |              |
| Development   | 15,400,475               | 13,988,378   |
| Licensing   | 8,078,870                | 5,724,457    |
| Other   | 23,479,345               | 19,712,835   |
|   | 19,437,900               | 13,369,030   |
| Expense:  |                          |              |
| General and administrative  | 14,794,205               | 12,923,841   |
| Development and engineering   | 3,766,160                | 2,653,337    |
| Marketing expense   | 18,560,365               | 15,577,178   |
| Depreciation and amortization   | 877,535                  | (2,208,148)  |
| Other   | (17,143)                 | 26,106       |
| Income  | 549,580                  | —            |
| Expense, net  | (124,344)                | (217,352)    |
| Income/(expense)  | 408,093                  | (191,246)    |
| Income from continuing operations before income taxes   | 1,285,628                | (2,399,394)  |
| Other   | (47,818)                 | 1,148,579    |
| Income/(loss) from continuing operations  | 1,237,810                | (1,250,815)  |
| Income from discontinued operations, net of income tax expense of \$183,921 and               | 1,170,634                | 194,692      |
| Income from discontinued operations, net of \$1,572,244 and \$912,298 of related income taxes | 8,595,797                | 15,671,028   |
| Income from discontinued operations, net of income taxes                                      | 9,766,431                | 15,865,720   |
| Other   | 11,004,241               | 14,614,905   |
| Dividend  | 257,302                  | 146,889      |
| Income attributable to common stockholders  | \$10,746,939             | \$14,468,016 |
| Income/(loss) per share from continuing operations:   | \$0.04                   | \$(0.05)     |
| Income/(loss) per share from discontinued operations:   | \$0.04                   | \$(0.05)     |
| Income/(loss) per share from continuing operations:   | \$0.35                   | \$0.58       |
| Income/(loss) per share from discontinued operations:   | \$0.30                   | \$0.58       |
| Income/(loss) per share attributable to common stockholders:                                  | \$0.39                   | \$0.52       |
| Income/(loss) per share attributable to common stockholders:                                  | \$0.33                   | \$0.52       |
| Weighted average shares:  | 27,596,401               | 27,579,988   |
| Weighted average shares:  | 32,452,228               | 27,579,988   |



The accompanying notes are an integral part of these consolidated financial statements.

## CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

|               | Preferred Stock |          | Common Stock |           | Treasury Stock |               | Additional      | Accumulated    | Total         |
|---------------|-----------------|----------|--------------|-----------|----------------|---------------|-----------------|----------------|---------------|
|               | Shares          | \$       | Shares       | \$        | Shares         | \$            | Paid in Capital | Deficit        |               |
| January 1,    | 1,321,514       | \$ 1,322 | 27,541,277   | \$ 28,600 | 446,827        | \$(517,987)   | \$82,451,958    | \$(46,874,205) | \$ 35,089,688 |
| Stock         | —               | —        | 83,888       | 84        | —              | —             | 99,769          | —              | 99,853        |
|               | —               | —        | 147,333      | 287       | —              | —             | 714,807         | —              | 715,094       |
|               | —               | —        | 135,497      | 136       | —              | —             | 149,864         | —              | 150,000       |
| (1)           | —               | —        | —            | 79        | —              | —             | 146,810         | (146,889)      | —             |
| Treasury      | —               | —        | (624,077)    | —         | 624,077        | (1,131,759)   | —               | —              | (1,131,759)   |
|               | —               | —        | —            | —         | —              | —             | —               | 14,614,905     | 14,614,905    |
| December 31,  | 1,321,514       | \$ 1,322 | 27,283,918   | \$ 29,186 | 1,070,904      | \$(1,649,746) | \$83,563,208    | \$(32,406,189) | \$ 49,537,781 |
| Change in     | —               | —        | —            | —         | —              | —             | —               | 354,028        | 354,028       |
| Balance as of | 1,321,514       | 1,322    | 27,283,918   | 29,186    | 1,070,904      | (1,649,746)   | 83,563,208      | (32,052,161)   | 49,891,809    |
| Stock         | —               | —        | 442,425      | 441       | —              | —             | 1,096,592       | —              | 1,097,033     |
| warrants      | —               | —        | 282,394      | 282       | —              | —             | 627,857         | —              | 628,139       |
|               | —               | —        | 129,865      | 131       | —              | —             | 199,871         | —              | 200,002       |
| (1)           | —               | —        | —            | 80        | —              | —             | 257,222         | (257,302)      | —             |
| Treasury      | —               | —        | (182,201)    | —         | 182,201        | (466,894)     | —               | —              | (466,894)     |
|               | —               | —        | —            | —         | —              | —             | —               | 11,004,241     | 11,004,241    |
| December 31,  | 1,321,514       | \$ 1,322 | 27,956,401   | \$ 30,120 | 1,253,105      | \$(2,116,640) | \$85,744,750    | \$(21,305,222) | \$ 62,354,330 |

Dividends payable in connection with the Series A Convertible Preferred Stock are issuable upon the request of

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

## CONSOLIDATED STATEMENTS OF CASH FLOWS

|   | Years ended December 31, |               |
|---|--------------------------|---------------|
|   | 2018                     | 2017          |
| Cash flows (used in)/provided by operating activities:                                      |                          |               |
| Net income  | \$ 11,004,241            | \$ 14,614,905 |
| Adjustments to reconcile net income to net cash (used in)/provided by operating activities: |                          |               |
| Depreciation and amortization   | 1,218,559                | 2,526,609     |
| Equity-based compensation   | 627,856                  | 715,094       |
| Gain on disposal of fixed assets  | (1,000)                  | 3,640         |
| Gain on sale of discontinued operations, net of income taxes                                | (8,595,797)              | (15,671,028)  |
| Change in debt  | 6,000                    | 99,888        |
| Changes in operating assets and liabilities:  |                          |               |
| Accounts receivable   | (6,240,377)              | 1,152,055     |
| Intangible assets   | (761,714)                | —             |
| Inventory   | (967,797)                | (1,902,311)   |
| Prepaid assets  | 1,849,630                | 83,428        |
| Accounts payable and accrued expenses   | (461,928)                | (896,534)     |
| Contract liabilities  | (986,498)                | —             |
| Deferred revenue  | —                        | 189,296       |
| Cash (used in)/provided by operating activities   | (3,308,825)              | 915,042       |
| Cash flows provided by investing activities:  |                          |               |
| Disposition of property and equipment   | (386,890)                | (1,352,531)   |
| Proceeds from sale of property and equipment  | 1,000                    | 3,000         |
| Acquirable property costs   | (374,766)                | (495,597)     |
| Disposition of Micron Optics  | (5,001,750)              | —             |
| Proceeds from sale of discontinued operations, net  | 15,799,529               | 28,026,528    |
| Cash provided by investing activities   | 10,037,123               | 26,181,400    |
| Cash flows used in financing activities:  |                          |               |
| Payments on debt obligations  | (1,833,333)              | (1,833,333)   |
| Payments on capital lease obligations   | (46,653)                 | (52,128)      |
| Repurchase of treasury stock  | (466,894)                | (1,131,759)   |
| Proceeds from the exercise of options and warrants  | 1,097,316                | 99,853        |
| Cash used in financing activities   | (1,249,564)              | (2,917,367)   |
| Change in cash and cash equivalents   | 5,478,734                | 24,179,075    |
| Cash and cash equivalents—beginning of period   | 36,981,533               | 12,802,458    |
| Cash and cash equivalents—end of period   | \$ 42,460,267            | \$ 36,981,533 |
| Supplemental disclosure of cash flow information  |                          |               |
| Cash paid for interest  | \$ 117,616               | \$ 209,497    |
| Cash paid for income taxes  | \$ 1,846,037             | \$ 377,907    |
| Cash received for income tax refunds  | \$ 17,834                | \$ —          |
| Cash from non stock issued pursuant to restricted stock vesting                             | \$ 200,202               | \$ 150,000    |
| Cash paid on preferred stock  | \$ 257,302               | \$ 146,889    |

The accompanying notes are an integral part of these consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Summary of Significant Accounting Policies

Luna Innovations Incorporated (“we” or the “Company”), headquartered in Roanoke, Virginia, was incorporated in the Commonwealth of Virginia in 1990 and reincorporated in the State of Delaware in April 2003. We are a leader in advanced optical technology, providing high performance fiber optic test products for the telecommunications and distributed fiber optic sensing products for industries utilizing composite and other advanced materials, such as the automotive, aerospace, energy and infrastructure industries. Our distributed fiber optic sensing products help designers and engineers more efficiently develop new and innovative products by providing valuable information such as highly detailed strain, and temperature measurements of a new design or manufacturing process. In addition, our distributed fiber optic products are used to monitor the structural integrity or operational health of critical assets, including large civil structures and bridges. Our communications test products accelerate the development of advanced fiber optic components and networks enabling fast and highly accurate characterization of components and networks. We also provide applied research services, primarily under research programs funded by the U.S. government, in areas of advanced materials, sensing, and healthcare. Our business model is designed to accelerate the process of bringing new and innovative products to market. We use in-house technical expertise across a range of technologies to perform applied research services for companies and for government funded projects. We continue to invest in product development and commercialization, which we anticipate will lead to increased product sales growth.

Consolidation Policy

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include our accounts and the accounts of our wholly owned subsidiaries. We eliminate from our financial statements results all intercompany transactions.

Reclassifications

Some amounts in the prior period have been reclassified to conform to current presentation. As a result of the adoption of Accounting Standards Codification (“ASC”) 2014-09, Revenue from Contracts with Customers (Topic 606), we presented intangible contract assets and contract liabilities within the consolidated balance sheet as well as the impact of the changes in revenues within the consolidated statement of cash flows. We reclassified comparable balances within the December 31, 2014 consolidated balance sheet as well as the impact of changes in those balances within the consolidated statement of cash flows in order to enhance comparability. These reclassifications had no effect on our reported financial condition, results of operations or cash flows. Any other reclassifications were immaterial to the consolidated interim financial statements taken as a whole.

Use of Estimates

In the preparation of our consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. These estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.

Technology Development Revenues

We perform research and development for U.S. Federal government agencies, educational institutions and commercial organizations. We account for a research contract when a contract has been executed, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the contract price is considered probable. Revenue is earned under cost reimbursable, time and materials and fixed price contracts. Direct contract costs are expensed as incurred.

Contracts with agencies of the U.S. government are subject to periodic funding by the respective contracting agency. Funding may be provided in full at inception of the contract or ratably throughout the contract as the services are provided. In determining the probability of funding for purposes of assessing collectability of the contract price, we consider our previous experience with our customers, communication with our customers regarding funding status and our knowledge of





Table of Contents

able funding for the contract or program. If funding is not assessed as probable, revenue recognition is deferred until realization is reasonably assured.

the typical payment terms of our U.S. government contracts, the customer pays us either performance-based payments or progress payments. PBPs, which are typically used in the firm fixed price contracts, are interim payments based on measurable measures of performance or on the achievement of specified events or milestones. Progress payments, which are typically used in our cost type contracts, are interim payments based on costs incurred as the work progresses. For our U.S. cost-type contracts, the customer generally pays us during the performance period for 80% to 90% of our actual costs because the customer retains a small portion of the contract price until completion of the contract and audit of allowable costs. Progress-type contracts generally result in revenue recognized in excess of billings which we present as contract assets on the balance sheet. Amounts billed and due from our customers are classified as receivables on the balance sheet. For non-U.S. contracts, we typically receive interim payments as work progresses, although for some contracts, we may be entitled to receive an advance payment. We recognize a liability for these advance payments and PBPs paid in advance which are in excess of the revenue recognized and present these amounts as contract liabilities on the balance sheet.

To determine the proper revenue recognition method for research and development contracts, we evaluate whether two or more contracts should be combined and accounted for as one single modified contract and whether the combined or single contract should be accounted for as more than one performance obligation. For instances where a contract has options that were bid with the original contract and awarded at a later date, we combine the options with the original contract when options are awarded. For our research contracts, the customer contracts for research with multiple milestones that are interdependent. Consequently, the contract is accounted for as one performance obligation. The effect of the combined or modified contract on the transaction measure of progress for the performance obligation to which it relates, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.

Revenue recognition is measured over time as we perform because of continuous transfer of control to the customer. For our research contracts which are typically subject to the Federal Acquisition Regulation, this continuous transfer of control to the customer is supported by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, at a price of cost incurred plus a reasonable profit and take control of any work in process. From time to time, as part of normal business processes, facts may change, causing revisions to estimated total costs or revenues expected. The cumulative impact of revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

Because of control transferring over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the services to be provided. We generally use the input method, more specifically the cost-to-cost measure of progress for our contracts because it best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The underlying bases for our contract research revenues are measurable expenses, such as labor, subcontractor costs and materials, and data that are reported on a regular basis for purposes of preparing our cost estimates. Our research contracts generally have a period of performance of six months to three years, and our estimates of contract costs have historically been consistent with actual results. Changes in these estimates between accounting periods to reflect changing facts and circumstances have not had a material impact on our operating results, and we do not expect future changes in these estimates to be material. The cumulative impact of revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

For our reimbursable contracts, we are reimbursed for costs that are determined to be reasonable, allowable and allocable to the contract and paid a fixed fee representing the profit negotiated between us and the contracting agency. Revenue from cost reimbursable contracts is recognized as costs are incurred plus an estimate of applicable fees earned. We consider fixed fees

cost reimbursable contracts to be earned in proportion to the allowable costs incurred in performance of the contract.

m time and materials contracts is recognized based on direct labor hours expended at contract billing rates plus other billable direct costs.

e contracts may include either a product delivery or specific service performance throughout a period. For fixed price contracts that are based on the proportional performance method and involve a specified number of deliverables, we recognize revenue based on the proportion of the cost of the deliverables compared to the cost of all deliverables included in

Table of Contents

contract as this method more accurately measures performance under these arrangements. For fixed price contracts that the development and delivery of a specific prototype or product, revenue is recognized based upon the percentage of completion method.

Certain costs under government contracts are allowable is subject to audit by the government. Certain indirect costs are contracts using provisional or estimated indirect rates, which are subject to later revision based on government audits of these costs. Management is of the opinion that costs subsequently disallowed, if any, would not likely have a significant impact on revenues recognized for those contracts.

## Product Sales Revenues

Revenues from product sales are generated by the sale of commercial products and services under various sales programs to the customer through distribution channels. We sell fiber optic sensing systems to end users for use in numerous fiber optic based applications. Revenues are recorded net of applicable sales taxes collected from customers and payable to state or local governmental entities.

To determine the proper revenue recognition method for Products and Licensing contracts, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. We recognize revenue when the performance obligation has been satisfied by transferring the control of the product or service to the customer. For tangible products that contain software that is integral to the tangible product's functionality, we consider the product and software to be a single performance obligation and recognize revenue accordingly. For contracts with multiple performance obligations, we allocate the contract's transaction price to each performance obligation based on their relative stand-alone selling prices. In such circumstances, we use the observable price for goods or services which are sold separately in similar circumstances to similar customers. If these prices are not observable, we estimate the stand-alone selling price using information that is reasonably available. For the majority of our standard products and services, price list and discount structures related to customer type are available. For products and services that do not have price list and discount structures, we may use one or more of the following: (i) adjusted market assessment approach, (ii) expected cost plus a margin approach, and (iii) residual approach. The adjusted market approach requires us to evaluate the market in which we sell goods or services and estimate the price that a customer in that market would be willing to pay for those goods or services. The expected cost plus margin approach requires us to forecast our expected costs of satisfying the performance obligation and then add a reasonable margin for that good or service. The residual approach decreases the total contract price by the sum of the observable standalone selling prices if either the company sells the same good or services to customers for a broad range of amounts or the company has not established a price for the good or service and that good or service has not been sold on a standalone basis. Shipping and handling activities primarily occur after a customer obtains control and are considered fulfillment cost rather than separate performance obligations. Similarly, sales and similar taxes imposed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer are excluded from the measurement of the transaction price.

For standard products, we recognize revenue at a point in time when control passes to the customer. Absent substantial product customization clauses, this is based on the shipping terms. For custom products that require engineering and development based on customer requirements, we will recognize revenue over time using the output method for any items shipped and any finished work in process that is produced for balances of open sales orders. For any finished goods or work in process that has been produced for the balance of open sales orders we recognize revenue by applying the average selling price for such open orders or the lesser of the on hand balance in finished goods or open sales order quantity which we present as a contract asset on the balance sheet. Cost of sales is recognized based on the standard cost of the finished goods and work in process associated with the contract and inventory balances are reduced accordingly. For extended warranties and product rentals, revenue is recognized over time using the output method based on the time elapsed for the warranty or service period. In the case of warranties, we recognize contract liability for amounts billed but that are not recognized until subsequent period. A separate contract liability is recognized for the cost associated with warranty repairs based on our estimate of future expense. For testing services where we are performing testing on an asset the customer controls, revenue is recognized over time by the output method using the percentage of completion to date. For training where the customer is receiving the benefit of training as it is occurring and for repairs to a

er controlled asset, revenue is recognized over time by the output method using the performance to date. For royalty  
apply the practical expedient “royalty exception” recognizing revenue based on the royalty agreement which specifies  
an amount based on sales or minimum amount, whichever is greater.

ne product rental contracts, a customer may be offered a discount on the purchase of an item that would provide for a  
right. When a material right has been provided to a customer, a separate performance obligation is established and a  
the rental revenue will be deferred until the future product is purchased or the option expires. This deferred revenue

Table of Contents

as a contract liability on the balance sheet. In certain circumstances we may offer a "right of return" to a distributor  
 contracts, in which case a contract liability is calculated based on the terms of the agreement and recorded as a reduction to  
 In addition, a contract asset for the rights to recover products from customers and a reduction of cost of sales is also  
 calculated and recorded.

## Allowance for Uncollectible Receivables

Accounts receivable are recorded at their face amount, less an allowance for doubtful accounts. We review the status of our  
 receivables on a regular basis. In determining the need for an allowance for uncollectible receivables, we consider our  
 customers' financial stability, past payment history and other factors that bear on the ultimate collection of such amounts. The  
 allowance was \$0.3 million at each of December 31, 2018 and 2017.

## Cash Equivalents

all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. To date,  
 we have not incurred losses related to cash and cash equivalents. Cash equivalents at December 31, 2018 and 2017 included  
 \$25.2 million and \$25.2 million, respectively, invested in U.S. Treasury obligations through a sweep account with our bank. The  
 majority of amounts invested through the sweep account are convertible to cash on a daily basis. Our cash transactions are  
 conducted through reputable commercial banks. We regularly maintain cash balances with financial institutions which exceed  
 FDIC Insurance Corporation ("FDIC") insurance limits. At December 31, 2018 and 2017, we had approximately \$4.0  
 million and \$11.5 million, respectively, in excess of FDIC insured limits.

outstanding term loans that require us to comply with certain financial covenants, including maintaining a minimum  
 cash balance of at least \$4.0 million.

## Fair Value Measurements

Assets and liabilities are measured at fair value, which is defined as the price that would be received to sell an asset,  
 or to transfer a liability, in an orderly transaction between market participants. Valuation techniques are based on observable  
 market inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs  
 reflect our market assumptions. These two types of inputs have created the following fair value hierarchy:

Level 1—Quoted prices for identical instruments in active markets.

Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that  
 are not active; and model-derived valuations in which significant value drivers are observable.

Level 3—Valuations derived from valuation techniques in which significant value drivers are unobservable.

The fair values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the  
 short-term nature of these instruments. We consider the terms of the Silicon Valley Bank ("SVB") debt facility including its  
 interest rate of prime plus 2%, to be at market based upon similar instruments that would be available to us.

## Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. We record depreciation using the straight-line method  
 over the following estimated useful lives:

|                        |  |
|------------------------|--|
| Equipment              | 3 – 7 years                                  |
| Furniture and fixtures | 7 years                                      |
| Software               | 3 years                                      |
| Leasehold improvements | Lesser of lease term or life of improvements |

## Intangible Assets

Intangible assets consist of patents related to certain intellectual property that we have developed or acquired and identifiable  
 intangible assets recognized in connection with our merger with Advanced Photonix, Inc. ("API") and Micron Optics, Inc.  
 We amortize our identified intangible assets over their estimated useful lives ranging between one and eleven years, and  
 periodically assess the reasonableness of the remaining useful life whenever events or circumstances indicate that the carrying amount may  
 not be recoverable to determine whether their carrying value has been impaired.

Table of Contents

Goodwill

viewed for impairment at least annually, or more frequently if events or circumstances indicate that goodwill might be impaired. We have established October 1 as our specified annual date for impairment testing.

Research, Development and Engineering

Research, development and engineering expenses not related to contract performance are expensed as incurred. We expensed \$2.7 million and \$2.7 million of non-contract related research, development and engineering expenses for the year ended December 31, 2018 and 2017, respectively.

Valuation of Long-Lived Assets

We test our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by comparing the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. Assets to be disposed of by sale are reflected at the lower of their carrying amount or fair value less cost to sell.

Inventory

Inventory consists of finished goods, work in process and raw materials valued at the lower of cost (determined on the first-in, first-out basis) or net realizable value.

Net Income/(Loss) per Share

Basic net income per share data is computed by dividing net income/(loss) attributable to common stockholders by the weighted average number of shares outstanding during the period. Diluted net income per share data is computed by dividing net income/(loss) attributable to common stockholders by the weighted average number of shares outstanding during the period increased to include, if dilutive, the number of common share equivalents that would have been outstanding if potential common shares had been issued using the treasury stock method. Diluted net income per share data would also include the potential common share equivalents relating to convertible securities by application of the if-converted method.

The effect of 4.9 million common stock equivalents (which include outstanding warrants, preferred stock, accrued stock and stock options) are included for the diluted net income per share data for the year ended December 31, 2018. The effect of 4.3 million common stock equivalents (which include outstanding warrants, preferred stock and stock options) are not included for the year ended December 31, 2017, as they are anti-dilutive to earnings per share due to us having a net loss from continuing operations.

Stock-Based Compensation

We have two stock-based compensation plans, which are described further in Note 10. We recognize compensation expense at the fair value of the underlying equity award as of the date of grant. We have elected to use the Black-Scholes option pricing model to value any stock options granted. Restricted stock and restricted stock units awarded are valued at the closing price of common stock on the date of the award. We recognize stock-based compensation for such awards on a straight-line basis over the requisite service period of the awards taking into account the effects of the employees' expected exercise. We do not reduce stock-based compensation expense for the value of any forfeitures of vested awards as such forfeitures occur. We do not recognize expense for equity instruments issued to non-employees based upon the fair value of the equity instruments issued.

Advertising

We recognize the cost of advertising as incurred. Advertising expenses were \$0.1 million for each of the years ended December 31, 2018 and 2017.

Income Taxes

We recognize income tax expense using the liability method. Deferred tax assets or liabilities are determined based on the difference between the carrying amount of an asset or liability in the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when the differences reverse. A valuation allowance against net deferred tax assets is provided unless we conclude it is more likely than not that the deferred tax assets will be realized.

Table of Contents

ize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be settled. We evaluate our ability to benefit from all deferred tax assets and establish valuation allowances for amounts that are not more-likely-than-not to be realizable. For uncertain tax positions, we use a more-likely-than-not threshold, which is 51% or greater, based on the technical merits of the income tax position taken. Income tax positions that meet the more-likely-than-not recognition threshold are measured in order to determine the tax benefit recognized in the financial statements. Penalties, if probable and reasonably estimable, and interest expense related to uncertain tax positions are recognized as a component of the tax provision.

For income taxes using the liability method, deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when the differences reverse. A valuation allowance against net deferred tax assets is provided unless we conclude it is more likely than not that the deferred tax assets will be realized.

## Recent Accounting Pronouncements

On January 1, 2018, we adopted Revenue from Contracts with Customers (Topic 606), using the modified retrospective method. Under the modified retrospective approach, we apply the standards to new contracts and those that were not completed as of January 1, 2018. For those contracts not completed as of January 1, 2018, this method resulted in a cumulative adjustment to decrease the accumulated deficit in the net amount of \$0.4 million. Prior periods will not be retrospectively adjusted but we will maintain dual reporting for the year of initial application in order to maintain comparability of the periods. The cumulative effect of the changes made to our January 1, 2018 consolidated balance sheet for the adoption of Topic 606 was as follows:

|                                   | Balance at<br>December 31,<br>2017 | Adjustment<br>for<br>Topic 606 | Adjusted<br>balance at<br>January 1,<br>2018 |
|-----------------------------------|------------------------------------|--------------------------------|--|
| <b>Assets:</b>                    |                                    |                                |  |
| Current assets held for sale      | \$4,336,105                        | \$ 379,891                     | \$4,715,996                                  |
| <b>Liabilities:</b>               |                                    |                                |  |
| Contract liabilities              | \$3,318,379                        | \$ 2,250                       | \$3,320,629                                  |
| Current liabilities held for sale | \$862,205                          | \$ 23,613                      | \$885,818                                    |
| <b>Stockholders' equity:</b>      |                                    |                                |  |
| Accumulated deficit               | \$(32,406,189)                     | \$ 354,028                     | \$(32,052,161)                               |

Contract assets were formerly reported as unbilled accounts receivable. Contract liabilities were formerly reported as accrued deferred revenue. Inventory was also impacted by the adoption of the new guidance. The titles have been changed in the table below to be consistent with accounts currently used under the new standard.

|                              | December 31, 2017 |               |
|------------------------------|-------------------|---------------|
|                              | As<br>Reported    | As<br>Adopted |
| Accounts receivables, net    | \$9,857,009       | \$5,929,042   |
| Contract assets              | —                 | 1,778,142     |
| Current assets held for sale | —                 | 1,940,126     |
| Long-term contract assets    | —                 | 209,699       |
| Accrued liabilities          | 8,959,935         | 6,547,230     |

|                                   |           |           |
|-----------------------------------|-----------|-----------|
| Contract liabilities              | —         | 3,318,379 |
| Current liabilities held for sale | —         | 120,665   |
| Deferred revenue                  | 1,026,339 | —         |



Table of Contents

new standard, contracts in our Technology Development segment, which primarily provide research services, are not impacted upon the adoption of Topic 606 as revenue will continue to be recognized over time using an input model. In our Products and Licensing segment generally provide for the following revenue sources: standard product sales, product development and sales, product rental, extended warranties, training/service, and certain royalties. Revenues for segment are recognized using either the “point in time” or “over time” methods of Topic 606, depending upon the revenue type. The major change in revenue recognition for the Products and Licensing segment related to custom optoelectronic products which changed from “point in time” to “over time” upon the adoption of Topic 606. This change results in the acceleration of revenue recognition when compared to existing standards with the cumulative adjustment relating to contracts that are not complete as of December 31, 2017 recognized as an adjustment to opening accumulated deficit on January 1, 2018. The revenue received from custom optoelectronic products segment is included as part of our discontinued operations (Note 17) and shown above in the assets and liabilities held for sale as of December 31, 2017. Our revenue for our standard products will continue to be recognized using the “point in time” model of Topic 606, and the timing of such revenue recognition is not expected to differ from our historical revenue recognition. Other immaterial adjustments related to the Products and Licensing segment sometimes offered to customers include discounts on future purchases related to rental agreements, customer rights of return, and volume discounts.

## Technology Development Revenues

We perform research and development for U.S. Federal government agencies, educational institutions and commercial organizations. We account for a research contract when a contract has been executed, the rights of the parties are identified, contract terms are identified, the contract has commercial substance, and collectability of the contract price is considered probable. Revenue is earned under cost reimbursable, time and materials and fixed price contracts. Direct contract costs are expensed as incurred.

Contracts with agencies of the U.S. government are subject to periodic funding by the respective contracting agency. Funding may be provided in full at inception of the contract or ratably throughout the contract as the services are provided. In determining the probability of funding for purposes of assessing collectability of the contract price, we consider our previous experience with our customers, communication with our customers regarding funding status and our knowledge of available funding for the contract or program. If funding is not assessed as probable, revenue recognition is deferred until realization is reasonably assured.

In the typical payment terms of our U.S. government contracts, the customer pays us either performance-based payments or progress payments. PBPs, which are typically used in the firm fixed price contracts, are interim payments based on measurable measures of performance or on the achievement of specified events or milestones. Progress payments, which are typically used in our cost type contracts, are interim payments based on costs incurred as the work progresses. For our U.S. cost-type contracts, the customer generally pays us during the performance period for 80% to 90% of our actual costs because the customer retains a small portion of the contract price until completion of the contract and audit of allowable costs. Cost-type contracts generally result in revenue recognized in excess of billings which we present as contract assets on the balance sheet. Amounts billed and due from our customers are classified as receivables on the balance sheet. For non-U.S. contracts, we typically receive interim payments as work progresses, although for some contracts, we may be entitled to receive an advance payment. We recognize a liability for these advance payments and PBPs paid in advance which are in excess of the revenue recognized and present these amounts as contract liabilities on the balance sheet.

In determining the proper revenue recognition method for research and development contracts, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. For instances where a contract has options that were bid with the initial contract awarded at a later date, we combine the options with the original contract when options are awarded. For most of our customer contracts for research with multiple milestones that are interdependent. Consequently, the entire contract

nted for as one performance obligation. The effect of the combined or modified contract on the transaction price and of progress for the performance obligation to which it relates, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.

enue recognition is measured over time as we perform because of continuous transfer of control to the customer. For ent contracts which are typically subject to the Federal Acquisition Regulation, this continuous transfer of control to is supported by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, or cost incurred plus a reasonable profit and take control of any work in process. From time to time, as part of normal management processes, facts may change, causing revisions to estimated total costs or revenues

Table of Contents

the cumulative impact of any revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

When the transfer of control is over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the services to be provided. We generally use the input method, more specifically the cost-to-cost measure of progress, for our contracts because it best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The underlying bases for our contract research revenues are measurable expenses, such as labor, subcontractor costs and materials, and data that is updated on a regular basis for purposes of preparing our cost estimates. Our research contracts generally have a period of performance of six months to three years, and our estimates of contract costs have historically been consistent with actual results. Changes in these estimates between accounting periods to reflect changing facts and circumstances have not had a material effect on our operating results, and we do not expect future changes in these estimates to be material. The cumulative impact of revisions to estimates and the full impact of anticipated losses on any type of contract are recognized in the period in which they become known.

For cost reimbursable contracts, we are reimbursed for costs that are determined to be reasonable, allowable and allocable to the contract and paid a fixed fee representing the profit negotiated between us and the contracting agency. Revenue from cost reimbursable contracts is recognized as costs are incurred plus an estimate of applicable fees earned. We consider fixed fees on cost reimbursable contracts to be earned in proportion to the allowable costs incurred in performance of the contract.

For time and materials contracts is recognized based on direct labor hours expended at contract billing rates plus other billable direct costs.

For fixed price contracts may include either a product delivery or specific service performance throughout a period. For fixed price contracts that are based on the proportional performance method and involve a specified number of deliverables, we recognize revenue based on the proportion of the cost of the deliverables compared to the cost of all deliverables included in the contract as this method more accurately measures performance under these arrangements. For fixed price contracts that provide for the development and delivery of a specific prototype or product, revenue is recognized based upon the percentage of completion method.

Certain costs under government contracts are allowable is subject to audit by the government. Certain indirect costs are recognized on contracts using provisional or estimated indirect rates, which are subject to later revision based on government audits of these costs. Management is of the opinion that costs subsequently disallowed, if any, would not likely have a significant effect on revenues recognized for those contracts. We have agreed on final billing rates with the government through December 31, 2017.

Products and Licensing Revenues

We produce standard and customized products for commercial organizations, educational institutions, and U.S. Federal government agencies. In addition we will also offer extended warranties, product rentals, and services which include testing, repairs for specific products. Customers also pay royalties as agreed based on sales or usage. We account for product sales when a contract has been executed, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the contract price is considered probable.

To determine the proper revenue recognition method for Products and Licensing contracts, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. We recognize revenue when the performance obligation has been

y transferring the control of the product or service to the customer. For tangible products that contain software that is  
to the tangible product's functionality, we consider the product and software to be a single performance obligation and  
revenue accordingly. For contracts with multiple performance obligations, we allocate the contract's transaction price to  
performance obligation based on their relative stand-alone selling prices. In such circumstances, we use the observable price  
for services which are sold separately in similar circumstances to similar customers. If these prices are not observable,  
we estimate the stand-alone selling price using information that is reasonably available. For the majority of our standard  
and services, price list and discount structures related to customer type are available. For products and services that do  
not have price list and discount structures, we may use one or more of the following: (i) adjusted market assessment approach, (ii)  
expected cost plus a margin approach, and (iii) residual approach. The adjusted market

Table of Contents

ch requires us to evaluate the market in which we sell goods or services and estimate the price that a customer in that could be willing to pay for those goods or services. The expected cost plus margin approach requires us to forecast our costs of satisfying the performance obligation and then add a reasonable margin for that good or service. The residual decreases the total transaction price by the sum of the observable standalone selling prices if either the company sells good or services to different customers for a broad range of amounts or the company has not established a price for the ce and that good or service has not been sold on a standalone basis. Shipping and handling activities primarily occur mer obtains control and are considered fulfillment cost rather than separate performance obligations. Similarly, sales and similar taxes assessed by a governmental authority that are both imposed on and concurrent with a specific ducing transaction and collected by the entity from a customer are excluded from the measurement of the transaction price.

rd products, we recognize revenue at a point in time when control passes to the customer. Absent substantial product clauses, this is based on the shipping terms. For custom products that require engineering and development based on r requirements, we will recognize revenue over time using the output method for any items shipped and any finished work in process that is produced for balances of open sales orders. For any finished goods or work in process that has duced for the balance of open sales orders we recognize revenue by applying the average selling price for such open e lesser of the on hand balance in finished goods or open sales order quantity which we present as a contract asset on eet. Cost of sales is recognized based on the standard cost of the finished goods and work in process associated with and inventory balances are reduced accordingly. For extended warranties and product rentals, revenue is recognized e using the output method based on the time elapsed for the warranty or service period. In the case of warranties, we ontract liability for amounts billed but that are not recognized until subsequent period. A separate contract liability is r the cost associated with warranty repairs based on our estimate of future expense. For testing services where we are performing testing on an asset the customer controls, revenue is recognized over time by the output method using the ance to date. For training where the customer is receiving the benefit of training as it is occurring and for repairs to a er controlled asset, revenue is recognized over time by the output method using the performance to date. For royalty apply the practical expedient "royalty exception" recognizing revenue based on the royalty agreement which specifies an amount based on sales or minimum amount, whichever is greater.

ne product rental contracts, a customer may be offered a discount on the purchase of an item that would provide for a right. When a material right has been provided to a customer, a separate performance obligation is established and a ne rental revenue will be deferred until the future product is purchased or the option expires. This deferred revenue is s a contract liability on the balance sheet. In certain circumstances we may offer a "right of return" to a distributor of cts, in which case a contract liability is calculated based on the terms of the agreement and recorded as a reduction to In addition, a contract asset for the rights to recover products from customers and a reduction of cost of sales is also calculated and recorded.

lled performance obligations represent amounts expected to be earned on executed contracts. Indefinite delivery and racts and unexercised options are not reported in total unfulfilled performance obligations. Unfulfilled performance obligations include funded obligations, which is the amount for which money has been directly authorized by the U.S. and for which a purchase order has been received by a commercial customer, and unfunded obligations, representing s for which funding has not yet been appropriated. The approximate value of our Technology Development segment lled performance obligations was \$26.0 million at December 31, 2018. We expect to satisfy 87% of the performance ions in 2019, 9% in 2020 and the remaining by 2022. The approximate value of our Products and Licensing segment lled performance obligations was \$5.8 million at December 31, 2018. We expect to satisfy 95% of the performance obligations in 2019, 4% in 2020 and the remaining by 2023.

ggregate our revenue from contracts with customers by geographic locations, customer-type, contract type, timing of tion, and major categories for each of our segments, as we believe it best depicts how the nature, amount, timing and

uncertainty of our revenue and cash flows are affected by economic factors. See details in the tables below.

Table of Contents

|   | Three Months Ended December 31,<br>2018<br>(unaudited) |                              |                     | Year Ended December 31, 2018 |                              |                     |
|---|--|------------------------------|---------------------|------------------------------|------------------------------|---------------------|
|   | Technology<br>Development                              | Products<br>and<br>Licensing | Total               | Technology<br>Development    | Products<br>and<br>Licensing | Total               |
| <b>Total Revenue by Geographic Location</b>     |  |                              |                     |                              |                              |                     |
| United States                                   | \$5,548,639  | \$3,624,247                  | \$9,172,886         | \$20,967,556                 | \$11,585,296                 | \$32,552,852        |
| Asia  | —  | 2,697,215                    | 2,697,215           | —                            | 5,977,563                    | 5,977,563           |
| Europe  | —  | 1,331,145                    | 1,331,145           | —                            | 3,873,161                    | 3,873,161           |
| Canada, Central and South America               | —  | 282,990                      | 282,990             | —                            | 382,797                      | 382,797             |
| All Others                                      | —  | 54,089                       | 54,089              | —                            | 130,872                      | 130,872             |
| <b>Total</b>                                    | <b>\$5,548,639</b>                                     | <b>\$7,989,686</b>           | <b>\$13,538,325</b> | <b>\$20,967,556</b>          | <b>\$21,949,689</b>          | <b>\$42,917,245</b> |
| <b>Total Revenue by Major Customer Type</b>     |  |                              |                     |                              |                              |                     |
| Sales to the U.S. government                    | \$5,418,679  | \$469,534                    | \$5,888,213         | \$20,703,338                 | \$1,834,289                  | \$22,537,627        |
| U.S. direct commercial sales and other          | 129,960  | 3,154,714                    | 3,284,674           | 264,218                      | 9,737,720                    | 10,001,938          |
| Foreign commercial sales & other                | —  | 4,365,438                    | 4,365,438           | —                            | 10,377,680                   | 10,377,680          |
| <b>Total</b>                                    | <b>\$5,548,639</b>                                     | <b>\$7,989,686</b>           | <b>\$13,538,325</b> | <b>\$20,967,556</b>          | <b>\$21,949,689</b>          | <b>\$42,917,245</b> |
| <b>Total Revenue by Contract Type</b>           |  |                              |                     |                              |                              |                     |
| Fixed-price contracts                           | \$2,777,012  | \$7,989,686                  | \$10,766,698        | \$9,388,770                  | \$21,949,689                 | \$31,338,459        |
| Cost-type contracts                             | 2,771,627  | —                            | 2,771,627           | 11,578,786                   | —                            | 11,578,786          |
| <b>Total</b>                                    | <b>\$5,548,639</b>                                     | <b>\$7,989,686</b>           | <b>\$13,538,325</b> | <b>\$20,967,556</b>          | <b>\$21,949,689</b>          | <b>\$42,917,245</b> |
| <b>Total Revenue by Timing of Recognition</b>   |  |                              |                     |                              |                              |                     |
| Goods transferred at a point in time            | \$—  | \$7,824,102                  | \$7,824,102         | \$—                          | \$21,329,999                 | \$21,329,999        |
| Goods/services transferred over time            | 5,548,639  | 165,584                      | 5,714,223           | 20,967,556                   | 619,690                      | 21,587,246          |
| <b>Total</b>                                    | <b>\$5,548,639</b>                                     | <b>\$7,989,686</b>           | <b>\$13,538,325</b> | <b>\$20,967,556</b>          | <b>\$21,949,689</b>          | <b>\$42,917,245</b> |
| <b>Total Revenue by Major Products/Services</b> |  |                              |                     |                              |                              |                     |
| Technology development                          | \$5,548,639  | \$—                          | \$5,548,639         | \$20,967,556                 | \$—                          | \$20,967,556        |
| Optical test and measurement systems            | —  | 7,625,325                    | 7,625,325           | —                            | 19,641,434                   | 19,641,434          |
| Optical components and sub-assemblies           | —  | —                            | —                   | —                            | —                            | —                   |
| Other   | —  | 364,361                      | 364,361             | —                            | 2,308,255                    | 2,308,255           |
| <b>Total</b>                                    | <b>\$5,548,639</b>                                     | <b>\$7,989,686</b>           | <b>\$13,538,325</b> | <b>\$20,967,556</b>          | <b>\$21,949,689</b>          | <b>\$42,917,245</b> |

Following tables summarize the impacts of adopting Topic 606 on our consolidated financial statements as of and for the three months and year ended December 31, 2018.

Table of Contents

|  | Impact of changes in accounting policies<br>December 31, 2018 |             |   |
|--|---|-------------|---|
|  | As Reported   | Adjustments | Balances<br>without<br>adoption of<br>Topic 606 |
| Equivalents  | \$42,460,267  | \$ —        | \$42,460,267                                    |
| Receivable, net  | 13,037,068  | —           | 13,037,068                                      |
| From sale of HSOR business   | 2,500,000   | —           | 2,500,000                                       |
| Assets   | 2,422,495   | —           | 2,422,495                                       |
| Prepaids and other current assets  | 6,873,742   | —           | 6,873,742                                       |
| Assets   | 935,185   | —           | 935,185   |
| Contract assets  | 68,228,757  | —           | 68,228,757                                      |
| Equipment, net   | 336,820   | —           | 336,820   |
| Assets, net  | 3,627,886   | —           | 3,627,886                                       |
|  | 3,302,270   | —           | 3,302,270                                       |
|  | 101,008   | —           | 101,008   |
|  | 1,995   | —           | 1,995   |
|  | \$75,598,736  | \$ —        | \$75,598,736                                    |
| Stockholders' equity   |   |             |   |
| Liabilities:   |   |             |   |
| Portion of long-term debt obligations  | \$619,315   | \$ —        | \$619,315                                       |
| Portion of capital lease obligations   | 40,586  | —           | 40,586  |
| Accounts payable   | 2,395,984   | —           | 2,395,984                                       |
| Liabilities  | 6,597,458   | —           | 6,597,458                                       |
| Liabilities  | 2,486,111   | (3,880 )    | 2,482,231                                       |
| Liabilities  | 12,139,454  | (3,880 )    | 12,135,574                                      |
| Deferred rent  | 1,035,974   | —           | 1,035,974                                       |
| Capital lease obligations  | 68,978  | —           | 68,978  |
| Assets   | 13,244,406  | (3,880 )    | 13,240,526                                      |
| Assets and contingencies   |   |             |   |
| Equity:  |   |             |   |
| Common stock, par value \$0.001, 1,321,514 shares authorized, issued and outstanding at December 31, 2018 and December 31, 2017, respectively                                      | 1,322   | —           | 1,322   |
| Common stock, par value \$0.001, 100,000,000 shares authorized, 29,209,506 and 27,956,401 shares issued, 27,283,918 shares outstanding at December 31, 2018 and 2017, respectively | 30,120  | —           | 30,120  |
| Common stock at cost, 1,253,105 and 1,070,904 shares at December 31, 2018 and December 31, 2017, respectively  | (2,116,640 )  | —           | (2,116,640 )                                    |
| Additional paid-in capital   | 85,744,750  | —           | 85,744,750                                      |
| Accumulated deficit  | (21,305,222 )   | 3,880       | (21,301,342 )                                   |
| Noncontrolling interest  | 62,354,330  | 3,880       | 62,358,210                                      |
| Assets and stockholders' equity  | \$75,598,736  | \$ —        | \$75,598,736                                    |





|   | Impact of changes in accounting policies<br>Three Months Ended December 31,<br>2018 |             |   | Year Ended December 31, 2018 |             |   |
|---|---|-------------|---|------------------------------|-------------|---|
|   | As reported   | Adjustments | Balances<br>without<br>adoption of<br>Topic 606 | As reported                  | Adjustments | Balances<br>without<br>adoption of<br>Topic 606 |
| Development   | \$5,548,639   | \$ —        | —\$5,548,639                                    | \$20,967,556                 | \$ —        | \$20,967,556                                    |
| Licensing   | 7,989,686   | —           | 7,989,686                                       | 21,949,689                   | 1,630       | 21,951,319                                      |
| Revenues  | 13,538,325  | —           | 13,538,325                                      | 42,917,245                   | 1,630       | 42,918,875                                      |
| Expenses:   |   |             |   |                              |             |   |
| Development   | 4,268,509   | —           | 4,268,509                                       | 15,400,475                   | —           | 15,400,475                                      |
| Licensing   | 2,697,538   | —           | 2,697,538                                       | 8,078,870                    | —           | 8,078,870                                       |
| Cost of revenues  | 6,966,047   | —           | 6,966,047                                       | 23,479,345                   | —           | 23,479,345                                      |
|   | 6,572,278   | —           | 6,572,278                                       | 19,437,900                   | 1,630       | 19,439,530                                      |
| Expense:  |   |             |   |                              |             |   |
| General and administrative                                  | 4,896,136   | —           | 4,896,136                                       | 14,794,205                   | —           | 14,794,205                                      |
| Development and engineering                                 | 1,252,663   | —           | 1,252,663                                       | 3,766,160                    | —           | 3,766,160                                       |
| Operating expense   | 6,148,799   | —           | 6,148,799                                       | 18,560,365                   | —           | 18,560,365                                      |
| Income  | 423,479   | —           | 423,479   | 877,535                      | 1,630       | 879,165   |
| Income tax expense:   |   |             |   |                              |             |   |
| Income tax expense  | (1,070 )  | —           | (1,070 )  | (17,143 )                    | —           | (17,143 )                                       |
| Income before income tax expense                            | 198,525   | —           | 198,525   | 549,580                      | —           | 549,580   |
| Income tax expense  | (21,136 )   | —           | (21,136 )                                       | (124,344 )                   | —           | (124,344 )                                      |
| Income from continuing operations                           | 176,319   | —           | 176,319   | 408,093                      | —           | 408,093   |
| Income from continuing operations before income tax expense | 599,798   | —           | 599,798   | 1,285,628                    | 1,630       | 1,287,258                                       |
| Income tax expense  | 722,148   | —           | 722,148   | 47,818                       | —           | 47,818  |
| Income from continuing operations                           | \$(122,350 )  | \$ —        | —\$(122,350 )                                   | \$1,237,810                  | \$ 1,630    | \$1,239,440                                     |

On January 1, 2018, we adopted Accounting Standards Update ("ASU") No. 2016-15, Statement of Cash Flows (Topic 230), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how cash receipts and cash payments are presented in the statement of cash flows. The adoption of ASU No. 2016-15 did not have a significant impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard revises the accounting for leases and requires lessees to recognize, for all leases with terms greater than one year, a right-of-use asset and liability which depicts the obligations arising from a lease. This standard also requires qualitative and quantitative disclosures designed to provide more information regarding the nature, amount and timing of lease expense. The new guidance is not expected to significantly change the recognition and measurement of lease expense. It is effective for the first interim and annual periods beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, permitting the recognition of a cumulative-effect adjustment to retained earnings on the date of adoption. We are adopting the standard beginning January 1, 2019 using the alternative transition method. We are finalizing the value as of the date of adoption of the right-of-use asset and lease liabilities and estimate that the right-of-use asset will be between \$4 million and \$5 million and that the lease liability will be reasonably consistent with the right-of-use asset amounts. We do not expect a

material impact from adopting the new standard on our results of operations or cash flows.

Table of Contents

2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, Intangibles—Goodwill and Other: Simplifying the Test for Goodwill Impairment. This update simplifies the subsequent measurement of goodwill. The update removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment loss will now be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for reporting periods beginning after December 15, 2019. We do not expect ASU 2017-04 will have a material impact on our financial statements.

In January 2018, the FASB issued ASU 2018-02: Income Statement – Reporting Comprehensive Income (Topic 220). Under the new accounting guidance, the income tax effects for changes in income tax rates and certain other transactions are recognized in income from continuing operations resulting in income tax effects recognized in AOCI that do not reflect the current tax rate of the period ("stranded tax effects"). The new guidance allows us the option to reclassify these stranded tax effects to accumulated other comprehensive income that relate to the change in the federal tax rate resulting from the passage of the Tax Cuts and Jobs Act. This update is effective for fiscal years beginning after December 15, 2018, including interim periods therein, and early adoption is permitted. We do not expect the adoption of this standard will have a significant impact on our consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Changes to the Disclosure Requirements for Fair Value Measurement. which amends the disclosure requirements in ASC 820 by adding, changing, or removing certain disclosures. The ASU applies to all entities that are required under this guidance to provide disclosures about nonrecurring fair value measurements. These amendments are effective for all entities for fiscal years beginning after December 15, 2019 including interim periods within those fiscal years. We do not expect ASU 2018-13 will have a material impact on our financial statements.

## 2. Inventory

Inventory consists of finished goods, work-in-process and raw materials valued at the lower of cost (determined on the first-in, first-out basis) or net realizable value.

Components of inventory are as follows:

|                 | December 31, |              |
|-----------------|--------------|--------------|
|                 | 2018         | 2017         |
| Finished goods  | \$ 1,339,832 | \$ 762,394   |
| Work-in-process | 643,420      | 288,165      |
| Raw materials   | 4,890,490    | 3,584,222    |
|                 | \$ 6,873,742 | \$ 4,634,781 |

## 3. Contract Balances

Contract assets consist of unbilled amounts for technology development contracts, custom product contracts, royalty revenue and the carrying amounts of right of returned inventory. Long-term contract assets include the fee withholding on cost of sale contracts that will not be billed within a year. Contract liabilities include excess billings, subcontractor accruals, warranty expense, extended warranty revenue, right of return refund, and customer deposits.

The following table shows the significant changes in contract balances for the year ended December 31, 2018:

Table of Contents

|   | Contract Assets | Contract Liabilities |
|---|-----------------|----------------------|
| Balance as of January 1, 2018   | \$ 1,987,841    | \$ 3,320,629         |
| Recognized that was included in the contract liabilities balance at the beginning of the period             | —               | (878,402 )           |
| Payables from contract liabilities recognized at the beginning of the period                                | —               | (2,078,640 )         |
| Change to cash received or adjustment of estimates, excluding amounts recognized as revenue                 | —               | 2,122,524            |
| Change in receivables from contract assets recognized at the beginning of the period                        | (1,679,363 )    | —                    |
| Change as a result of cumulative catch-up adjustment arising from changes in the estimate of the completion | 2,450,837       | —                    |
| Balance as of December 31, 2018   | \$ 2,759,315    | \$ 2,486,111         |

## 4. Debt

## Silicon Valley Bank Facility

We currently have a Loan and Security Agreement with SVB (the "Credit Facility") under which, as amended on May 8, 2015, we have a term loan with an original borrowing amount of \$6.0 million (the "Original Term Loan"). The Original Term Loan is payable in 48 monthly installments of \$125,000, plus accrued interest payable monthly in arrears, and unless earlier terminated, the Original Term Loan is scheduled to mature in May 2019. The Original Term Loan carries a floating annual interest rate equal to SVB's prime rate then in effect plus 2%. We may prepay amounts due under the Original Term Loan at any time, subject to an early termination fee of up to 2% of the amount of prepayment.

In December 2015, we entered into the Waiver and Seventh Loan Modification Agreement, which provided an additional \$1.0 million of available financing for purchases of equipment through December 31, 2015, which we fully borrowed in December 2015 (the "Second Term Loan" and, together with the Original Term Loan, the "Term Loans"). The Second Term Loan was repaid in December 2018.

The Credit Facility requires us to maintain a minimum cash balance of \$4.0 million and to maintain at each month end a ratio of current assets to total liabilities of 100% of accounts receivable greater than or equal to 1.5 times the outstanding principal of the Term Loans. The Credit Facility also requires us to observe a number of additional operational covenants, including protection and registration of intellectual property rights, and certain customary negative covenants. As of December 31, 2018, we were in compliance with all covenants under the Credit Facility.

Amounts due under the Credit Facility are secured by substantially all of our assets, including intellectual property, personal property and bank accounts. In addition, the Credit Facility contains customary events of default, including nonpayment of interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated agreements, incorrectness of representations and warranties in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may immediately terminate all borrowings under the Credit Facility and foreclose on the collateral. Furthermore, an event of default under the Credit Facility would result in an increase in the interest rate on any amounts outstanding. As of December 31, 2018, there were no events of default on the Credit Facility.

The carrying amount of the Term Loans at December 31, 2018 and December 31, 2017 was \$0.6 million and \$2.5 million, respectively. The remaining term loan, with a balance of \$0.6 million as of December 31, 2018, matures on May 1, 2019. The effective rate of our Term Loan at December 31, 2018 was 7%.

The following table presents a summary of debt outstanding:

Table of Contents

|                                       | December 31, |             |
|---------------------------------------|--------------|-------------|
|                                       | 2018         | 2017        |
| Silicon Valley Bank Term Loans        | \$625,000    | \$2,458,333 |
| Less: unamortized debt issuance costs | 5,685        | 21,993      |
| Less: current portion                 | 619,315      | 1,833,333   |
| Total long-term debt obligations      | \$—          | \$603,007   |

ance costs associated with the issuance of the SVB Term Loans totaled \$55 thousand. Amortization of debt issuance costs computed using the effective interest method and is included in interest expense. Amortization of the debt issuance costs totaled \$16 thousand for the year ended December 31, 2018.

Maturities on outstanding debt are as follows:

| Year  | Amount    |
|-------|-----------|
| 2019  | \$625,000 |
| Total | \$625,000 |

Interest expense for the years ended December 31, 2018 and 2017 consisted of the following:

|                                     | Years ended December 31, |           |
|-------------------------------------|--------------------------|-----------|
|                                     | 2018                     | 2017      |
| Interest expense on Term Loans      | \$108,062                | \$201,696 |
| Amortization of debt issuance costs | 16,308                   | 16,308    |
| Other interest income               | (26 )                    | (652 )    |
| Total interest expense              | \$124,344                | \$217,352 |

#### 5. Accounts Receivable, Net

Accounts receivable, net consist of the following:

|                                       | December 31, |             |
|---------------------------------------|--------------|-------------|
|                                       | 2018         | 2017        |
| Billed                                | \$13,289,790 | \$6,189,625 |
| Other                                 | 31,361       | 20,000      |
|                                       | 13,321,151   | 6,209,625   |
| Less: allowance for doubtful accounts | (284,083 )   | (280,583 )  |
|                                       | \$13,037,068 | \$5,929,042 |

Table of Contents

## 6. Property and Equipment

Property and equipment, net, consists of the following:

|                               | December 31, |              |
|-------------------------------|--------------|--------------|
|                               | 2018         | 2017         |
| Building                      | \$69,556     | \$69,556     |
| Equipment                     | 9,341,007    | 8,213,626    |
| Furniture and fixtures        | 640,890      | 565,885      |
| Software                      | 1,122,231    | 1,122,231    |
| Leasehold improvements        | 4,950,510    | 4,840,510    |
|                               | 16,124,194   | 14,811,808   |
| Less—accumulated depreciation | (12,496,308) | (11,957,167) |
|                               | \$3,627,886  | \$2,854,641  |

ion for the years ended December 31, 2018 and 2017 was approximately \$0.5 million and \$0.7 million, respectively.

## 7. Intangible Assets

Intangible assets, net consist of the following:

|                                     |                | December 31, |              |
|-------------------------------------|----------------|--------------|--------------|
|                                     | Estimated Life | 2018         | 2017         |
| Patent costs                        | 1 - 18 years   | \$4,991,460  | \$4,658,198  |
| Developed technology                | 5 years        | 2,600,000    | 1,400,000    |
| In-process research and development | N/A            | 200,000      | —            |
| Customer base                       | 7 years        | 100,000      | —            |
| Trade names                         | 3 years        | 150,000      | —            |
|                                     |                | 8,041,460    | 6,058,198    |
| Accumulated amortization            |                | (4,739,190 ) | (4,330,808 ) |
|                                     |                | \$3,302,270  | \$1,727,390  |

ion for the years ended December 31, 2018 and 2017 was approximately \$0.4 million and \$0.5 million, respectively.

ed aggregate amortization, based on the net value of intangible assets at December 31, 2018, for each of the next five

years and beyond is as follows:

| Year Ending December 31, |             |
|--------------------------|-------------|
| 2019                     | \$591,120   |
| 2020                     | 558,156     |
| 2021                     | 535,288     |
| 2022                     | 480,219     |
| 2023                     | 279,631     |
| 2023 and beyond          | 857,856     |
|                          | \$3,302,270 |

## 8. Accrued Liabilities

Accrued liabilities consist of the following:

Table of Contents

|                            | December 31, |             |
|----------------------------|--------------|-------------|
|                            | 2018         | 2017        |
| Accrued compensation       | \$4,467,587  | \$5,274,005 |
| Accrued professional fees  | 198,062      | 117,445     |
| Accrued income tax         | 236,636      | 403,547     |
| Deferred rent              | 146,542      | 144,740     |
| Royalties                  | 302,428      | 290,235     |
| Accrued liabilities-other  | 404,752      | 317,258     |
| Working capital payable    | 542,983      | —           |
| Liability to related party | 298,468      | —           |
| Total accrued liabilities  | \$6,597,458  | \$6,547,230 |

64



Table of Contents

## 9. Income Taxes

Income tax expense/(benefit) from continuing operations consisted of the following for the periods indicated:

|                              | Years ended December 31, |               |
|------------------------------|--------------------------|---------------|
|                              | 2018                     | 2017          |
| Current:                     |                          |               |
| Federal                      | \$(44,727)               | \$(1,154,105) |
| State                        | 92,545                   | 5,526         |
| Deferred federal             | —                        | —             |
| Deferred state               | —                        | —             |
| Income tax expense/(benefit) | \$47,818                 | \$(1,148,579) |

Deferred tax assets consist of the following components:

|  | December 31, 2018 | December 31, 2017 |
|--|-------------------|-------------------|
|  | Long-Term         | Long-Term         |
| Bad debt and inventory reserve           | \$ 332,721        | \$ 226,358        |
| Inventory adjustment                     | (21,785 )         | 405,242           |
| UNICAP                                   | 2,804             | 32,579            |
| Deferred revenue                         | 115,676           | 84,669            |
| Deferred rent                            | 288,017           | 340,199           |
| Depreciation and amortization            | (838,540 )        | (1,238,458 )      |
| Charitable contributions                 | —                 | 3,385             |
| Net operating loss carryforwards- Luna   | 349,421           | 349,421           |
| Net operating loss carryforwards- API    | 1,265,538         | 1,436,568         |
| Net operating loss carryforwards - state | 179,149           | 534,194           |
| Net operating loss carryforwards- Canada | 10,503            | 10,503            |
| Research and development credits         | —                 | 235,613           |
| California manufacturing credit          | —                 | 15,554            |
| Accrued liabilities                      | 394,118           | 504,472           |
| Deferred compensation                    | 216,944           | 223,607           |
| Stock-based compensation                 | 803,757           | 1,275,372         |
| Restricted stock                         | 60,681            | —                 |
| State bonus                              | 44,861            | —                 |
| AMT credit                               | —                 | 581,467           |
| Transaction costs                        | 63,668            | —                 |
| Total                                    | 3,267,533         | 5,020,745         |
| Valuation allowance                      | (3,267,533 )      | (5,020,745 )      |
| Net deferred tax asset                   | \$ —              | \$ —              |

Table of Contents

expense/(benefit) from income taxes from continuing operations differs from the amount computed by applying the federal statutory income tax rate to our loss from continuing operations before income taxes as follows for the periods indicated:

|   | Years ended |   | December 31, |   |
|---|-------------|---|--------------|---|
|   | 2018        |   | 2017         |   |
| Income tax expense at federal statutory rate  | 21.00       | % | 34.00        | % |
| State taxes, net of federal tax effects       | —           | % | (10.84)      | % |
| Change in tax rate from Tax Cuts and Jobs Act | —           | % | (79.17)      | % |
| Change in valuation allowance                 | (27.65)     | % | 113.86       | % |
| Incentive stock options                       | (1.05)      | % | (9.65)       | % |
| Provision to return adjustments               | 21.16       | % | 3.87         | % |
| Meals and entertainment                       | 0.97        | % | (0.65)       | % |
| Capitalized merger costs                      | —           | % | —            | % |
| AMT Carryover                                 | (9.83)      | % | —            | % |
| Other permanent differences                   | (0.88)      | % | (3.55)       | % |
| Income tax expense/(benefit)                  | 3.72        | % | 47.87        | % |

The utilization of our deferred income tax assets is dependent upon sufficient taxable income in future periods. In assessing whether our deferred tax assets may be realized, we consider whether it is more likely than not that some portion, or all, of the asset will be realized. We consider scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies that we can implement in making our assessment. We have no U.S. federal income tax net operating loss carryforwards at December 31, 2018 for Luna and net operating loss carryforwards of approximately \$6.0 million for API expiring at varying dates through 2025.

In 2017, we performed a formal section 382 study and determined that we do not have a limitation on our net operating loss to offset future income for the Luna net operating losses. As a result of the acquisition of API, the API net operating loss carryover and research and development credits will be subject to the Section 382 limitation. A formal Section 382 study was conducted in 2017, and it was determined that there was no ownership changes in 2017 resulting in a limitation on NOLs, but the net operating losses will expire unutilized. As there is a full valuation allowance against all of the API deferred tax assets, there will not be a statement of operations impact to any expiration of the net operating losses or research and development credits.

The U.S. federal statute of limitations remains open for the year 2015 and onward. We currently have no federal income tax returns under examination. U.S. state jurisdictions have statutes of limitation generally ranging from three to seven years. We currently have no state income or franchise tax returns under examination. We currently do not file tax returns in any foreign tax jurisdiction other than Canada.

We currently have no positions for which we expect that the amount of unrecognized tax benefit will increase or decrease significantly within twelve months of the reporting date or for which we believe there is significant risk of disallowance upon audit. We have no tax interest or penalties reported in either our statement of operations or statement of financial position for any period reported herein. Management believes it is not more likely than not that the deferred tax assets at December 31, 2018 or December 31, 2017 will be realized, and as a result a valuation allowance was established against all such deferred tax assets. On January 1, 2018, we adopted ASC Topic 606, Revenue from Contracts with Customers, which changes the timing of revenue recognition from recognizing at customer delivery to recognizing over a period of time. The adoption of ASC

Topic 606 did not have a significant impact on our consolidated financial statements. On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation



Table of Contents

and the U.S. corporate tax rate from the current rate of 35% to 21%. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities at the enacted rate. This revaluation resulted in a \$1.9 million reduction in the deferred tax liability and a corresponding reduction in the valuation allowance. In 2018, we realized a benefit of \$0.7 million in recovery of the minimum tax credit from prior periods. The other provisions of the Tax Cuts and Jobs Act did not have a material impact on our consolidated financial statements.

## 10. Stockholders' Equity

## Series A Convertible Preferred Stock

In 2010, we entered into a transaction with Carilion, in which Carilion agreed to exchange all of its Senior Convertible Notes with an original principal amount of \$5.0 million plus all accrued but unpaid interest, totaling \$1.2 million, for 14 shares of our newly designated Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock is non-voting, carries a dividend of 6% payable in shares of common stock and maintains a liquidation preference up to \$6.2 million. As of December 31, 2018, 710,985 shares of common stock were issuable to Carilion as dividends and have been included in the statement of stockholders' equity. These dividends are issuable on demand. Each share of Series A Convertible Preferred Stock may be converted into one share of our common stock at the option of the holder. We recorded the fair value of the Series A Convertible Preferred Stock, determined based upon the conversion value immediately prior to the exchange, the fair value of a new warrant issued to Carilion, determined using the Black-Scholes valuation model, and the incremental fair value of the prior warrant due to the re-pricing and extension of maturity to stockholders' equity.

## Equity Incentive Plans

In 2016, we adopted our 2016 Equity Incentive Plan (the "2016 Plan") as a successor to the 2006 Plan. Under the 2016 Plan, the Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to our employees, directors, and consultants. The 2016 Plan provides for the issuance of 3,500,000 shares of common stock, less amounts forfeited from grants under the 2006 Plan after the expiration date of the 2006 Plan. Options generally have a strike price and exercise price equal to or greater than the fair market value of the Common Stock as determined by the Board of Directors.

Vesting for employees typically occurs over a four-year period.

The following table sets forth the activity of the options to purchase common stock under the 2006 Plan and the 2016 Plan. The prices represent the closing price of our Common Stock on the Nasdaq Capital Market on the respective dates.

Table of Contents

|                              | Options Outstanding |                          |  | Aggregate<br>Intrinsic<br>Value (1) | Options Exercisable    |  |                                     |
|------------------------------|---------------------|--------------------------|--|-------------------------------------|------------------------|--|-------------------------------------|
|                              | Number of<br>Shares | Price per<br>Share Range | Weighted<br>Average<br>Exercise<br>Price |                                     | Number<br>of<br>Shares | Weighted<br>Average<br>Exercise<br>Price | Aggregate<br>Intrinsic<br>Value (1) |
| Balance at January 1, 2017   | 2,857,114           | \$0.61 - 6.83            | \$ 1.89                                  | \$107,063                           | 2,367,630              | \$ 1.93                                  | \$101,071                           |
| Forfeited                    | (178,665 )          | \$1.27 - 6.83            | \$ 2.24                                  |                                     |                        |  |                                     |
| Exercised                    | (83,888 )           | \$0.82 - 1.40            | \$ 1.19                                  |                                     |                        |  |                                     |
| Granted                      | 120,000             | \$1.51 - 2.40            | \$ 1.82                                  |                                     |                        |  |                                     |
| Balance at December 31, 2017 | 2,714,561           | \$0.61 - 6.55            | \$ 1.88                                  | \$2,098,195                         | 2,590,030              | \$ 1.89                                  | \$2,013,034                         |
| Forfeited                    | (675,607 )          | \$1.15 - 6.55            | \$ 1.90                                  |                                     |                        |  |                                     |
| Exercised                    | (96,425 )           | \$0.65 - 2.46            | \$ 2.07                                  |                                     |                        |  |                                     |
| Granted                      | 1,166,339           | \$2.67 - 3.53            | \$ 3.09                                  |                                     |                        |  |                                     |
| Balance at December 31, 2018 | 3,108,868           | \$0.61 - 6.55            | \$ 2.26                                  | \$3,669,794                         | 1,986,740              | \$ 1.81                                  | \$3,314,494                         |

ic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the n-the-money options only.

value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

|                                 | Years ended<br>December<br>31,<br>2018 | 2017  |
|---------------------------------|--|-------|
| Risk-free interest rate range   | 3.0%                                   | 2.05% |
| Expected life of option-years   | 7                                      | 6.5   |
| Expected stock price volatility | 67%                                    | 69%   |
| Expected dividend yield         | —%                                     | —%    |

Interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of our common stock over the period rate with the expected term of the related instrument. The expected life and estimated post-employment termination based upon historical experience of homogeneous groups, executives and non-executes, within our company. We do not currently pay dividends on our common stock nor do we expect to in the foreseeable future.

|                              | Range of<br>Exercise Prices | Options Outstanding    |  | Options Exercisable                      |                        |   |
|------------------------------|-----------------------------|------------------------|--|--|------------------------|---|
|                              |                             | Options<br>Outstanding | Weighted<br>Average<br>Remaining<br>Life in<br>Years | Weighted<br>Average<br>Exercise<br>Price | Options<br>Exercisable | Weighted<br>Average<br>Exercise<br>Price of<br>Options<br>Exercisable |
| Year ended December 31, 2017 | \$0.61 - 6.55               | 2,714,561              | 4.23   | \$1.88                                   | 2,590,030              | \$1.89  |
| Year ended December 31, 2018 | \$0.61 - 6.55               | 3,108,868              | 5.72   | \$2.26                                   | 1,986,740              | \$1.81  |

|                              | Total Intrinsic Value of<br>Options Exercised | Total Fair Value of<br>Options Vested |
|------------------------------|---|---------------------------------------|
| Year ended December 31, 2017 | \$ 62,549                                     | \$ 3,962,746                          |
| Year ended December 31, 2018 | \$ 112,213                                    | \$ 2,980,110                          |



Table of Contents

years ended December 31, 2018 and 2017, the weighted average grant date fair value of options granted was \$2.07 and \$1.95, respectively. We estimate the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through December 31, 2018, the weighted average remaining service period is 3.6 years. Estimated stock option expense at December 31, 2018 that will be amortized over the weighted-average remaining service period of 3.6 years totaled \$2.2 million.

## Restricted Stock and Restricted Stock Units

In 2018, we issued 280,000 and 349,000 shares of restricted stock, respectively, to certain employees. Shares issued to employees vest in three equal annual installments on the anniversary dates of their grant. In 2018 and 2017, 182,500 and 530,542 shares of restricted stock vested, respectively.

In 2018 and 2017, we issued 16,286 and 129,865, respectively, restricted stock units to members of our Board of Directors in respect of the annual equity compensation under our non-employee director compensation policy. Restricted stock units granted to our Board of Directors vest at the earlier of the one year anniversary of their grant or the next annual stockholders' meeting. In 2018 and 2017, 129,865 and 86,956 restricted stock units, respectively, vested.

The following table summarizes our aggregate restricted stock awards and restricted stock unit activity in 2018 and 2017:

|                              | Number<br>of<br>Unvested<br>Shares | Weighted Average Grant Date Fair Value | Aggregate<br>Value of<br>Unvested<br>Shares |
|------------------------------|------------------------------------|--|---|
| Balance at January 1, 2017   | 829,998                            | \$1.19                                 | \$988,763                                   |
| Granted                      | 478,865                            | \$1.63                                 | \$780,252                                   |
| Vested                       | (617,498)                          | \$1.23                                 | \$(758,653)                                 |
| Forfeitures                  | (201,667)                          | \$1.35                                 | \$(272,017)                                 |
| Balance at December 31, 2017 | 489,698                            | \$1.51                                 | \$738,345                                   |
| Granted                      | 296,287                            | \$3.07                                 | \$909,600                                   |
| Vested                       | (312,365)                          | \$1.45                                 | \$(454,339)                                 |
| Forfeitures                  | (15,000)                           | \$1.41                                 | \$(21,150)                                  |
| Balance at December 31, 2018 | 458,620                            | \$2.56                                 | \$1,172,456                                 |

We recognized \$0.6 million and \$0.7 million in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the years ended December 31, 2018 and 2017, respectively, and we will recognize \$0.9 million over the remaining requisite service period.

Estimated unamortized restricted stock and restricted stock units expense at December 31, 2018 that will be amortized over the weighted-average remaining service period of 2 years totaled \$1.0 million.

## Non-employee Director Deferred Compensation Plan

We maintain a non-employee director deferred compensation plan (the "Deferred Compensation Plan") that permits our non-employee directors to defer receipt of certain of the compensation that they receive for serving on our board and board committees. During the years ended December 31, 2018 and 2017, the Deferred Compensation Plan permitted the participants to defer cash fees to which they were entitled for board and committee service. For 2018, the Deferred Compensation Plan permitted participants to defer the annual equity compensation for board service (which would otherwise be issued in the form of restricted stock units) under our non-employee director compensation policy. For participating directors, we credit their accounts under the Deferred Compensation Plan with a number of stock units based on the trading price of our common





Table of Contents

f the date of the deferral. These stock units are vested immediately, in the case of stock units in lieu of cash fees, and earlier of the one year anniversary date of the grant or next annual meeting of stockholders, in the case of annual equity distribution, although the participating directors do not receive the shares represented by such units until a future qualifying event. A summary of stock unit activity under the Deferred Compensation Plan for 2018 and 2017 is as follows.

|                   | Number<br>of<br>Stock<br>Units | Weighted Average Grant Date Fair Value per Share | Intrinsic<br>Value<br>Outstanding |
|-------------------|--------------------------------|--|-----------------------------------|
| January 1, 2017   | 393,012                        | \$1.37   |                                   |
| Granted           | 73,690                         | \$1.54   |                                   |
| Vested            | —                              | \$1.15   |                                   |
| Converted         | —                              | \$0.00   |                                   |
| December 31, 2017 | 466,702                        | \$1.40   | \$ 1,134,086                      |
| Granted           | 40,588                         | \$2.99   |                                   |
| Vested            | —                              | \$1.15   |                                   |
| Converted         | —                              | \$0.00   |                                   |
| December 31, 2018 | 507,290                        | \$1.40   | \$1,699,422                       |

## Stock Repurchase Program

On May 16, 2017, our board of directors authorized us to repurchase up to \$2.0 million of our common stock through May 31, 2017. As of May 31, 2017, we had repurchased a total of 205,500 shares for an aggregate purchase price of \$0.2 million under this stock repurchase program, after which this stock repurchase program expired.

On September 19, 2017, our board of directors authorized a new stock repurchase program and providing for the repurchase of up to \$2.0 million of our common stock through September 19, 2018. Our stock repurchase program did not obligate us to acquire any minimum number of shares. Under the program, shares may be repurchased in privately negotiated or open market transactions, including tender offers, under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. As of December 31, 2017, we had repurchased a total of 565,629 and 433,179 shares, respectively, for an aggregate purchase price of \$1.1 million under this stock repurchase program. We currently maintain all repurchased shares under these stock repurchase programs as treasury stock.

## 11. Commitments and Contingencies

### Obligation under Operating Leases

Our operating lease obligations consist of lease agreements for office facilities in Virginia, Michigan, and Georgia under operating leases that as of December 31, 2018 were scheduled to expire between March 2020 and December 2024. Certain of the leases are subject to fixed escalations and provide for possible termination prior to their expiration dates. We recognize rent expense on such leases on a straight-line basis over the lease term. The difference between the straight line method and cash paid is reflected in changes to the deferred rent balance in our consolidated balance sheets. Deferred rent primarily resulted from recognition of the value of certain leasehold improvements at our Blacksburg, Virginia facility at the inception of the lease. Rent expense under these leases recorded in selling, general and administrative expense on our statements of operations totaled approximately \$1.0 million and \$1.1 million, respectively, for the years ended December 31, 2018 and 2017. Our estimated future payments, as of December 31, 2018, under the aforementioned operating leases for each of the next five years and thereafter are:

|      |           |
|------|-----------|
| 2019 | 1,216,124 |
| 2020 | 1,117,684 |
| 2021 | 640,800   |

|            |             |
|------------|-------------|
| 2022       | 544,704     |
| 2023       | 544,704     |
| Thereafter | 544,704     |
|            | \$4,608,720 |

Purchase Commitment

a non-cancelable purchase order totaling \$0.5 million in the fourth quarter of 2017, a non-cancelable purchase order totaling \$1 million in the first quarter of 2018, and a non-cancelable purchase order totaling \$0.7 million in the second quarter of 2018, for multiple shipments of tunable lasers to be delivered over an 18-month period. At December 31, 2018, approximately \$0.8 million of these commitments remained and is expected to be delivered by July 30, 2019.

Royalty Agreement

licensed certain third-party technologies from vendors for which we owe minimum royalties aggregating \$0.4 million payable over the remaining patent terms of the underlying technology.

12. Employee Profit Sharing Plan

a salary reduction/profit-sharing plan under provisions of Section 401(k) of the Internal Revenue Code. The plan is available to all of our permanent employees. We contribute 25% of the salary deferral elected by each employee up to a maximum deferral of 10% of annual salary.

We contributed approximately \$0.3 million to the plan for each of the years ended December 31, 2018 and 2017.

13. Litigation and Other Contingencies

From time to time, we may become involved in litigation in relation to claims arising out of our operations in the normal course of business. While management currently believes it is not reasonably possible the amount of ultimate liability, if any, with respect to these actions will have a material adverse effect on our financial position, results of operations or liquidity, the ultimate outcome of any litigation is uncertain.

In December 2018, we received a notice of claim (the "Claim") from Macom Technology Solutions, Inc. ("Macom"), who acquired our HSOR business in August 2017 pursuant to an asset purchase agreement. Under the asset purchase agreement, we indemnify Macom for certain matters, including, among other things, the collection of accounts receivable from certain customers, and placed \$4.0 million of the purchase price into an escrow account for the potential settlement of any valid claims. The Claim received from Macom totaled \$2.1 million under various indemnity provisions. We have disputed Macom's assertion of right to payment for the matters described in the Claim. It is uncertain what amount, if any, will be owed in connection with the Claim. As of December 31, 2018, \$1.5 million of the escrow balance had been received with the remaining \$2.5 million in the escrow account pending resolution of the dispute.

In December 2018, we sold the assets associated with our optoelectronic components and sub-assemblies ("Opto") business to an unrelated third party. The asset purchase agreement provides for additional consideration of up to \$1.0 million contingent upon the achievement of a specified revenue level by the sold business during the 18 months following the sale. There have been no adjustments recorded in reference to the above matter in the financial statements as of December 31, 2018. It is uncertain what amount, if any, will be received with respect to this potential adjustment.

We have made, and will continue to make, efforts to comply with current and future environmental laws. We anticipate that we will incur additional capital and operating costs in the future to comply with existing environmental laws and new requirements arising from new or amended statutes and regulations. In addition, because the applicable regulatory agencies have not yet promulgated final standards for some existing environmental programs, we cannot at this time reasonably estimate

Table of Contents

for compliance with these additional requirements. The amount of any such compliance costs could be material. We cannot predict the impact that future regulations will impose upon our business.

14. Relationship with Major Customers  
 years ended December 31, 2018 and 2017, approximately 53% and 48%, respectively, of our consolidated revenues were attributable to contracts with the U.S. government.  
 December 31, 2018 and 2017, receivables with respect to contracts with the U.S. government represented 23% and 20% of total trade receivables, respectively.

15. Financial Information About Segments  
 Operations are divided into two operating segments: Technology Development and Products and Licensing. Our engineers collaborate with our network of government, academic and industry experts to identify technologies and ideas with market potential. We then compete to win fee-for-service contracts from government agencies and industrial customers for innovative solutions to practical problems that require new technology. The Technology Development segment derives revenue primarily from services. The Technology Development segment provides applied research to customers in our areas of focus.

The Products and Licensing segment develops and sells products or licenses technologies based on commercially viable concepts developed by the Technology Development segment. The Products and Licensing segment derives its revenue from product sales, and funded product development and technology licenses.

The President and Chief Executive Officer and his direct reports collectively represent our chief operating decision makers, and they evaluate segment performance based primarily on revenue and operating income or loss.

Information about the results of operations for each segment is set forth in the table below. There were no significant inter-segment sales during the years ended December 31, 2018 and 2017.

For the years ended December 31, 2018 and 2017, 24% and 19%, respectively, of our total sales took place outside the United States. No single country, outside of the United States, represented more than 10% of total revenues during the years ended

|  | December 31, 2018 or 2017. |                |
|--|----------------------------|----------------|
|  | Years ended December 31,   |                |
|  | 2018                       | 2017           |
| Technology Development revenue                 | \$20,967,556               | \$18,576,383   |
| Products and Licensing revenue                 | 21,949,689                 | 14,505,482     |
| Total revenue                                  | 42,917,245                 | 33,081,865     |
| Technology Development operating income/(loss) | 378,212                    | (120,417 )     |
| Products and Licensing operating income/(loss) | 499,323                    | (2,087,731 )   |
| Total operating income/(loss)                  | \$877,535                  | \$(2,208,148 ) |
| Depreciation, Technology Development           | \$379,952                  | \$359,626      |
| Depreciation, Products and Licensing           | \$273,185                  | \$747,216      |
| Amortization, Technology Development           | \$130,765                  | \$139,067      |
| Amortization, Products and Licensing           | \$418,349                  | \$1,280,699    |

The Products and Licensing segment's depreciation includes amounts from discontinued operations of \$0.1 million and \$0.4 million for the years ended December 31, 2018 and 2017, respectively. Products and licensing amortization includes amounts from discontinued operations of \$0.1 million and \$0.9 million for the years ended December 31, 2018 and 2017, respectively.

Additional segment information is as follows:

Table of Contents

|  | December 31, |              |
|--|--------------|--------------|
|  | 2018         | 2017         |
| Total segment assets:  |              |              |
| Technology Development   | \$34,823,525 | \$32,011,084 |
| Products and Licensing   | 40,775,211   | 34,211,552   |
| Total  | \$75,598,736 | \$66,222,636 |
| Property plant and equipment and intangible assets, Technology Development | \$2,103,711  | \$2,361,663  |
| Property plant and equipment and intangible assets, Products and Licensing | \$4,927,453  | \$4,831,671  |

December 31, 2017, the products and licensing segment assets include assets held for sale in the amount of \$7.0 million. Property plant and equipment, and intangible assets as of December 31, 2017 excludes assets associated with the optoelectronic components business sold during 2018.

## 16. Quarterly Results (unaudited)

The following table sets forth our unaudited historical revenues, operating loss and net (loss)/income by quarter during 2018 and 2017.

|  | Quarter Ended  |               |                    |                   |                |               |                    |                   |
|--|----------------|---------------|--------------------|-------------------|----------------|---------------|--------------------|-------------------|
|  | March 31, 2018 | June 30, 2018 | September 30, 2018 | December 31, 2018 | March 31, 2017 | June 30, 2017 | September 30, 2017 | December 31, 2017 |
| (in thousands, unless otherwise indicated)             |                |               |                    |                   |                |               |                    |                   |
| Revenue  | \$4,637        | \$5,466       | \$5,316            | \$5,549           | \$4,235        | \$4,602       | \$4,591            | \$5,549           |
| Operating expenses                                     | 4,131          | 4,457         | 5,371              | 7,990             | 2,398          | 3,681         | 3,713              | 4,637             |
| Operating income                                       | 8,768          | 9,923         | 10,687             | 13,538            | 6,633          | 8,283         | 8,304              | 10,186            |
| Operating loss   | 4,929          | 5,693         | 5,998              | 6,572             | 1,770          | 2,414         | 2,385              | 4,384             |
| Operating loss from continuing operations              | (373)          | 205           | 581                | 423               | (1,374)        | (237)         | (150)              | (61)              |
| Operating loss from discontinued operations            | (272)          | 299           | 1,293              | (122)             | (1,254)        | (195)         | 194                | 257               |
| Income tax expense                                     | 421            | 768           | 7,556              | 1,062             | (102)          | (26)          | 15,563             | 749               |
| Income   | 149            | 1,067         | 8,849              | 940               | (1,356)        | (221)         | 15,757             | 1,006             |
| Income attributable to common shareholders             | \$84           | \$1,004       | \$8,785            | \$873             | \$(1,390)      | \$(251)       | \$15,723           | \$939             |
| Operating loss per share from continuing operations:   |                |               |                    |                   |                |               |                    |                   |
|  | \$(0.01)       | \$0.01        | \$0.05             | \$—               | \$(0.05)       | \$(0.01)      | \$0.01             | \$0.01            |
|  | \$(0.01)       | \$0.01        | \$0.04             | \$—               | \$(0.05)       | \$(0.01)      | \$0.01             | \$0.01            |
| Operating loss per share from discontinued operations: |                |               |                    |                   |                |               |                    |                   |
|  | \$0.02         | \$0.03        | \$0.27             | \$0.04            | \$—            | \$—           | \$0.56             | \$0.03            |
|  | \$0.02         | \$0.02        | \$0.23             | \$0.04            | \$—            | \$—           | \$0.48             | \$0.02            |
| Operating loss attributable to common shareholders:    |                |               |                    |                   |                |               |                    |                   |
|  | \$—            | \$0.04        | \$0.31             | \$0.03            | \$(0.05)       | \$(0.01)      | \$0.57             | \$0.03            |
|  | \$—            | \$0.03        | \$0.27             | \$0.03            | \$(0.05)       | \$(0.01)      | \$0.48             | \$0.03            |
| Weighted average shares:                               |                |               |                    |                   |                |               |                    |                   |
|  | 27,204,987     | 27,531,367    | 27,901,631         | 28,067,348        | 27,541,356     | 27,600,147    | 27,692,539         | 27,485,278        |
|  | 27,204,987     | 27,506,743    | 27,055,881         | 28,067,348        | 27,541,356     | 27,600,147    | 27,714,389         | 31,790,418        |



## 17. Discontinued Operations

In 2017, we completed the sale of our high speed optical receivers ("HSOR") business, which was part of our Products and Licensing segment, to an unaffiliated third party for an initial purchase price of \$33.5 million, of which \$29.5 million in cash was received, and \$4.0 million was placed into escrow until December 15, 2018 for possible working capital adjustments to purchase price and potential satisfaction of certain post-closing indemnification obligations (the "Transaction"). The purchase price is subject to adjustment in the future based upon a determination of final working capital, as defined in the asset purchase agreement. The HSOR business was a component of the operations of Advanced Photonix, Inc., which we acquired in May 2015. As part of the Transaction, the buyer also hired approximately 49 of our employees who were engaged in the development, production, and sale of HSOR products in addition to certain corporate administrative functions. The buyer provided certain services to us with respect to infrastructure and administration for which we paid \$0.3 million per month for a period of 18 months for a total of \$1.5 million. We recorded this obligation as a reduction of the value of the purchase price. In assessing the fair value of the services expected to be received by us in relation to those we expected to deliver to the buyer, we concluded that transition service payments were more closely aligned with the fair value of the assets sold than the services received and, therefore, should be accounted for as part of the consideration reconciliation rather than operating activities. Our HSOR business accounted for 16.1% of revenues and 18.5% of our costs of revenues for the year ended December 31, 2017.

In 2018, we sold the assets and operations related to our Opto business, which was part of our Products and Licensing segment, to an unaffiliated third party for an initial purchase price up to \$18.5 million, of which \$17.5 million was received at closing and \$1.0 million has been properly recorded in the financial statements in accordance with GAAP with the remaining purchase price contingent upon the attainment of specified revenue targets during the eighteen months following the closing of the sale. The purchase price is subject to adjustment in the future based upon a determination of final working capital, as defined in the asset purchase agreement. The Opto business was a component of the operations of API, which we acquired in May 2015, and represented all of our operations in our Camarillo, California and Montreal, Quebec facilities. We have reported the results of operations of both our HSOR and Opto businesses as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the relative share of the discontinued business's loss before allocations. We allocated a portion of the consolidated tax (benefit)/expense to discontinued operations based on the ratio of the discontinued business's loss/(income) before allocations.

The following table presents a summary of the transactions related to the sales of Opto in the year ended December 31, 2018 and HSOR in the year ended December 31, 2017:

|   | Year Ended December 31, |               |
|---|-------------------------|---------------|
|   | 2018                    | 2017          |
| Sale price                              | \$ 17,500,000           | \$ 33,500,000 |
| Less: transition services payments      | —                       | (1,500,000 )  |
| Adjusted purchase price                 | 17,500,000              | 32,000,000    |
| Assets held for sale                    | (8,193,184 )            | (16,851,540 ) |
| Liabilities held for sale               | 989,453                 | 2,330,052     |
| Transaction costs                       | (858,227 )              | (895,186 )    |
| Return of working capital               | 730,000                 | —             |
| Income tax expense                      | (1,572,245 )            | (912,298 )    |
| Gain on sale of discontinued operations | \$ 8,595,797            | \$ 15,671,028 |

Assets and liabilities held for sale as of December 31, 2017 were as follows:

Table of Contents

|   | December<br>31, 2017 |
|---|----------------------|
| Assets                                    |                      |
| Current assets:                           |                      |
| Accounts receivable, net                  | \$1,940,125          |
| Inventory                                 | 2,316,329            |
| Prepaid expenses and other current assets | 79,651               |
| Total current assets                      | 4,336,105            |
| Property and equipment, net               | 599,102              |
| Intangible assets, net                    | 1,510,203            |
| Goodwill                                  | 502,000              |
| Other assets                              | 16,028               |
| Total non-current assets                  | 2,627,333            |
| Total assets held for sale                | \$6,963,438          |
| Liabilities                               |                      |
| Current liabilities:                      |                      |
| Accounts payable                          | \$851,785            |
| Accrued liabilities                       | 120,666              |
| Deferred revenue                          | —                    |
| Total current liabilities                 | 972,451              |
| Long-term deferred rent                   | —                    |
| Total non-current liabilities             | —                    |
| Total liabilities held for sale           | \$972,451            |

The key components of income from discontinued operations were as follows:

|   | Year Ended December 31, |              |
|---|-------------------------|--------------|
|   | 2018                    | 2017         |
| Net revenues                                  | \$8,363,606             | \$19,511,646 |
| Cost of revenues                              | 5,294,268               | 12,994,656   |
| Operating expenses                            | 1,728,113               | 5,413,952    |
| Other (income)/expenses                       | (13,330)                | 31,758       |
| Income before income taxes                    | 1,354,555               | 1,071,280    |
| Allocated tax expense                         | 183,921                 | 876,588      |
| Operating income from discontinued operations | 1,170,634               | 194,692      |
| Gain on sale, net of related income taxes     | 8,595,797               | 15,671,028   |
| Net income from discontinued operations       | \$9,766,431             | \$15,865,720 |

s ended December 31, 2018 and 2017, depreciation and amortization from discontinued operations were \$0.2 million  
ion, respectively. For the years ended December 31, 2018 and 2017, the acquisition of property plant and equipment  
continued operations were \$0.1 million in each period. For the years ended December 31, 2018 and 2017, intangible  
sts associated with discontinued operations were \$0.01 million and \$0.1 million, respectively. Proceeds from the sale  
business which were included in cash flows from investing activities in 2018 were \$16.0 million and proceeds from  
the HSOR business which are included in cash flows from investing activities for 2017 were \$28.0 million. The gain  
discontinued operations included in non-cash adjustments to cash flows from operating activities for 2018 and 2017  
was \$8.6 million and \$15.7 million, respectively.





Table of Contents

## 18. Business Acquisitions

On December 15, 2018, we acquired substantially all of the assets, other than cash, the United States operations of Micron Optics, for cash consideration of \$5.5 million, of which \$5.0 million was paid during 2018, with the remaining \$0.5 million in accrued liabilities. The transaction has been accounted for under the acquisition method of accounting in accordance with ASC 805. We incurred approximately \$0.8 million of costs associated with the acquisition during 2018, which are included in general and administrative expenses in our consolidated statement of operations. For the period from the closing of the acquisition through December 31, 2018, we recognized revenues of \$2.6 million and income of \$1.1 million associated with the operations of MOI.

Under the acquisition method of accounting, the total estimated purchase consideration is allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Any excess of the fair value of the acquisition consideration over the identifiable assets acquired and liabilities assumed is recognized as goodwill. We completed a preliminary allocation of the purchase consideration with the assistance of a third-party valuation expert. The preliminary allocation of the purchase consideration is subject to revision as additional information becomes known in the future.

|                                       | Preliminary<br>Allocation |
|---------------------------------------|---------------------------|
| Accounts receivable                   | \$ 1,742,693              |
| Inventory                             | 1,435,606                 |
| Other current assets                  | 69,951                    |
| Property and equipment                | 996,460                   |
| Identifiable intangible assets        | 1,650,000                 |
| Goodwill                              | 101,008                   |
| Accounts payable and accrued expenses | (450,985 )                |
| Total purchase consideration          | \$5,544,733               |

The preliminary identifiable intangible assets and their estimated useful lives were as follows:

|                                     | Estimated<br>Fair Value | Estimated<br>Useful Life |
|-------------------------------------|-------------------------|--------------------------|
| Developed technology                | \$ 1,200,000            | 5.0 years                |
| In process research and development | 200,000                 | 7.0 years                |
| Trade names                         | 150,000                 | 3.0 years                |
| Customer base                       | 100,000                 | 7.0 years                |
|                                     | \$ 1,650,000            |                          |

The developed technologies acquired primarily consists of MOI's existing technologies related to fiber optic sensing instruments, and components. The developed technologies were valued using the "multi-period excess earnings" method, under the same approach. The multi-period excess earnings method reflects the present value of the projected cash flows that are attributable to the developed technologies less charges representing the contribution of other assets to those cash flows. A discount rate of 24.5% was used to discount the cash flows to present value.

The in process research and development represents the fair value of incomplete MOI research and development projects that had not reached technological feasibility as of the closing date of the acquisition. In the future, the fair value of such project at



Table of Contents

closing date of the acquisition will be either amortized or impaired depending on whether the project is completed or abandoned. The fair value of in process research and development was determined using the multi-period excess earnings method. A discount rate of 29.5% was used to discount the cash flows to the present value.

base represents the fair value of projected cash flows that will be derived from the sale of products to MOI's existing customers as of the closing date of the acquisition. Customer relationships were valued using the "distributor" method, under the income approach. Under this premise, the margin of a distributor within the industry is deemed to be the margin attributable to customer relationships. This isolates the cash flows attributable to the customer relationships for which a market participant would be willing to pay. A discount rate of 24.5% was used to discount cash flows to present value.

Names and trademarks are considered a type of guarantee of a certain level of quality or performance represented by the brand. Trade names and trademarks were valued using the "relief from royalty" method of the income approach. This is based on the assumption that in lieu of ownership, a market participant would be willing to pay a royalty in order to obtain the related benefits of this asset. A discount rate of 17% was used to discount the cash flows to the present value.

Goodwill represents the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed in connection with the acquisition.

## Pro forma consolidated results of operations

The following unaudited pro forma financial information presents combined results of operations for each of the periods as if the acquisition of MOI had been completed on January 1, 2017. The pro forma information includes adjustments for depreciation expense for property and equipment acquired, to amortize expense for the intangible assets acquired, and to allocate the acquisition transaction expenses recognized in each period. Transaction-related expenses associated with the acquisition and excluded from the pro forma income/(loss) from continuing operations were \$0.8 million. The pro forma data are for informational purposes only and are not necessarily indicative of the consolidated results of operations or the combined results had the acquisition of MOI actually occurred on January 1, 2017, or the results of future operations of the combined entity. For instance, planned or expected operational synergies following the acquisition are not reflected in the pro forma information. Consequently, actual results will differ from the unaudited pro forma information presented below.

|  | Year ended December 31, |               |
|--|-------------------------|---------------|
|  | 2018                    | 2017          |
|  | (unaudited)             | (unaudited)   |
| Revenue                                  | \$49,494,358            | \$40,954,093  |
| Income/(loss) from continuing operations | \$1,579,318             | \$(2,778,487) |

In 2019, we acquired the outstanding stock of General Photonics Corporation for cash consideration of \$19.0 million. The purchase price, \$17.1 million was paid at closing and \$1.9 million was placed into escrow for possible working capital adjustments to the purchase price and potential satisfaction of certain post-closing indemnification obligations. Additionally, we became obligated to pay additional cash consideration of up to \$1.0 million if certain revenue targets for the General Photonics Corporation historical business are met for the twelve month period following the closing. The purchase price is also subject to adjustment based upon the determination of final working capital as of the closing date compared to a target working capital amount specified in the stock purchase agreement. We have not yet completed its analysis of the fair market value of the assets acquired and liabilities assumed as of the closing date and the associated allocation of the purchase price.

## 19. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

76

---

## ITEM 9A. CONTROLS AND PROCEDURES.

## Evaluation of Disclosure Controls and Procedures

“disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. In connection with the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this report. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of December 31, 2018, our disclosure controls and procedures were effective at the reasonable assurance level.

## Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15(e) and Rule 15d-15(e) that occurred in the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed, under the supervision of our principal executive and principal financial officers, and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that our receipts and expenditures are being made only in accordance with authorizations of our management and other personnel; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Because of the inherent limitations in the effectiveness of any internal control over financial reporting, including the possibility of collusion and the circumvention or overriding of controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Further, because of changes in conditions, effectiveness of internal control over financial reporting may vary over time. Our internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. In connection with the supervision and with the participation of our management, including our President and Chief Executive Officer, and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial



Table of Contents

s of December 31, 2018. This evaluation was based on the criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation excluded the internal control over financial reporting of the United States operations of Micron Optics, Inc. ("MOI"), which were acquired on October 15, 2018. The total acquired assets, based on the preliminary purchase allocation is approximately 8% of our total assets. Revenues and income from continuing operations from MOI for the period from October 16, 2018 through December 31, 2018, were approximately 6% and 83%, respectively, of our consolidated operations. In our evaluation under the framework established in the 2013 Internal Control—Integrated Framework, our President and Chief Executive Officer, and our Chief Financial Officer concluded that our internal control over financial reporting was effective as of December 31, 2018 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

ITEM 9B. OTHER INFORMATION.

None

78

---

## PART III

## ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information required by Item 10 of Form 10-K will be included in the proxy statement related to our 2019 Annual Meeting of (the "2019 Proxy Statement"), anticipated to be filed with the SEC within 120 days after December 31, 2018, and is incorporated into this report by reference.

## ITEM 11. EXECUTIVE COMPENSATION.

Information required by Item 11 of Form 10-K is incorporated into this report by reference to the information to be provided in our 2019 Proxy Statement.

## 2. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information other than the information below relating to securities authorized for issuance under our equity compensation plans, the information required by Item 12 of Form 10-K is incorporated into this report by reference to the information to be provided in our 2019 Proxy Statement.

## EQUITY COMPENSATION PLANS

The following table summarizes our equity compensation plans as of December 31, 2018:

| Category   | Number of securities to be issued upon exercise of outstanding options, warrants and rights<br>(a) | Weighted-average exercise price of outstanding options, warrants and rights<br>(b) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))<br>(c) |
|--|--|--|--|
| Equity compensation plans approved by security holders | 3,316,888 (1)  | 2.16 (2)   | 2,702,667  |
| 1  | 3,316,888 (1)  | 2.16 (2)   | 2,702,667  |

(1) Consists of 3,035,238 shares underlying stock options and 281,650 shares underlying restricted stock units.

(2) Does not take into account restricted stock units, which have no exercise price.

Our Equity Incentive Plan allows for forfeited awards to be added back to our pool of available awards, including awards forfeited from the 2006 Plan after the expiration date of our 2006 Plan.

## ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information required by Item 13 of Form 10-K is incorporated into this report by reference to the information to be provided in our 2019 Proxy Statement.

## ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Information required by Item 14 of Form 10-K is incorporated into this report by reference to the information to be provided in our 2019 Proxy Statement.



## PART IV

## ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULE

(a) The following documents are filed as part of this Annual Report on Form 10-K:

(1) Financial Statements. See Index to Consolidated Financial Statements at Item 8 of this Report on Form 10-K.

(2) Schedules.

Schedule II

Luna Innovations Incorporated

Valuation and Qualifying Accounts

| Column A   | Column B     | Column C  | Column D       | Column E    |
|--|--------------|-----------|----------------|-------------|
|  | Balance      | Additions | Deductions     | Balance at  |
|  | at beginning |           |                | end         |
|  | of Period    |           |                | of period   |
| Year Ended December 31, 2017                       |              |           |                |             |
| Reserves deducted from assets to which they apply: |              |           |                |             |
| Deferred tax valuation allowance                   | \$21,309,546 | \$ —      | \$(16,288,802) | \$5,020,744 |
| Allowances for doubtful accounts                   | 247,239      | 99,888    | (60,410 )      | 286,717     |
|  | \$21,556,785 | \$ 99,888 | \$(16,349,212) | \$5,307,461 |
| Year Ended December 31, 2018                       |              |           |                |             |
| Reserves deducted from assets to which they apply: |              |           |                |             |
| Deferred tax valuation allowance                   | \$5,020,744  | \$ —      | \$(1,753,211 ) | \$3,267,533 |
| Allowances for doubtful accounts                   | 286,717      | 3,500     | (6,134 )       | 284,083     |
|  | \$5,307,461  | \$ 3,500  | \$(1,759,345 ) | \$3,551,616 |

schedules are omitted as the required information is inapplicable or the information is presented in the Consolidated Financial Statements and notes thereto in Item 8 of Part II of this Annual Report on Form 10-K.

(3) Exhibits. The exhibits filed as part of this report are listed under "Exhibits" at subsection (b) of this Item 15.

(b) Exhibits

Table of Contents

EXHIBIT INDEX

Exhibit Document

- Agreement and Plan of Merger and Reorganization dated as of January 30, 2015, by and among Luna Innovations Incorporated, API Merger Sub, Inc. and Advanced Photonix, Inc. (Exhibit 2.1)
- Asset Purchase Agreement, dated July 31, 2018 by and among Luna Innovations Incorporated, Advanced Photonix, Inc., Advanced Photonix Canada, Inc. and OSI Optoelectronics, Inc. (Exhibit 2.1)
- Asset Purchase Agreement, dated October 15, 2018 by and among Luna Innovations Incorporated, Luna Technologies, Inc. and Micron Optics, Inc. (Exhibit 2.1)
- Stock Purchase Agreement, dated March 1, 2019 by and among Luna Innovations Incorporated, Luna Technologies, Inc., Steve Yao and General Photonics Corporation (Exhibit 2.1)
- Amended and Restated Certificate of Incorporation of the Registrant (Exhibit 3.2)
- Certificate of Designations of the Series A Convertible Preferred Stock (Exhibit 3.1)
- Amended and Restated Bylaws of the Registrant (Exhibit 3.4)
- Amendment to Amended and Restated Bylaws (Exhibit 3.1)
- Amendment to Amended and Restated Bylaws (Exhibit 3.1)
- Specimen Common Stock certificate of the Registrant (Exhibit 4.1)
- 2006 Equity Incentive Plan (Exhibit 10.9)
- Form of Stock Option Agreement under 2006 Equity Incentive Plan (Exhibit 4.7)
- 2016 Equity Incentive Plan (Exhibit 4.7)
- Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan (Exhibit 4.8)
- Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2016 Equity Incentive Plan (Exhibit 4.1)
- Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under 2016 Equity Incentive Plan (Exhibit 10.1)
- Form of Indemnification Agreement for directors and executive officers (Exhibit 10.1)
- License Agreement No. DN-982, dated June 10, 2002, by and between the National Aeronautics and Space Administration (NASA) and Luna Innovations Incorporated; Modification No. 1 to License Agreement No. DN-982, dated January 23, 2006, by and between NASA and Luna Innovations Incorporated (Exhibit 10.22)
- License Agreement No. DN-951, dated December 20, 2000, by and between NASA and Luna Technologies, Inc. (Exhibit 10.23)
- Amended and Restated License Agreement, dated March 19, 2004, by and between Virginia Tech Intellectual Properties, Inc. and Luna Innovations Incorporated (Exhibit 10.26)
- Asset Transfer and License Agreement by and between Luna Innovations Incorporated and Coherent, Inc. (Exhibit 10.21)
- Development and Supply Agreement, dated December 12, 2006, by and between Luna Innovations Incorporated and Intuitive Surgical, Inc. dated June 11, 2007 (Exhibit 10.1)
- Amendment to Commercial Lease, by and between Luna Innovations Incorporated and Canvasback Real Estate & Investments LLC dated March 18, 2008 (Exhibit 10.5)
- Securities Purchase and Exchange Agreement, dated January 12, 2010, by and between Luna Innovations Incorporated and Carilion Clinic (Exhibit 10.1)
- Warrant No. 1 to Purchase Common Stock, dated January 13, 2010, issued to Carilion Clinic (Exhibit 10.2)
- Warrant No. 2 to Purchase Common Stock, dated January 13, 2010, issued to Carilion Clinic (Exhibit 10.3)
- Amended and Restated Investor Rights Agreement, dated January 13, 2010, by and among Luna Innovations Incorporated, Carilion Clinic, and certain stockholders of Luna Innovations Incorporated (Exhibit 10.4)
- Non-Employee Directors' Deferred Compensation Plan (Exhibit 10.13)
- License Agreement, effective January 12, 2010, by and among Luna Innovations Incorporated, Luna Technologies, Inc. and Hansen Medical, Inc. (Exhibit 10.6)
- License Agreement, effective January 12, 2010, by and among Luna Innovations Incorporated, Luna Technologies, Inc. and Intuitive Surgical, Inc. (Exhibit 10.8)

Industrial Lease Agreement, dated as of March 21, 2006, by and between Luna Innovations Incorporated and the Economic Development Authority of Montgomery County, Virginia, as amended by a First Amendment effective as of May 11, 2006, a Second Amendment effective as of July 15, 2009 and a Third Amendment effective as of March 23, 2010 (Exhibit 10.14)

Loan and Security Agreement, dated February 18, 2010, by and between Luna Innovations Incorporated, Luna Technologies, Inc. and Silicon Valley Bank (Exhibit 10.5)

Third Amendment to Commercial Lease dated June 21, 2010, by and between Canvasback Real Estate & Investments, LLC and Luna Innovations, Incorporated (Exhibit 10.5)

First Loan Modification Agreement, dated as of March 7, 2011, by and between Luna Innovations Incorporated and Silicon Valley Bank (Exhibit 10.1)

Fourth Amendment to Industrial Lease Agreement, dated as of March 1, 2011, by and between The Economic Development Authority of Montgomery County and Luna Innovations Incorporated (Exhibit 10.3)

Second Loan Modification Agreement, dated as of May 18, 2011, by and between Luna Innovations Incorporated, Luna Technologies, Inc. and Silicon Valley Bank (Exhibit 10.1)

Fifth Amendment to Industrial Lease Agreement, dated as of November 1, 2011, by and between The Economic Development Authority of Montgomery County and Luna Innovations Incorporated (Exhibit 10.39)

Employment Agreement dated December 5, 2017, by and between Scott A. Graeff and Luna Innovations Incorporated (Exhibit 10.25)

Third Amendment to Commercial Lease, dated as of April 15, 2012, by and between Canvasback Real Estate & Investments, LLC and Luna Innovations Incorporated (Exhibit 10.3)

Second Loan Modification Agreement, dated as of May 17, 2012, by and between Luna Innovations Incorporated, Luna Technologies, Inc. and Silicon Valley Bank (Exhibit 10.1)

Fourth Loan Modification Agreement, dated March 21, 2013, by and between Luna Innovations Incorporated, Luna Technologies, Inc. and Silicon Valley Bank (Exhibit 10.1)

Cross-License Agreement by and among Luna Innovations Incorporated and Luna Technologies, Inc. and Intuitive Surgical Operations, Inc. and Intuitive Surgical International, Ltd., dated as of January 17, 2014 (Exhibit 10.2)

Consent, Release and Fifth Loan Modification Agreement between Luna Innovations Incorporated and Silicon Valley Bank dated as of January 21, 2014 (Exhibit 10.3)

Sixth Amendment to Industrial lease Agreement by and between the Economic Development Authority of Montgomery County, Virginia and Luna Innovations Incorporated dated October 1, 2014 (Exhibit 10.47)

Industrial Lease Agreement by and between The Economic Development Authority of Montgomery County, Virginia and Luna Innovations Incorporated dated October 1, 2014 (Exhibit 10.48)

Lease Agreement by and between SBA Tenant, LLC and Luna Innovations Incorporated dated November 2014 (Exhibit 10.49)

Under, Consent, and Sixth Loan Modification Agreement between Luna Innovations Incorporated, Luna Technologies, Inc., Advanced Photonix, LLC and Silicon Valley Bank, dated as of May 8, 2015 (Exhibit 10.1)

Under, Consent, and Seventh Loan Modification Agreement between Luna Innovations Incorporated, Luna Technologies, Inc., Advanced Photonix, LLC and Silicon Valley Bank, dated as of September 29, 2015 (Exhibit 10.1)

First Amendment to Industrial Lease Agreement by and between the Economic Development Authority of Montgomery County, Virginia and Luna Innovation Incorporated, dated January 20, 2015 (Exhibit 10.3)

Amended and Restated Non-Employee Director Compensation Policy, dated June 30, 2015 (Exhibit 10.1)

Fifth Amendment to Commercial Lease by and between Canvasback Real Estate and Investments, LLC and the Registrant, dated as of August 5, 2015 (Exhibit 10.2)

Eighth Loan Modification Agreement, dated December 15, 2016, by and between Luna Innovations Incorporated, Luna Technologies, Inc., Advanced Photonix, LLC and Silicon Valley Bank (Exhibit 10.54)

Employment Agreement, dated May 1, 2018 by and between the Registrant and Dale E. Messick (Exhibit 10.1)

List of Subsidiaries

Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm

Power of Attorney (see signature page)

Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

ertification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of  
e Sarbanes-Oxley Act of 2002.

Following materials from the Registrant's Annual Report on Form 10-K for the year ended December 31, 2018, are in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets at December 31, 2018 and Consolidated Statements of Operations for the years ended December 31, 2018 and 2017, (iii) Consolidated Statements of Changes in Stockholder's Equity for the years ended December 31, 2018 and 2017 (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2018 and 2017, and (v) Notes to Audited Consolidated Financial Statements.

Referenced by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated May 13, 2014. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated February 2, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated June 8, 2006. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated January 15, 2010 (reporting under Items 1.01, 3.02, 3.03, 5.03 and 9.01). The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to the Registrant's Registration Statement on Form S-1, Commission File No. 333-131764, filed on February 10, 2006. The number given in parentheses indicates the corresponding exhibit number in such Form S-1.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated May 10, 2010. The number in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to Amendment No. 5 of the Registrant's Registration Statement on Form S-1, Commission File No. 333-131764, filed on May 19, 2006. The number given in parentheses indicates the corresponding exhibit number in such Form S-1.

Referenced by reference to the exhibit to Amendment No. 3 of the Registrant's Registration Statement on Form S-1, Commission File No. 333-131764, filed on April 28, 2006. The number given in parentheses indicates the corresponding exhibit number in such Form S-1.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated July 17, 2009 (reporting under Items 1.01, 5.02 and 9.01). The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to Amendment No. 1 to Registrant's Annual Report on Form 10-K, Commission File No. 000-52008, filed on April 6, 2007. The number given in parentheses indicates the corresponding exhibit number in such Form 10-K/A.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated June 14, 2007. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated May 9, 2008. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

Referenced by reference to the exhibit to Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated May 17, 2010. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

Referenced by reference to the exhibit to Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated August 16, 2010. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

Referenced by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, dated March 9, 2011. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

Referenced by reference to the exhibit to Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated May 16, 2011. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

Referenced by reference to the exhibit to Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, dated August 12, 2011. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.



Table of Contents

ated by reference to the exhibit to the Registrant's Annual Report on Form 10-K, Commission File No. 000-52008, March 29, 2012. The number given in parentheses indicates the corresponding exhibit number in such Form 10-K.

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, August 9, 2012. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, July 11, 2012. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, filed on , 2013. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-K, Commission File No. 000-52008, March 16, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 10-K.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, May 11, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, October 5, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, May 14, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

ated by reference to the exhibit to the Registrant's Current Report on Form 10-Q, Commission File No. 000-52008, August 14, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, November 13, 2015. The number given in parentheses indicates the corresponding exhibit number in such Form

ated by reference to the exhibit to the Registrant's Annual Report on Form 10-K, Commission File No. 000-52008, March 20, 2017. The number given in parentheses indicates the corresponding exhibit number in such Form 10-K.

ated by reference to the exhibit to the Registrant's Registration Statement on Form S-8, Commission File No. 000-52008, filed on June 3, 2016. The number given in parentheses indicates the corresponding exhibit number in such

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, August 10, 2016. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, August 1, 2018. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Quarterly Report on Form 10-Q, Commission File No. 000-52008, August 1, 2018. The number given in parentheses indicates the corresponding exhibit number in such Form 10-Q.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, October 16, 2018. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, March 4, 2018. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Current Report on Form 8-K, Commission File No. 000-52008, January 14, 2019. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.

ated by reference to the exhibit to the Registrant's Annual Report on Form 10-K, Commission File No. 000-52008, March 21, 2018. The number given in parentheses indicates the corresponding exhibit number in such Form 10-K.

Confidential treatment has been requested with respect to portions of this exhibit, indicated by asterisks, which has been filed separately with the Securities and Exchange Commission.



Item 601(b)(2) of Regulation S-K, the schedules and exhibits to this agreement are omitted, but will be furnished to the Securities and Exchange Commission upon request.

Special treatment has been granted with respect to portions of this exhibit, indicated by asterisks, which has been filed with the Securities and Exchange Commission.

These schedules and exhibits are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation of references in such filing.

Table of Contents

ITEM 16. FORM 10-K SUMMARY

Not applicable.

SIGNATURES

to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LUNA INNOVATIONS INCORPORATED

By: /s/ Dale E. Messick  
 Dale E. Messick  
 Chief Financial Officer

March 14, 2019

BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and authorizes Scott A. Graeff and Dale E. Messick, and each of them acting individually, as his true and lawful attorneys-in-fact and agents with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead in all capacities, to sign any and all amendments to this Annual Report on Form 10-K with all exhibits thereto and to all statements in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done in and about the premises by virtue hereof.

In compliance with the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

|                 | Title  | Date           |
|-----------------|--|----------------|
| Scott A. Graeff | President, Chief Executive Officer and Director (Principal Executive Officer)          | March 14, 2019 |
| Dale E. Messick | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 14, 2019 |
| W. Wise         | Director   | March 14, 2019 |
| Director        | Director   | March 14, 2019 |
| Williamson III  | Director   | March 14, 2019 |
| Anderson        | Director   | March 14, 2019 |
| Phelps, III     | Director   | March 14, 2019 |
| Director        | Director   | March 14, 2019 |
| Roedel          | Chairman of the Board of Directors   | March 14, 2019 |